




HIV-1 Infection of Hematopoietic Progenitor Cells 
by 
Lucy Alexandra McNamara 
 
 
A dissertation submitted in partial fulfillment 
of the requirements for the degree of 
Doctor of Philosophy 
(Microbiology and Immunology) 









Professor Kathleen L. Collins, Chair 
Professor John V. Moran 
Associate Professor Akira Ono 









© Lucy Alexandra McNamara 
____________________________ 
 















 I would first like to thank my mentor, Dr. Kathleen Collins, for her guidance and 
support throughout my graduate training.  None of the research presented in this 
dissertation would have been possible without her wisdom and scientific expertise.   
 The work described in this dissertation was a collaborative effort, and many 
individuals deserve recognition for their contributions.  I first thank Dr. Christoph Carter, 
Dr. Mark Shackleton, and Dr. Sean Morrison for their contributions to Chapter 2.  Dr. 
Carter performed many of the methylcellulose assays and several of the flow experiments 
described in this chapter and, in conjunction with Dr. Shackleton, performed the 
xenograft assay.  Dr. Morrison provided valuable assistance in designing and interpreting 
these experiments.  I also thank Janani Ganesh for her assistance with the reactivation 
assays described in Chapter 3 and Dr. Adewunmi Onafuwa-Nuga, Dr. James Riddell IV, 
Dr. Dale Bixby, and Dr. Michael Savona for collecting and processing the samples from 
HIV-infected donors that were studied in Chapters 2 and 4.  I am grateful to Dr. 
Onafuwa-Nuga and Nadia Sebastian for their assistance with the flow cytometric and 
quantitative PCR analysis of donor samples described in Chapter 4.  Finally, I would also 
like to thank Carole Ramm, Colleen Harvey, and Mary Reyes for recruiting HIV-infected 
donors, as well as all of the donors who provided samples for our studies. 
 I am also grateful to all of the members of the Collins lab, past and present, for 
their help and support throughout my graduate career.  In addition to the lab members 
mentioned above, I thank Dr. Estelle Chiari, David Collins, Dr. Steve King, Dr. Deanna 
Kulpa, Dr. Jolie Leonard, Kay Leopold, Michael Mashiba, Dr. Jason Norman, Kirsten 
Peterson, Wenwen Shen, Frances Taschuk, and Dr. Elizabeth Wonderlich for their 
 iv 
friendship and many helpful discussions of our research.  I would also like to thank my 
dissertation committee for their excellent scientific advice. 
 Finally, I thank my friends and family for their love and support. 
 
 v 








List of Figures 
 
 vi 






Chapter 1. Introduction 
 
1 
Chapter 2. HIV-1 Utilizes the CXCR4 Chemokine Receptor to 




Chapter 3. Latent HIV-1 Infection Occurs in Multiple Subsets of 




Chapter 4. HIV genomes in CD133
+
 hematopoietic progenitors in 
optimally treated people with long-term viral suppression 
cannot be explained by CD3
+
 T cell contamination 
 
143 
Chapter 5. Discussion 169 
 vi 
List of Figures 
 
1.1 Prevalence of HIV in different regions of the world 
 
33 
1.2 HIV disease progression 
 
34 
1.3 HIV structure, genome organization, and life cycle 
 
35 








Model for the establishment of latency in resting memory T cells 37 
1.6 Hematopoiesis 38 
 
1.7 Summary of recent findings on  HIV infection in HPCs 39 
 
1.8 Model of HIV-1 infection in hematopoietic progenitor cells 
 
41 
2.1 Total bone marrow mononuclear cells are correlated with year of 
diagnosis in HIV
+








 HSPCs 83 
 




 cells without spin infection 85 
 










 HSPCs is dependent on CD4 and CXCR4 88 
2.6 
 




 cells 90 
2.7 
 
Infection of multipotent cells requires CXCR4 91 
2.8 
 
CXCR4-tropic HIV can infect HSCs that stably engraft and generate 





Analysis of mice that did not engraft with GFP
+
 hematopoietic cells 93 
2.10 
 











GM-CSF and TNF-# reactivate latent virus in a primary cell model for 








Latent infection occurs in all subsets of CD34
+
 HPCs defined by CD38 





GM-CSF and TNF-#-treated HPCs have increased nuclear NF-!B DNA 











NF-!B inhibitor IKK2 VI counteracts TNF-#-induced reactivation of 











Prostratin and SAHA reactivate latent virus in CD34
+
 HPCs 134 
3.8 
 
Aza-CdR does not reactivate latent virus in CD34
+





 cells isolated by magnetic sorting are minimally contaminated 
with CD3
+





HIV genomes detected in CD133-sorted samples are not attributable to 
contamination with CD3
+











Donors with detectable HIV DNA in CD133-sorted samples were 
diagnosed significantly more recently than donors without detectable 
HIV DNA in CD133-sorted cells 
 
166 
5.1 Updated model of HIV-1 infection in hematopoietic progenitor cells 190 
 viii 
List of Tables 
2.1 Summary of murine xenotransplantation results 
 
80 
4.1 Donor characteristics 
 
159 
4.2 Purity of samples and frequency of HIV genomes detected 160 
 ix 
Abstract 
 Latent HIV infection allows virus to persist in HIV-infected individuals in spite of 
antiretroviral therapy.  In addition to the well-studied reservoir of latent virus in resting 
memory CD4
+
 T cells, we have recently proposed that hematopoietic progenitor cells 
(HPCs) in the bone marrow serve as a reservoir for latent HIV.  Here, I first investigate 
whether HIV envelope tropism impacts the ability of the virus to infect different types of 
HPCs.  I find that HIV envelopes that are able to use CXCR4 as a co-receptor permit 
infection of immature, multipotent HPCs defined by expression of the cell surface marker 
CD133, whereas CCR5-tropic HIV has a greatly reduced capacity to infect these cells.  
Furthermore, I find that a CXCR4-tropic HIV envelope can infect hematopoietic stem 
cells that support long-term, multilineage engraftment in mice.  As hematopoietic stem 
cells can live for the entire lifespan of a person, latent HIV infection of these cells could 
create a very long-lived reservoir of virus.  I next examine the cellular factors that 
promote latency in HPCs and find that HIV can establish a latent infection in multiple 
HPC subsets, including immature HPCs.  Latent infection in these cells can be reversed 
by activation of the transcription factor NF-!B as well as by inhibition of histone 
deacetylases.  Finally, I investigate whether the CD133
+
 subset of HPCs harbors HIV 
genomes in HAART-treated patients with undetectable viral loads.  I detect HIV 
genomes in CD133-sorted cell populations in 6 of 11 donors, including two donors who 
have had undetectable viral loads for more than 8 years.  Furthermore, for at least 5 of 
these 6 donors I demonstrate that CD3
+
 T cells are present at extremely low levels in the 
CD133-sorted populations and are therefore unlikely to contribute to the HIV DNA 




 HPCs to serve as a reservoir for latent virus in HIV-infected individuals.  Further 
study of how latent infection in HPCs and T cells can be reversed to eliminate these viral 







 A major barrier to finding a cure for HIV is the existence of long-lived reservoirs 
of virus in the body that are not depleted by the existing treatment for HIV, highly active 
antiretroviral therapy (HAART).  Ultimately, the goal of the work described in this 
dissertation is to improve our understanding of these viral reservoirs and begin to 
elucidate mechanisms through which these reservoirs can be eliminated.  As an 
introduction to the research described in later chapters, this chapter will discuss the 
existing knowledge of HIV biology and pathogenesis and explore the viral and cellular 
factors that contribute to persistence of the virus during therapy.  We will then examine 
the evidence suggesting that hematopoietic progenitor cells may serve as a reservoir for 
latent HIV in treated individuals.  Our analysis of these topics will provide the necessary 
background for the characterization of HIV infection in HPCs that follows in chapters 2-4 
of this dissertation. 
 
HIV epidemiology 
 It is estimated that there are more than thirty-four million people living with 
human immunodeficiency virus type 1 (HIV-1) infection worldwide, including more than 
3 million children under the age of 15 (UNAIDS 2012). In 2011, approximately 2.5 
million people acquired HIV infection and more than 1.5 million died from acquired 
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immunodeficiency syndrome (AIDS), the clinical endpoint of HIV infection (UNAIDS 
2012). 
 The majority of HIV-infected individuals – more than 23 million people – live in 
sub-Saharan Africa, where the prevalence of HIV-1 infection in adults is nearly 5% 
(UNAIDS 2012).  However, HIV has spread to every region of the world.  Although 
North America is far from the epicenter of the HIV pandemic, 1.4 million people on this 
continent are living with HIV infection; in 2011, 58,000 North Americans acquired HIV 
infection and 20,000 died from AIDS (UNAIDS 2012).  The prevalence of HIV 
worldwide is summarized in Figure 1.1. 
 HIV infection can be treated with antiretroviral therapy, which suppresses viral 
replication and allows the immune system to recover, thereby prolonging the lifespan of 
infected individuals.  However, antiretroviral therapy is a lifelong course of treatment 
rather than a cure.  Although the availability of treatment has increased dramatically in 
recent years, fewer than 7 million people worldwide were receiving antiretroviral therapy 
at the end of 2010 (UNAIDS 2011).  This figure represents only 47% of the people in 
need of therapy worldwide based on the World Health Organization’s guidelines for 
initiating treatment (UNAIDS 2011) and only 20% of the total population with HIV.  
Thus, a large proportion of HIV
+
 individuals remain at risk of serious morbidity and 
mortality as a result of HIV infection, highlighting the urgent need for a less expensive 




Clinical features of HIV infection 
 HIV can be transmitted horizontally through sexual contact or contact with 
contaminated blood as well as vertically from mother to child.  Within 6 weeks of 
becoming infected with HIV, 50-90% of individuals experience symptoms of acute 
infection that may include fever, rash, fatigue, and sore throat; however, others evince no 
sign of HIV infection (Anonymous 1984, Cooper et al. 1985, Fox et al. 1987, Ho et al. 
1985, Pedersen et al. 1989, Schacker et al. 1996, Tindall et al. 1988, Tucker et al. 1985, 
Vanhems et al. 1997).  During acute infection, HIV loads in the plasma can reach levels 




 copies of HIV RNA per ml (Piatak et al. 1993, Schacker et al. 1996).  
As the symptoms of acute infection, if any, subside, the plasma viral load drops to a level 




 copies of HIV RNA per ml in different individuals, then 
stabilizes (Daar et al. 1991, Jurriaans et al. 1994, Piatak et al. 1993).  This level of 
viremia is known as the viral setpoint and is generally reached by 1-6 months after initial 
infection (Piatak et al. 1993, Jurriaans et al. 1994) (Figure 1.2). 
 CD4
+
 T cells are the primary targets of active HIV infection, and thus CD4
+
 T cell 
counts decline dramatically during acute HIV infection (Cooper et al. 1988, Pedersen et 





cell populations expand and help to reduce viral replication to the levels described above 
(Cooper et al. 1988, Pedersen et al. 1990).  At this point, CD4
+
 T cell levels are high 
enough and viremia low enough that HIV-infected individuals generally do not evince 
symptoms of infection aside from possible lymphadenopathy (Crowe et al. 1991, Fox et 
al. 1987, Moss et al. 1988, Pedersen et al. 1987, Polk et al. 1987).  However, continuing 
viral replication results in CD4
+
 T cell counts that decline at a rate of approximately 100 
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cells/!l per year (Lyles et al. 2000) (Figure 1.2).  When CD4
+
 T cell counts drop below 
500 cells/!l, patients may again begin to experience symptoms such as respiratory tract 
infections or candidiasis (Hirschtick et al. 1995, Crowe et al. 1991). 
 Once CD4
+
 T cell counts have dropped below 200 cells/!l, HIV-infected persons 
are considered to have progressed to AIDS.  AIDS generally develops an average of 8 – 
10 years after infection in untreated people (Medley et al. 1987, reviewed in Feinberg 
1996), but about 20% of individuals develop AIDS within 5 years of infection (Blaxhult 
et al. 1990).  The severe immune dysfunction present at this stage allows for the 
development of opportunistic infections including cryptosporidiosis, active tuberculosis, 
and Pneumocystis jirovecii (formerly P. carinii) pneumonia (Chaisson et al. 1987, 
Flanigan et al. 1992, Phair et al. 1990).  Additionally, certain types of cancer as well as 
neuropathy and dementia may occur (Crowe et al. 1991, Feingold et al. 1990, Snider et 
al. 1983).  In untreated patients, opportunistic infections typically lead to death 1-2 years 
after the development of AIDS (Mellors et al. 1996). 
 Highly active antiretroviral therapy (HAART) for HIV suppresses viral 
replication, leading to very low viral loads, increased CD4
+
 T cell counts, and greatly 
prolonged lifespan in treated individuals (summarized in Figure 1.2) (Collier et al. 1996, 
Gulick et al. 1997, Hammer et al. 1997)).  HAART consists of a combination of at least 
three antiretroviral agents that inhibit viral replication through at least two mechanisms, a 
feature of the treatment that is imperative to prevent the development of drug resistance.  
Current recommendations suggest that HAART therapy consist of two nucleoside reverse 
transcriptase inhibitors and either a nonnucleoside reverse transcriptase inhibitor, a 
protease inhibitor, or an integrase inhibitor (Thompson et al. 2012).  The requirement for 
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reverse transcriptase, protease, and integrase in the HIV life cycle is reviewed below in 
the section on HIV virology. 
 Although HAART suppresses viral replication and greatly increases the lifespan 
of infected individuals, it is clear that HAART is not a cure for HIV.  First, although the 
viral loads of individuals on HAART are often clinically undetectable, sensitive assays 
are generally still able to detect low levels of virus in the plasma of infected individuals 
(Maldarelli et al. 2007).  In addition, even people with viral loads that are usually 
undetectable with clinical assays will sometimes experience “blips” of detectable viremia 
at intermittent timepoints (Figure 1.2) (Di Mascio et al. 2003).  Finally, if HAART is 
discontinued even after years of therapy, HIV viremia will rebound to readily detectable 
levels within weeks (Figure 1.2) (Joos et al. 2008).  For all of these reasons, it is evident 
that although HAART is an effective treatment for HIV, it is not a cure. 
 While the vast majority of HIV-infected individuals progress to AIDS in the 
absence of antiretroviral treatment, there are rare individuals in whom disease 
progression does not occur or is substantially delayed.  These individuals fall into two 
broad groups: long term non-progressors (LTNPs), who have detectable but often 
relatively low viral loads and maintain normal CD4
+
 T cell counts for at least 10 years 
after HIV infection; and elite controllers (ECs) who maintain viral loads below the 
clinical limit of detection (<50 copies HIV RNA/ml) in the absence of treatment (Hubert 
et al. 2000, Lambotte et al. 2005, reviewed in Deeks and Walker 2007).  While some 
LTNPs and ECs appear to be infected with HIV that is less pathogenic due to mutations 
or deletions in various viral genes (Alexander et al. 2000, Deacon et al. 1995, Kirchoff et 
al. 1995, Lum et al. 2003, Wang et al. 1996, Yamada and Iwamoto 2000), host variation 
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in the major histocompatibility complex (MHC) class I region of chromosome 6 also 
clearly contributes to the ability to control viral replication (The International HIV 
Controllers Study 2010).  Current estimates suggest that about 5-15% of HIV-infected 
people have the potential to be long term non-progressors, while less than 1% are elite 




 HIV is an enveloped retrovirus of the genus Lentivirus.  The virus is spherical in 
shape and approximately 110nm in diameter (Gelderblom et al. 1987).  Within the lipid 
envelope of the virus is the protein capsid, which contains two copies of the viral 
genome, a positive-sense, single-stranded RNA (Figure 1.3A).  The genome encodes the 
viral structural proteins Gag, Pol, and Env, the regulatory proteins Tat and Rev, and the 
accessory proteins Vif, Vpr, Vpu, and Nef (reviewed in Haseltine 1988).  At either end of 
the genome is the viral long terminal repeat (LTR), which serves as the promoter for the 
transcription of the viral genes.  In the RNA genome the 5’ LTR consists of only the 5’ 
UTR (U5) and R regions, while the 3’ LTR contains the 3’ UTR (U3) and R regions; the 
DNA provirus has the U3, R, and U5 regions at each end (reviewed in Hu and Hughes 
2012).  In its proviral form, the genome is approximately 9700 base pairs in length 
(Ratner et al. 1985).  The structure of the viral genome is shown in Figure 1.3B. 
 
Structural proteins and the life cycle of HIV-1.  The HIV-1 life cycle (Figure 1.3C) can 
be thought of as beginning with viral assembly, which is dependent upon the expression 
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of HIV-1 Gag (Gheysen et al. 1989).  Gag is initially translated as the p55 polyprotein; in 
addition, about 5% of all Gag proteins made in the cell are in fact Gag-Pol polyproteins, 
which are produced when the ribosome shifts frame to read through the end of the Gag 
polyprotein during translation (Jacks et al. 1988).  The N-terminal matrix domain of p55 
mediates targeting of Gag or Gag-Pol to the plasma membrane of the cell as well as 
membrane binding (Bryant and Ratner 1990, Fäcke et al. 1993).  Meanwhile, the 
nucleocapsid domain of Gag and Gag-Pol mediates binding to the viral RNA genome and 
Gag multimerization (Burniston et al. 1999).  Multimerization of Gag forms an inherently 
curved lattice, thereby leading to the formation of spherical viral particles (Briggs et al. 
2009). 
 The final HIV-1 structural protein, Env, is a glycoprotein that is initially 
synthesized in a precursor form, gp160.  Gp160 is then cleaved by one of several cellular 
proteases into gp120 and gp41 (Decroly et al. 1997).  Then, gp120 and gp41 assemble 
into a complex that localizes to the plasma membrane and subsequently to the viral 
envelope through interactions with the matrix domain of Gag (Chan et al. 1997, Cosson 
1996, Murakami and Freed 2000). 
 Once all of the viral structural proteins as well as two copies of the RNA genome 
have assembled, the virion buds from the plasma membrane (reviewed in Sundquist and 
Kräusslich 2012).  In addition to the viral genome and proteins, these viral particles 
contain small cellular RNAs, including the Lys3 tRNA required for initiation of reverse 
transcription (see below) (Jiang et al. 1993).  As the virion buds, Gag p55 is cleaved by 
the viral protease, which is part of Pol, to form the matrix (p17), capsid (p24), 
nucleocapsid (p7), and p6 proteins as well as the p2 and p1 spacer peptides (Henderson et 
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al. 1992, Wiegers et al. 1998). These cleavage events result in major structural changes 
within the virion, including the formation of the cone-shaped protein capsid around the 
viral proteins and RNA genome (Wiegers et al. 1998).  These structural changes are 
required for the formation of the mature, infectious virion (Figure 1.3A) (Kohl et al. 
1988).  Finally, the viral protease also cleaves Pol into the viral enzymes required for the 
remaining steps of the viral life cycle: the viral protease itself; reverse transcriptase, 
responsible for reverse transcribing the viral RNA genome into a DNA provirus; and 
integrase, which catalyzes the integration of the DNA provirus into the host cell’s 
genome (Darke et al. 1988; described in more detail below). 
 For the mature virion to infect a new cell, HIV Env must bind to the cellular 
receptor CD4 as well as a co-receptor, usually CCR5 or CXCR4 (Alkhatib et al. 1996, 
Choe et al. 1996, Deng et al. 1996, Doranz et al. 1996, Dragic et al. 1996, Feng et al. 
1996, reviewed in Berger et al. 1999).  Env then undergoes a conformational change that 
allows the viral envelope to fuse with the cell membrane, permitting release of the viral 
capsid into the cell (Furuta et al. 1998, Kowalski et al. 1987).  Viral uncoating – the 
disassembly of the viral capsid – may occur immediately following entry into the cell 
(Fassati and Goff 2001); alternatively, uncoating may happen during reverse transcription 
and/or nuclear transport of the provirus  (Dismuke and Aiken 2006, reviewed in Arhel 
2010).  In either case, shortly after entry the viral RNA genome is reverse transcribed to 
produce a double-stranded DNA provirus, using the Lys3 tRNA as the primer to initiate 
DNA synthesis (Ratner et al. 1985, Isel et al. 1996).  Following reverse transcription, the 
the proviral genome associates with the viral integrase as well as other proteins to form 
the preintegration complex (PIC), which is imported into the nucleus of the cell through a 
 9 
mechanism that has not been fully elucidated (reviewed in Craigie and Bushman 2012).  
Once in the nucleus, HIV-1 integrase and cellular enzymes catalyze the integration of the 
proviral genome into the host cell’s DNA (Bushman et al. 1990).  The life cycle of HIV-1 
is summarized in Figure 1.3C. 
 Following integration into the host cell’s genomic DNA, transcription of the HIV 
genes results in the production of both spliced and unspliced viral RNA.  The unspliced 
RNA serves as the mRNA for Gag and Gag-Pol proteins as well as the viral genome for 
new virions (Feinberg et al. 1986).  By contrast, singly or multiply spliced viral RNA 
serves as the mRNA for Env and the viral accessory and regulatory proteins (Feinberg et 
al. 1986, Malim et al. 1988, Purcell and Martin 1993).  The functions of these additional 
proteins as well as the mechanisms controlling the transcription of the HIV genome are 
discussed in more detail below. 
 
Accessory and regulatory proteins.  In addition to the structural proteins highlighted 
above, HIV-1 also encodes accessory proteins that help the virus evade the host immune 
system.  First, the accessory protein Vif promotes the degradation of APOBEC3G, a 
cellular protein that both deaminates cytidine residues in the minus strand of the HIV 
provirus, thereby causing G to A hypermutation in the viral genome (Mangeat et al. 2003, 
Marin et al. 2003), and inhibits HIV reverse transcription through a deaminase-
independent mechanism (Bishop et al. 2006, Bishop et al. 2008, Chiu et al. 2005, Guo et 
al. 2006, Mbisa et al. 2007).  In addition, Nef downregulates cell surface expression of 
several cellular proteins, notably CD4 and MHC Class I (Garcia and Miller 1991, Collins 
et al. 1998, Leonard et al. 2011).  Downregulation of MHC Class I prevents infected cells 
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from being recognized by CD8
+
 cytotoxic T cells and thereby promotes the survival of 
HIV-infected cells (Collins et al. 1998).  Meanwhile, removal of CD4 from the surface 
promotes Env incorporation into virions and virion release while preventing 
superinfection of the already-infected cell, thus promoting viral spread (Benson et al. 
1993, Lama et al. 1999, Ross et al. 1999).  Finally, Vpu also degrades CD4 (Willey et al. 
1992a, Willey et al. 1992b) and furthermore enhances the release of nascent virions from 
the cell membrane by counteracting the cellular factor Tetherin, which otherwise 
“tethers” virions to the cell (Neil et al. 2008).   
 The function of the accessory protein Vpr is less well understood.  Vpr expression 
is known to lead to cell cycle arrest and apoptosis, but it is not clear why these functions 
are beneficial to the virus (Ayyavoo et al. 1997, Jowett et al. 1995, Re et al. 1995, Rogel 
et al. 1995, Stewart et al. 1997).  Vpr has also been reported to assist in nuclear import of 
the viral pre-integration complex in non-dividing cells (Agostini et al. 2002, Heinzinger 
et al. 1994).  In addition, we have recently reported that Vpr interacts with the host uracil 
glycosylase UNG2 to reduce APOBEC3G-mediated uridine incorporation in the proviral 
genome (Norman et al. 2011).  However, this recruitment activates a DNA damage-
response pathway that enhances recognition of HIV-infected cells by natural killer (NK) 
cells (Norman et al. 2011).  Further research is needed to better understand the function 
of Vpr and the mechanisms through which it may promote nuclear import and/or repair of 
proviral DNA. 
 Finally, HIV-1 encodes two regulatory proteins, Rev and Tat.  Rev is responsible 
for the export of unspliced HIV-1 RNAs from the nuclei of infected cells, an essential 
activity as unspliced HIV-1 RNA serves as both the template for translation of the 
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structural proteins and as the RNA genome for nascent virions (Malim et al. 1989, 
Sodroski et al. 1986).  The Tat protein, on the other hand, is required for the efficient 
transcription of the viral genes.  During transcription, Tat binds to the Tat response 
element (TAR) at the 5’ end of viral RNAs (Berkhout et al. 1989) and recruits the cellular 
positive transcription elongation factor b (P-TEFb) complex to the viral genome (Wei et 
al. 1998) by competitively displacing inhibitory factors that otherwise bind this complex 
(Barboric et al. 2007, Sedore et al. 2007).  The importance of Tat in promoting viral gene 
expression and the impact that Tat expression has on the establishment and maintenance 
of viral latency are discussed in more detail below. 
 
Control of HIV gene expression 
 Transcription of the HIV genome immediately following integration results in the 
production of new viral proteins that form new virions, which can then infect additional 
cells and continue the viral replication cycle.  Sometimes, however, viral genes are not 
immediately transcribed after the provirus integrates.  When this happens, a latent, 
transcriptionally silent infection is established.  Because the latently infected cell evinces 
no outward sign of HIV infection, neither the immune system nor current antiretroviral 
therapies are able to eliminate latently infected cells.  Instead, the HIV-1 provirus can be 
maintained in the infected cell or in daughter cells from subsequent cell divisions for as 
long as these cells survive.  However, changes in cellular conditions at a later time point 
can lead to reactivation of latent virus and, in the absence of antiretroviral therapy, the 
initiation of new cycles of viral replication.  Because the potential for viral reactivation is 
always present, latent HIV infection represents a barrier to curing HIV. 
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 In order to understand how latent infection can occur, it is essential to understand 
the factors that control the expression of HIV genes.  In this section, we will explore the 
cellular, viral, and stochastic factors that impact HIV gene expression.  Most studies of 
HIV gene expression have been conducted in T cell lines and primary T cells, and it is 
evidence from these cell types that will be focused on here.  The factors that impact HIV 
gene expression in other cell types, such as hematopoietic progenitor cells, are less well 
understood and will be further investigated in Chapter 3. 
 
Transcription factors involved in HIV gene expression.  Binding sites for numerous 
transcription factors exist within the HIV-1 LTR (Figure 1.4), and many of these 
transcription factors have been shown to impact the transcription of HIV genes (reviewed 
in Pereira et al. 2000).  Notably, YY1, homodimers of NF-!B p50, and Sp1 have been 
reported to recruit histone deacetylase 1 to the viral LTR and thereby repress viral 
transcription (Doetzlhofer et al. 1999, He and Margolis 2002, Williams et al. 2006).  
However, the Sp1 and NF-!B binding sites can also recruit activating factors, including 
NF-!B p65-p50 heterodimers and histone acetyltransferases, and these sites are in fact 
essential for efficient transcription of viral genes (Li et al. 1994, Perkins et al. 1993, 
reviewed in Trono et al. 2010).  Additional transcription factors, including the nuclear 
factor of activated T cells (NF-AT) and activator protein-1 (AP-1), have also been shown 
to promote the transcription of viral proteins in some systems (Kinoshita et al. 1997, 
reviewed in Pereira et al. 2000).  Overall, it is clear that cellular transcription factors are 
required for the transcription of HIV genes, and thus understanding the transcription 
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factors that promote or repress transcription in different cell types is key to furthering our 
understanding of latent infection. 
 
Additional factors that impact HIV gene expression.  As mentioned above, the 
recruitment of histone deacetylases to the HIV-1 LTR by transcription factors promotes a 
restricted transcriptional state, whereas histone acetyltransferase recruitment promotes 
transcription of viral genes.  Methylation of both histones and DNA has also been shown 
to repress HIV gene expression and promote the establishment of latent infection 
(Blazkova et al. 2009, Kauder et al. 2009, Pearson et al. 2008, Tyagi et al. 2010) (Figure 
1.4).  These repressive chromatin modifications may be induced by specific recruitment 
of repressive factors to the HIV-1 LTR as described above; however, they can also be a 
consequence of the initial integration site of the HIV genome.  Although HIV 
preferentially integrates into actively transcribed genes (Schröder et al. 2002), it has also 
been shown that latent infection in T cell lines is preferentially established when an HIV 
provirus integrates into heterochromatic chromosomal regions (Jordan et al. 2003).  It is 
thus apparent that chromatin modifications at or near the HIV-1 LTR play a key role in 
the regulation of HIV gene transcription. 
 Production of the viral protein Tat and recruitment of P-TEFb to the nascent viral 
transcript are also essential for the transcription of viral genes.  As noted above, Tat 
recruits P-TEFb to the viral TAR; once there, P-TEFb phosphorylates the C-terminal 
domain of RNA polymerase II (RNAPII) to stimulate transcription elongation (Marshall 
et al. 1996) (Figure 1.4).  T cell receptor signaling has also been shown to promote 
dissociation of P-TEFb from its repressive complex with 7SK RNA and HEXIM1 (Kim 
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et al. 2011).  In resting T cells, which as discussed below are a known reservoir for latent 
HIV in vivo, P-TEFb activation appears to be a major factor in the reactivation of latent 
virus through T cell activation. 
 Tat is essential for the efficient transcription of viral genes, but as a viral gene 
product itself it is produced at very low levels immediately following infection.  Whether 
sufficient Tat is produced to initiate the positive feedback loop required for efficient viral 
gene transcription depends upon the chromatin environment and availability of the 
transcription factors noted above; however, stochastic variation in the amount of Tat 
initially produced can also influence whether viral gene transcription continues 
(Weinberger et al. 2005).  Finally, mutations in Tat or the viral TAR can also promote 
latent infection in vitro (Emiliani et al. 1998, Pearson et al. 2008, Reza et al. 2003) and in 
vivo (Yukl et al. 2009). 
 There is also evidence that additional factors may impact HIV gene expression.  
Transcriptional interference has been proposed as a mechanism underlying HIV latency 
in spite of integration into actively transcribed genes (Han et al. 2008, Lenasi et al. 2008).  
When the viral genome is integrated in the reverse orientation as the host gene, active 
transcription of the host gene can result in the physical exclusion of transcription factors 
and RNA polymerase from the HIV-1 LTR, preventing the transcription of viral genes 
(Han et al. 2008, Lenasi et al. 2008). HIV gene expression may also be inhibited at the 
RNA level through binding of cellular microRNAs (Huang et al. 2007) or by retention of 
spliced viral RNA in the nucleus of resting T cells due to low levels of polypyrimidine 
tract binding protein (Lassen et al. 2006).  Further study is required to better understand 
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how these factors interact with transcription factors and chromatin modifications to 
promote viral latency in different cell types. 
 
HIV envelope tropism 
 In order for HIV to infect a cell, the HIV envelope glycoprotein must interact with 
the cellular receptor CD4 as well as a co-receptor, usually CXCR4 or CCR5 (reviewed in 
Berger et al. 1999).  Although there is evidence that HIV can occasionally use alternative 
co-receptors, such as CCR2B or CCR3 (Doranz et al. 1996, Choe et al. 1996, reviewed in 
Berger et al. 1999), the use of such co-receptors is in uncommon in vivo (Zhang et al. 
1998).  Thus, our discussion of HIV envelope tropism will focus on the ability of the 
envelope to use CXCR4 and/or CCR5 as a co-receptor. 
 The ability of HIV Env to use CXCR4 vs. CCR5 as a co-receptor is determined in 
large part by the sequence of the third variable loop (V3) of the HIV envelope (De Jong 
et al. 1992, Raymond et al. 2008).  A change in the net charge of the V3 loop, which can 
result from as few as one or two amino acid changes in this region, can shift the HIV 
envelope from CCR5-tropic to CXCR4- or dual-tropic (i.e. able to use either co-receptor) 
(De Jong et al. 1992, Raymond et al. 2008).  As HIV has a very high mutation rate of 
approximately 3.4 x 10
-5
 substitutions per base per replication cycle (Mansky and Temin 
1995), the few mutations required to permit a shift in viral tropism means that the co-
receptor tropism of the virus can readily change in vivo. 
 CCR5-utilizing HIV predominates in most patients at early time points after 
infection (van’t Wout et al. 1994, Zhu et al. 1993).  It has been proposed that the 
prevalence of CCR5-tropic virus early in infection is due to a requirement for CCR5 
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utilization in transmission (reviewed in Margolis and Shattock, 2006).  However, recent 
evidence suggests that CXCR4-tropic isolates can be transmitted as well and are simply 
less common in the individuals who are most likely to transmit (Chalmet et al. 2012), 
perhaps due to the association between CXCR4-utilization and disease progression noted 
below.  Furthermore, deep sequencing of the viral populations present in recently infected 
individuals has demonstrated that populations of CXCR4-utilizing virus are present in 
12-50% of these patients (Abbate et al. 2011, Chalmet et al. 2012, Daar et al. 2007).  
Thus although CCR5-using virus appears to be more common early in infection, it is 
clear that that many recently infected individuals also harbor CXCR4- or dual-tropic 
HIV. 
 In about half of individuals with subtype B HIV infection and at least some 
individuals infected with other HIV subtypes, CXCR4-using virus becomes more 
common later in the course of disease (Abebe et al. 1999, Cilliers et al. 2003, Juriaans et 
al. 1994, Shankarappa et al. 1999, Karlsson et al. 1994, Scarlatti et al. 1997, Tersmette et 
al. 1988).  Furthermore, the emergence of CXCR4-using virus is associated with more 
rapid disease progression (Connor et al. 1997, Daar et al. 2007, Karlsson et al. 1994, 
Richman and Bozzette 1994, Schuitemaker et al. 1992, Shepherd et al. 2008, Waters et al. 
2008, Weiser et al. 2008, Yu et al. 1998).  The reasons for the association between the 
emergence of CXCR4-using virus and disease progression have not yet been elucidated.  
It is also not understood whether CXCR4-using virus becomes more prevalent over time 
in patients with fully suppressed viral loads on HAART (Delobel et al. 2005); however, it 
is clear that CXCR4-using virus does at least persist in such patients (Delobel et al. 2005, 
Seclén et al. 2010, Soulié et al. 2007).  Further study is required to better understand the 
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relationship between HIV envelope tropism, disease progression, and the persistence of 
HIV during therapy. 
 
HIV persistence during therapy 
 Although HAART is able to reduce viral replication to levels that are often 
clinically undetectable, HIV persists in spite of therapy and viremia rebounds if HAART 
is discontinued.  The two explanations that have been proposed for the ability of HIV to 
persist in spite of effective antiretroviral therapy are reviewed below. 
 
Ongoing active replication.  One explanation for the persistence of HIV in spite of 
HAART is that HAART is unable to prevent all viral replication in vivo.  This ongoing 
replication has been proposed to occur in sanctuary sites within the body where drug 
penetrance is reduced (reviewed in Dahl et al. 2010).  Alternatively, cell-to-cell spread, 
which can result in the transfer of very large quantities of virus to an individual cell, may 
permit the virus to persist in spite of HAART by increasing the probability that at least 
one of the virions infecting an individual evades the drugs that are present (Sigal et al. 
2011). 
 Several studies have suggested that ongoing replication does occur in vivo in spite 
of HAART treatment.  One study found that when suppressive HAART therapy was 
intensified with the integrase inhibitor raltegravir, an increase in the levels of 
unintegrated HIV DNA was observed (Buzón et al. 2010).  This finding suggested that in 
the patients studied, raltegravir was blocking integration of virions that would otherwise 
have completed a full cycle of replication in spite of HAART.  However, additional 
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studies of intensification of HAART with raltegravir or other antiretroviral agents have 
failed to replicate this finding or to demonstrate any decrease in the amount of residual 
viremia present in the patients studied (Besson et al. 2012, Dinoso et al. 2009, Gandhi et 
al. 2010, Hatano et al. 2011). 
 Other studies have found that the residual viral sequences present in HAART-
treated patients evolve over time in some individuals, which should only be possible in 
the context of ongoing replication (Shiu et al. 2009, Tobin et al. 2005).  However, 
contrasting studies have not been able to find evidence of evolution in the residual 
viremia (Joos et al. 2008, Kieffer et al. 2004).  Overall, although residual viral replication 
may occur in some HAART-treated patients, it does not seem to account for viral 
persistence in all HIV-infected individuals on HAART. 
 
Latent infection. A latent HIV infection occurs when the HIV DNA provirus integrates 
into the cellular genome but the viral genes are not immediately transcribed or translated.  
As described above, insufficient levels of transcriptional activators such as P-TEFb or the 
transcription factor NF-!B as well as a restrictive chromatin state at the HIV-1 LTR can 
promote the establishment of latent infection.  The latent virus can then be maintained 
throughout the lifetime of the infected cell, and proliferation of this infected cell can lead 
to expansion of the latent reservoir (Chomont et al. 2009). 
 Although latent virus is transcriptionally inactive, changes to cellular conditions 
can cause the virus to reactivate, resulting in the production of new virions that could 
contribute to the residual viremia detected during HAART and to the rebound of virus 
following therapy cessation.  As latent virus could contribute to residual viremia without 
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completing full cycles of replication, viral particles derived from latent viral genomes 
would not be expected to evolve.  Thus, latent infection provides an explanation for the 
non-evolving residual viral populations observed in many HAART-treated patients (Joos 
et al. 2008, Kieffer et al. 2004, Tobin et al. 2005). 
 Many studies have demonstrated that resting memory CD4
+
 T cells can serve as a 
reservoir for latent HIV genomes in vivo, and that these latent genomes can give rise to 
replication-competent virus upon T cell activation (Chun et al. 1995, Finzi et al. 1997, 
Finzi et al. 1999, Zhang et al. 1999).  More recent evidence has suggested that central and 
transitional resting memory CD4
+
 T cells in particular are the primary T cell reservoir for 
latent virus (Chomont et al. 2009).  HIV infection in resting T cells has been 
demonstrated to be blocked at reverse transcription (Zack et al. 1990); thus, it is generally 
believed that latent infection in resting memory T cells is established when HIV infects 
an activated T cell but the cell reverts to a resting state before cytotoxic viral proteins are 
produced.  However, there is also evidence that the block to infection of resting T cells is 
not absolute and that HIV can infect these cells directly (Agosto et al. 2009, Cameron et 
al. 2010, Saleh et al. 2007, Yoder et al. 2008, Yu et al. 2009).  These explanations for 




Evidence for additional reservoirs of HIV
1
.  Recent data on the structure of the residual 
viral population suggests that in addition to latently infected resting memory T cells, 
there is at least one other long-lived viral reservoir in many patients.  Several studies have 
demonstrated that many viral sequences found in the residual viremia of some HIV-
infected individuals on successful HAART therapy do not match those found in the 
resting CD4+ T cell reservoir (Bailey et al. 2006, Sahu et al. 2009) or indeed from any 
peripheral blood cells (Brennan et al. 2009), though plasma viral sequences are more 
closely related to sequences in peripheral blood monocytes than to sequences in CD4+ T 
cells (Lopez et al. 2010).  These data suggest that a major source of residual viremia in 
treated patients may be a heretofore uncharacterized reservoir of HIV. 
 There is also evidence that residual plasma viremia is largely homogenous, with 
just one or two viral clones accounting for most residual viremia in many patients on 
HAART (Bailey et al. 2006) or most rebounding virus during treatment interruptions 
(Joos et al. 2008).  Given the high mutation rate of HIV, these data suggest that the major 
source of persistent HIV production is either a single cell or a clonal population of cells 
originating from a single infected cell with a substantial capacity for cell division.   
 Finally, a recent analysis of the decay kinetics of HIV reservoirs in HAART-
treated patients suggests the existence of two long-term viral reservoirs: one with a half-
life of 9-15 months, approximately consistent with the previously reported half-life of the 
resting T cell reservoir (6-44 months) (Siliciano et al. 2003, Finzi et al. 1999, Zhang et al. 
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1999, Ramratnam et al. 2000), and a second reservoir with no appreciable decay over at 
least seven years (Palmer et al. 2008).  This analysis suggests that not only is there an 
additional reservoir of latent virus aside from that in resting memory T cells, but that this 
reservoir may permit even more durable persistence of virus than the T cell reservoir 
does.  The identity of this long-lived viral reservoir has yet to be established; however, as 
we will discuss later in this chapter, the indefinite half-life of this reservoir is consistent 
with the exceedingly long lifespan of hematopoietic stem cells (HSCs). 
 
Cell types that could serve as additional reservoirs for HIV 
 The evidence that resting memory CD4
+
 T cells are not the sole source of residual 
viremia in HAART-treated patients has led researchers to search for additional cell types 
that might serve as long-term reservoirs for HIV.  These cells might be latently infected, 
or they might be cells that can endure active virion production without cytotoxicity.  The 
evidence that various cell types can serve as either a latent or a persistent active reservoir 
for HIV is examined below. 
 
Monocytes, macrophages, and dendritic cells.  Although peripheral blood monocytes are 
resistant to HIV infection, HIV can nevertheless infect these cells at low rates (Sonza et 
al. 2001, Zhu et al. 2002).  Furthermore, HIV readily infects mature macrophages and 
dendritic cells, which have a half-life that varies from days to years in vivo (reviewed in 
Gonzalez-Mejia and Doseff 2009, Merad and Manz 2009).  Macrophages have been 
shown to be less susceptible to the cytotoxic effects of HIV than are CD4
+
 T cells, and as 
such may remain persistently actively infected months (Ho et al. 1986, Collman et al. 
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1989).  In addition, macrophages have been shown to support latent HIV infection in 
vitro (Brown et al. 2006).  Although some dendritic cells can also survive the cytopathic 
effects of active HIV infection for up to several weeks (Popov et al. 2005), latent 
infection of these cells has not been reported and HIV DNA does not persist in dendritic 
cells of patients with suppressed viral loads on HAART (Otero et al. 2003).  Thus, while 
both actively and latently infected macrophages may serve as reservoirs for HIV in vivo, 
dendritic cells are less likely to serve as a source of persistent virus.   
 Infection of monocytes that then cross the blood-brain barrier also provides a 
mechanism for the establishment of HIV infection in the central nervous system (Liu et 
al. 2000).  Once HIV has been introduced to the central nervous system, it is able to 
infect microglial cells and other macrophages and may establish a persistent reservoir 
(Schnell et al. 2009).  Of note, microglial cells are extremely long-lived cells that can 
persist for decades in vivo (Lassmann et al. 1993).  While the ability of HIV to establish a 
latent infection in this cell type is poorly understood, microglia do appear to be resistant 
to the cytotoxic effects of HIV infection (Cosenza et al. 2004).  Further study is required 
to better understand the contribution of persistent HIV infection in the central nervous 




.  Committed mast cell progenitors (prMCs) have also been shown to be 
susceptible to HIV infection (Bannert et al. 2001).  Mast cells are tissue-resident immune 
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cells important in allergy, inflammation, and helminthic infection (Casale et al. 1987, 
Lantz et al. 1998).  Although HIV-1 cannot infect mature mast cells (Sundstrom et al. 
2007), HIV-1 can infect prMCs in peripheral blood (Bannert et al. 2001).  As prMCs 
eventually migrate to tissues, where they survive for at least ten months (Padawer et al. 
1974, Gurish et al. 2002), infection of prMCs could create a reservoir of HIV-1.  
 Recently, placental tissue mast cells were shown to harbor latent HIV in vivo in 
pregnant, HAART-treated women with detectable viral loads (Sundstrom et al. 2007), 
suggesting that infection of prMCs creates a reservoir in mast cells of patients with 
ongoing viral replication.  However, a recent study could not detect active HIV-1 
replication in tissue mast cells from ten donors (Nelson et al. 2009), suggesting that 
actively infected mast cells are rapidly cleared in successfully treated patients even 
though HIV-1 is not cytopathic in these cells (Sundstrom et al. 2007).  At present, the 
long-term significance of the possible mast cell reservoir is unclear, and it is not known 
whether a mast cell reservoir exists in HAART-treated patients with undetectable viral 
loads.  
 
Hematopoietic progenitor cells (HPCs).  The possibility that hematopoietic progenitor 
cells in the bone marrow serve as a reservoir for HIV has been debated for more than 20 
years and is the focus of the research presented in chapters 2-4 of this dissertation.  In this 
section, we will first describe hematopoiesis and the different types of hematopoietic 
progenitor cells that exist in humans; next, we will review the evidence for infection and 




 Hematopoiesis begins with hematopoietic stem cells (HSCs), cells that are 
capable of differentiating into all of the different blood cell lineages and that have the 
potential for indefinite self-renewal.  HSCs then differentiate into multipotent progenitor 
cells (MPPs), which can also give rise to all of the different blood cell lineages but have a 
more restricted capacity for self-renewal (Doulatov et al. 2012).  The immediate progeny 
of MPPs are two types of cells: common myeloid progenitors (CMPs), which can give 
rise to all of the myeloid cell lineages, and multilymphoid progenitors (MLPs) that can 
differentiate into all of the lymphoid lineages as well as some monocytes and dendritic 
cells (Doulatov et al. 2012).  These progenitor cells then differentiate into more 
committed progenitors and eventually into the mature blood cells found in the peripheral 
blood.  Hematopoietic differentiation is summarized in Figure 1.6. 
 Several cell surface markers and assays are commonly used to distinguish subsets 
of HPCs.  HPCs are often broadly characterized by the expression of the cell surface 
marker CD34, which is found on immature hematopoietic stem cells as well as more 
committed progenitors (Berenson et al. 1991, Leary et al. 1985).  The cell surface marker 
CD133 can be used to enrich for more immature HPCs with multilineage differentiation 
capacity (Yin et al. 1997).  Multipotency can be directly tested with the use of colony-
forming assays, which assess the ability of HPCs to form colonies in methylcellulose 
agar.  Cells are plated such that each colony will be formed from the proliferation of a 
single cell, then the cells are allowed to divide and differentiate for two weeks.  If 
multiple mature blood cell lineages are found in the final colony, it is clear that the 
initially plated cell had the capacity for multilineage differentiation.  However, 
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methylcellulose agar only supports the growth of myeloid lineages, and so this assay 
cannot be used to assess whether cells are HSCs or MPPs.  Xenograft assays in 
immunocompromised mice remain the gold standard for determining whether an HPC is 
a stem cell, as only HSCs are capable of long-term multilineage engraftment in mice 
(Christensen and Weissman 2001, Jones et al. 1990, Uchida and Weissman 1992).  The 
types of HPCs distinguished by these cell markers and assays are highlighted in Figure 
1.6. 
 




Evidence for HIV infection of HPCs.  A proportion of CD34
+
 cells express the HIV 
receptors CD4, CXCR4, and CCR5, making these cells potentially susceptible to HIV-1 
infection (reviewed in Alexaki and Wigdahl 2008).  Beginning more than twenty years 
ago, multiple studies suggested that HIV infection in CD34
+
 cells was possible, though 
rare, both in vitro and in vivo (Folks et al. 1988, Stanley et al. 1992, Slobold et al. 1996, 
Von Laer et al. 1990, Davis et al. 1991, Zauli et al. 1992, Neal et al. 1995).  However, 
these studies could not rule out contamination by other cell types.  Furthermore, studies 
assessing HIV-1 infection of more immature subsets of CD34
+
 cells, including 
multipotent colony-forming and CD133
+
 HPCs, failed to detect either HIV-1 infection or 
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expression of any of the three main HIV receptors in these cells (Chelucci et al. 1995, 
Shen et al. 1999, Hariharan et al. 1999, Weichold et al. 1998). 
 Based on these reports, there was a consensus that CD34
+
 cells are not an 
important target of HIV-1 infection and that HIV cannot infect multipotent HPCs at all.  
Recently, however, improved techniques have permitted reexamination of this topic, and 
this reexamination has unambiguously shown that immature, multipotent HPCs are 
susceptible to HIV infection.  First, a 2007 study investigated the ability of HIV-1 
subtype C to infect multipotent CD34
+
 HPCs in vitro and in vivo (Redd et al. 2007a).  
While the authors could not detect HIV-1 subtype B infection in HPCs capable of 
forming multilineage colonies, they found that several isolates of HIV-1C could infect 
multipotent cells.  Furthermore, the authors were able to detect HIV proviruses in CD34
+
 
cells from the peripheral blood of 12 out of 19 donors infected with HIV-1C (Redd et al. 
2007a).  Importantly, the level of HIV detected in 11/12 of these CD34
+
 samples was 
greater than the level observed in total peripheral blood mononuclear cells from the same 
patient, reducing the potential for contamination that plagued earlier studies (Redd et al. 
2007a).   
 While this study showed that HIV-1C infects multipotent HPCs, the ability of 
HIV-1B to infect multipotent HPCs remained ambiguous.  Redd and colleagues 
concluded that HIV-1B could not infect multipotent HPCs because they could not detect 
HIV DNA in multilineage colonies generated from HPCs exposed to HIV-1B isolates.  
However, the absence of HIV
+
 colonies could instead indicate that although HIV-1B can 
infect multipotent cells, the infection is cytotoxic either immediately or upon proliferation 
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and differentiation of the cells, leading to cell death rather than infected colony 
formation. 
 We undertook a study to definitively assess whether HIV-1B could infect 
multipotent HPCs (Carter et al. 2010).  Using a flow cytometric assay to detect the 
expression of HIV proteins in individual CD34
+
 cells after very short incubation periods 
(three days), we found that a variety of HIV-1B isolates could infect CD34+ cells derived 
from bone marrow or umbilical cord blood (Carter et al. 2010) (Figure 1.7A).  Because 
the virus was cytopathic to the cells, however, the number of infected cells declined 
dramatically over time. We furthermore showed that exposure of CD34
+
 cells to a non-
cytotoxic, GFP-expressing HIV-1B construct permitted the formation of multilineage 
colonies that were uniformly GFP
+
, demonstrating that HIV-1B infects multipotent HPCs 
in vitro (Carter et al. 2010) (Figure 1.7B).  
 We next examined whether CD34
+
 HPCs could support latent as well as active 
HIV-1 infection, a distinction that had not previously been assessed.  As noted above, the 
initially robust infection in CD34
+
 HPCs declined over time until active infection could 
no longer be observed (Carter et al. 2010).  If these cells were exposed to agents that 
stimulated myeloid differentiation, however, we observed a resurgence of viral gene 
expression (Carter et al. 2010) (Figure 1.7C).  This finding demonstrates that latent HIV-
1 infection of HPCs is possible in vitro.  
 Finally, our study assessed the infection of CD34
+
 bone marrow HPCs in HIV-
infected patients.  In a sample of HIV
+
 individuals with clinically detectable viremia (>50 





 cells from a subset of donors (Carter et al. 2010) (Figure 1.7D).  In the 
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remaining donors, we observed HIV Gag expression when we stimulated the CD34
+
 cells 
with cytokines to induce myeloid differentiation, thus demonstrating that latent HIV 
infection occurs in CD34
+
 cells in vivo (Carter et al. 2010).  CD34
-
 cells rapidly died 
under our culture conditions for CD34
+
 cells, thus minimizing the potential for 
contamination (Carter et al. 2010).  We also looked for HIV-1 proviral DNA in CD34
+
 
cells from a group of HIV-positive individuals on HARRT with clinically undetectable 
(<50 copies/mL) viral loads.  We detected HIV-1 DNA in CD34
+
 cells from more than 
40% of these donors; in each case, we did not detect comparable amounts of HIV DNA 
from bone marrow depleted for CD34, indicating that infected CD34
-
 bone marrow cells 
do not persist at similar levels in people on HAART (Carter et al. 2010) (Figure 1.7E).  
The sensitivity of this assay was low – we could detect HIV genomes in CD34+ cells 
only if at least 1 in 10,000 cells harbored an HIV genome.  This limit of detection is 
higher than the frequency of integrated genomes that have been observed in the resting 
CD4
+
 T cell reservoir in some patients (Chun et al. 1997); thus, it is likely that other 
patients in our cohort harbor HIV-infected CD34
+
 cells at a lower frequency.  The ability 
of CD34
+
 cells to harbor HIV DNA in vivo, even in patients undergoing successful 
HAART treatment, demonstrates that CD34
+
 cells can act as a long-lived reservoir of 
HIV. 
 Although we were readily able to detect HIV genomes in CD34
+
 cells from 
donors with undetectable viral loads on HAART, more recent studies have been unable to 
replicate these results (Durand et al. 2012, Josefsson et al. 2012).  Instead, these studies 
have suggested that contamination with T cells may account for the HIV genomes 






cells may not persist in patients who have had undetectable viral loads for many years of 
HAART (Josefsson et al. 2012).  While we found that CD34-depleted samples in our 
cohort harbored very little HIV DNA, making contaminating CD34-depleted cells 
unlikely to serve as a source of genomes in the CD34-sorted samples, we did not directly 
assess whether T cells were present in the CD34-sorted samples and whether these cells 
could contribute to the HIV genomes observed.  In chapter 4, we directly assess whether 
contaminating T cells might contribute to the HIV genomes detected in HPC samples and 
begin to examine whether there may be other differences in the methodology or donor 
cohorts used in these studies that can account for the discrepancies in our results. 
 
HIV infection and hematological abnormalities.  In addition to creating a latent viral 
reservoir, HIV infection of CD34
+
 cells might lead to HPC death and hematopoietic 
abnormalities.  Consistent with this possibility, many studies have reported hematopoietic 
defects associated with HIV infection (Adetifa et al. 2006, Calis et al. 2008, Dikshit et al. 
2009, Isgrò et al. 2005, Meira et al. 2005, Mlisana et al. 2008, Moses et al. 1998, Redd et 
al. 2007b), including the depletion of CD34
+
 bone marrow cells (Banda et al. 1999, Isgrò 
et al. 2008).  The existence of HIV-associated hematologic abnormalities is well known 
and has been attributed to a variety of factors, including altered stromal cytokine 
production (Isgrò et al. 2008) and use of specific antiretrovirals (Carr et al. 2000).  
Recently, however, Redd and colleagues were able to show a direct association between 
infection of CD34
+
 cells and anemia in their cohort (Redd et al. 2007a).  This evidence 
suggests that in addition to creating a latent reservoir of virus, HIV-1 infection of HPCs 
can cause HPC death that leads to defects in hematopoiesis. 
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A model of HIV infection in multipotent HPCs.  Based on the studies described above, we 
have developed the following model describing HIV infection of HPCs in vivo (Figure 
1.8).  When multipotent HPCs become infected with HIV, there are two possible 
outcomes: either an active infection leads to HPC death, contributing to the HIV-
associated hematologic abnormalities described above, or a latent infection occurs.  If 
latent infection occurs in a cell with self-renewal capacity, such as a hematopoietic stem 
cell, continued self-renewal can generate a long-lived reservoir of latent HIV.  If a 
latently infected daughter cell is stimulated to differentiate, however, the latent virus 
reactivates, leading to the death of the cell and further contributing to hematologic 
dysfunction.  Viral reactivation also results in virion release, contributing to the low-level 
viremia observed even in HAART-treated patients. 
 One consequence of this model is that defective HIV-1 proviruses incapable of 
reactivation should be detectable in multiple hematopoietic lineages that cannot be 
infected by HIV-1.  The presence of such defective proviruses in CD8
+
 T lymphocytes 
and granulocytes was reported in one patient (Kaneda et al. 2001); however, a second 
study detected only minimal integration of HIV genomes in naïve CD8
+
 cells from 
patients and could not rule out contamination by other cell types (Brenchley et al. 2004).  
Additional studies are required to determine whether defective HIV-1 genomes can be 
observed in CD8
+






 Although HAART therapy dramatically prolongs the life expectancy of HIV-
infected people, it is unable to eradicate the virus.  The ability of HIV to establish a latent 
infection has been proposed as the major mechanism for viral persistence in spite of 
HAART.  Resting memory CD4
+
 T cells are known to harbor latent HIV genomes in 
optimally treated individuals (Finzi et al. 1997, Finzi et al. 1999); however, there is 
substantial evidence suggesting that these cells are not the sole or even primary source of 
residual plasma virus during HAART treatment or rebounding virus upon cessation of 
therapy (Bailey et al. 2006, Brennan et al. 2009).  Thus, it has been proposed that an 
additional reservoir of virus must exist. 
 We have recently proposed that bone marrow hematopoietic progenitor cells may 
serve as an additional reservoir of latent HIV.  As described above, we have shown that 
CD34
+
 HPCs can be actively and latently infected by multiple HIV isolates both in vitro 
and in vivo (Carter et al. 2010).  Based on these findings, we have proposed a model of 
latent HIV infection in HPCs in which latent virus is maintained and expanded through 
the self-renewal of immature hematopoietic progenitor cells, but can be reactivated upon 
progenitor cell differentiation.  These reactivation events would result in viral release, 
potentially contributing to the residual viremia observed during HAART, as well as to the 
death of the infected progenitor cell, potentially contributing to the hematopoietic 
abnormalities observed in HIV-infected patients. 
 To substantiate the model of HIV infection in HPCs described above, further 
study is required to understand whether long-lived HPCs can serve as a latent reservoir 
for virus.  Although we have observed that HIV genomes persist in CD34
+
 HPCs during 
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months of treatment, it remains to be seen whether the lifespan of these cells is sufficient 
to serve as a barrier to HIV eradication in vivo.  To address this point, it is important to 
assess whether the most long-lived HPCs, hematopoietic stem cells (HSCs), are 
susceptible to infection by HIV.  This point will be addressed in Chapter 2.  Furthermore, 
although we have shown that HIV can infect multipotent HPCs, it is not known whether 
these cells can be latently infected or whether they support only active infection.  This 
point will be addressed in Chapter 3.  Finally, it is important to determine whether a more 
immature subset of HPCs, those expressing CD133 in addition to CD34, harbor HIV 
genomes in HIV
+
 individuals with undetectable viral loads and whether these cells persist 
in patients who have had undetectable viral loads for more than 5 years.  These findings 
would demonstrate the potential of HPCs to serve as a long-term reservoir of latent virus 
in vivo.  Chapter 4 addresses these questions. 
 A better understanding of the viral and cellular factors involved in the 
establishment of latent infection in HPCs would help us to understand whether all HIV-
infected individuals are likely to harbor latent infection in HPCs and how we might be 
able to reverse this latent infection to eliminate the reservoir of virus in these cells.  The 
impact of HIV-1 envelope tropism on the infection of different subsets of HPCs will be 
addressed in Chapter 2, while Chapter 3 will examine the cellular factors that promote 
latent infection in HPCs and strategies through which latent infection in these cells can be 
reactivated.  Together, these studies further our understanding of the potential of HPCs to 
serve as a latent reservoir of virus and bring us closer to discovering how latent reservoirs 




Figure 1.1. Prevalence of HIV in different regions of the world.  Prevalence is expressed 




Figure 1.2.  HIV disease progression.  The course of HIV infection in terms of CD4
+
 T 
cell counts and HIV plasma viral loads in an untreated patient (upper panel) or a patient 
on highly active antiretroviral therapy (HAART) (lower panel).  The clinical limit of 




Figure 1.3.  HIV structure, genome organization, and life cycle.  A. Structure of the 
mature viral particle.  B. Genome organization.  The LTR and structural proteins are in 
white, regulatory proteins in black, and accessory proteins in grey.  C. Generalized HIV-
1 life cycle.  Binding of the HIV virion to the cellular receptors CD4 and CXCR4/CCR5 
as well as viral gene transcription are highlighted in green as they will be focused on in 
chapters 2 and 3, respectively.  Parts A and C were modified from the original by Daniel 
Beyer under the Creative Commons Attribution-Share Alike 3.0 Unported license 
(original file available at: http://commons.wikimedia.org/wiki/File:HIV_gross.png; 




Figure 1.4. Factors associated with the HIV-1 LTR in activated vs. resting CD4
+
 T cells.  
Factors associated with the LTR in activated T cells, which support high levels of HIV 
gene expression, are shown above the HIV-1 LTR while factors associated with the LTR 
in resting T cells, which support latent HIV infection and repress HIV transcription, are 
shown below the HIV-1 LTR.  In activated T cells, the NF-!B p50/p65 heterodimer 
recruits histone acetyltransferases (HAT) and promotes gene expression; meanwhile, 
HIV-1 Tat recruits positive transcription elongation factor B (P-TEFb) to the 
transactivation response element (TAR) to promote transcript elongation by RNA 
polymerase II (RNAP II).  Additional transcription factors, including activator protein-1 
(AP-1) or nuclear factor of activated T cells (NFAT), may also promote viral gene 
expression.  In resting T cells, the NF-!B p50/p50 homodimer and the transcriptional 
repressor YY1 recruit histone deacetylases (HDAC) and repress gene expression.  P-
TEFb is sequestered by HEXIM1 and the 7SK snRNA and HIV-1 Tat is absent. DNA 





Figure 1.5. Model for the establishment of latency in resting memory T cells.  Activated 
T cells that become infected with HIV may occasionally revert to a resting state prior to 
viral cytotoxicity, resulting in viral latency instead of cell death.  Direct infection of 
resting T cells may also generate latently infected cells.  Homeostatic proliferation of the 






Figure 1.6. Hematopoiesis.  Hematopoietic stem cells (HSC) with extensive self-renewal 
capacity differentiate into multipotent progenitor cells (MPP).  MPPs then differentiate 
into either multilymphoid progenitors (MLP) or common myeloid progenitors (CMP).  
MLPs further differentiate into B/NK cell precursors (B/NK) or monocyte/dendritic cell 
precursors (MDP) or into committed T cell progenitor cells.  Meanwhile, CMPs 
differentiate into megakaryocyte/erythrocyte progenitors (MEP) or granulocyte/monocyte 
progenitors (GMP), the latter of which can also differentiate into MDPs or into 
committed granulocyte progenitor cells.  These progenitors then give rise to a series of 





Figure 1.7.  Summary of recent findings on HIV infection in HPCs.  A. Infection of 
HPCs by HIV molecular clones.  Umbilical cord blood (UCB)-derived CD34
+
 HPCs 
were infected with NL4-3, 89.6, 94UG114.1, MJ4, or YU-2.  48 hours post-infection, 
cells were analyzed for CD34 and intracellular Gag expression by flow cytometry.  
 40 




 cells.  The shaded overlays represent 
mock-treated CD34
+
 cells stained with an isotype-matched control antibody.  B. HIV 
infects multipotent HPCs.  CD34
+
 UCB were infected with a highly deleted, GFP-
expressing HIV construct (HIV-7SF-GFP) pseudotyped with the dual tropic 89.6 HIV 
envelope.  Three days after infection, GFP
+
 HPCs were sorted by FACS and plated in 
methylcellulose agar at single-cell density.  Colonies were photographed 14-18 days 
later.  CFU-E, colony forming unit-erythroid; CFU-M, colony-forming unit-macrophage; 
CFU-GM, colony forming unit-granulocyte/macrophage; BFU-GEMM, burst forming 
unit-granulocyte, erythrocyte, megakaryocyte, macrophage (multilineage colony).  C. 
Latent HIV infection can be established in HPCs in vitro.  CD34
+
 UCB were infected 
with HIV-1 NL4-3 (0 d), then cultured in a cytokine cocktail to maintain the cells in an 
immature state (CC110).  Gag expression in infected cells was evaluated beginning 48 
hours post-infection.  Cells were stained with the dead cell exclusion reagent 7-AAD, 
permeabilized, stained with an antibody to Gag, and analyzed by flow cytometry.  When 
less than 0.1% of live, initially CD34
+
 cells were Gag
+
 (d7), the cells were stimulated 
with GM-CSF and TNF-# in the presence (GMR) or absence (GM) of the integrase 
inhibitor raltegravir.  Gag expression in all conditions was evaluated 3 and 7 days after 
stimulation.  D. Active HIV infection occurs in vivo.  Flow cytometric analysis of HIV-1 






BMMCs.  The 
middle plots show background staining with an isotype control for the Gag-specific 
antibody (Anti-Gag) only.  Numbers are the percentage of gated cells falling within the 
indicated region.  Lin, lineage markers (cocktail of markers for mature blood cell 
lineages).  E. HIV DNA is found in CD34
+
 HPCs from donors with clinically 
undetectable viral loads.  Shown is the real-time PCR analysis of HIV genomes from 
donor CD34
+
 or immunodepleted cells.  The limit of detection was approximately one 
HIV genome per 10,000 cells.  Means +/- s.d., n = two independent experiments with 




Figure 1.8. Model of HIV-1 infection in hematopoietic progenitor cells.  Multipotent 
hematopoietic progenitor cells (HPCs) can become infected with HIV-1, leading either to 
active infection, cell death, and virion release, or to latent infection.  Latently infected 
HPCs with self-renewal capacity will then continue to self-renew, generating an 
expanded reservoir of latent HIV-1 in these cells.  If the host cell is stimulated to 
differentiate, the latent virus reactivates, leading to cell death and virion release. 
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HIV-1 Utilizes the CXCR4 Chemokine Receptor to Infect Multipotent 





 HIV infection is characterized by gradual immune system collapse and 
hematopoietic dysfunction. We recently showed that HIV enters multipotent 
hematopoietic progenitor cells and establishes both active cytotoxic and latent infections 
that can be reactivated by myeloid differentiation. However, whether these multipotent 
progenitors include long-lived hematopoietic stem cells (HSCs) that could establish viral 
reservoirs for the life of the infected person remains unknown. Here we provide direct 
evidence that HIV targets long-lived HSCs and show that infected HSCs yield stable, 
multilineage engraftment in a xenograft model. Furthermore, we establish that the 
capacity to use the chemokine receptor CXCR4 for entry determines whether a virus will 
enter multipotent versus differentiated progenitor cells. Because HSCs live for the 
lifespan of the infected person and are crucial for hematopoietic health, these data may 
                                                
4
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explain the poor prognosis associated with CXCR4-tropic HIV infection and suggest 
HSCs as long-lived cellular reservoirs of latent HIV. 
 
Introduction 
 The natural course of HIV disease is characterized by progressive destruction of 
the host immune system, manifested as a decline in CD4
+
 T cell counts over several 
years. Depletion of CD4
+
 T cells invariably causes an immunocompromised state in the 
host, leading to the onset of AIDS and ultimately death from opportunistic infections. 
Despite extensive study, the exact mechanisms triggering the progression to AIDS remain 
unclear. 
 HIV entry into permissive cells is mediated by interactions of the HIV envelope 
(Env) protein with CD4 and a chemokine coreceptor (CCR5 or CXCR4 (Alkhatib et al. 
1996, Deng et al. 1996, Dragic et al. 1996, Feng et al. 1996)). Initial transmission is 
mediated primarily by CCR5-utilizing (R5-tropic) HIV (Lathey et al. 1999, van't Wout et 
al. 1994) and R5-tropic isolates are more commonly detected early in disease (reviewed 
in Margolis and Shattock 2006), but eventually, X4-tropic isolates predominate in most 
infected individuals (Richman and Bozzette 1994, Shankarappa et al. 1999). The 
conversion of HIV Env from R5-tropic to X4-tropic requires only a small number of 
changes in the Env V3 region. This conversion has been associated with more rapid 
disease progression manifested as reduced CD4
+
 T cell counts and a poor clinical 
prognosis (Connor et al. 1997, Daar et al. 2007, Karlsson et al. 1994, Scarlatti et al. 1997, 
Schuitemaker et al. 1992, Shepherd et al. 2008, Waters et al. 2008, Weiser et al. 2008, Yu 
et al. 1998, Zhou et al. 2008). Furthermore, in the rare instances when infection is 
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initiated by dual or X4-tropic HIV, CD4 counts decline rapidly and disease progression is 
sometimes accelerated (Sheppard et al. 2002, Yu et al. 1998). It is not clear whether the 
conversion to CXCR4-tropic virus plays a causal role in disease progression or whether 
other factors account for this association. 
 CD4
+
 T cells, myeloid cells and subsets of HSPCs express HIV receptors (CD4 
(Morrison and Weissman 1994) and CCR5 or CXCR4 (Carter et al. 2010, Ishii et al. 
1999, Majka et al. 1999, Peled et al. 1999, Shen et al. 1999, Viardot et al. 1998), but 
whether HSPCs can be infected has been controversial in the literature (Folks et al. 1988, 
Redd et al. 2007, Shen et al. 1999, Stanley et al. 1992, Zhang et al. 2007) and there is 
evidence that these cells may be relatively resistant to infection (Shen et al. 1999, Zhang 
et al. 2007).  Recent reports indicate that low-level infection of multi-potent HSPCs 
occurs in vivo and in vitro (Carter et al. 2010, Redd et al. 2007) but active infection is 
cytotoxic and hard to detect in long term culture (Carter et al. 2010). Importantly, the 
assays used in these studies could not distinguish whether infected cells were long-lived 
hematopoietic stem cells (HSCs) or short lived common myeloid progenitor cells.  Thus, 
it is still unknown whether HIV infects HSCs, a subset of HSPCs defined by their ability 
to stably engraft and generate multiple lineages upon transplantation into 
immunocompromised mice. The distinction between HSCs and other multipotent 
hematopoietic progenitor cells (HPCs) is of key importance, as infection of the long-lived 
HSC population would have a greater impact on hematopoiesis and this population would 
have greater potential to serve as a long-term reservoir of HIV in infected people. 
 In this study, we provide evidence that HIV Envs can target HSCs and that 
integration can occur within these cells. Moreover, we show that HIV Env tropism 
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influences which subset(s) of HSPCs are infected: only CXCR4-tropic envelopes permit 
entry into multipotent HSPCs, including HSCs. These findings suggest not only that 
HSCs can become infected by HIV and thus have the potential to serve as a long-term 
reservoir of virus, but also that the association between the emergence of CXCR4-tropic 
isolates and declining CD4
+




 Recent work has indicated that bone marrow CD34
+
 HSPCs from HIV
+
 donors 
are targets of HIV infection in vivo (Carter et al. 2010). In this study, three of six donors 
with high viral loads had evidence of active HIV infection of bone marrow CD34
+
 cells. 
In the remaining three donors, active infection could be induced by culturing the cells in 
GMCSF and TNF# (Carter et al. 2010). However, CD34+ cells are a heterogeneous 
population and it is not known whether stem cells or multipotent progenitor cells are 
infected in HIV
+
 people. Healthy stem cells and multipotent progenitor cells are needed 
to maintain all hematopoietic lineages as well as normal bone marrow cellularity. Thus, it 
is expected that infection of primitive HSPCs by HIV would eventually be reflected in a 
loss of total bone marrow mononuclear cells. To examine this, we quantified the bone 
marrow cellularity of high viral load (>50,000 copies/ml) donors (Carter et al. 2010) who 
had relatively normal complete white blood cell counts (Figure 2.1a).  Interestingly, we 
found a striking correlation between the number of mononuclear cells isolated from 10 
ml of aspirate and the year of diagnosis (Figure 2.1b). This correlation was more 
significant in our cohort (p<0.03) than the correlation between CD4 cell count and year 
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of diagnosis (p=0.12, Figure 2.1c) and was significant even when an outlier with a very 
high cell count was excluded (p<0.02, Figure 2.1d).  A second cohort of patients with 
undetectable (<48 copies/ml) viral loads on highly active antiviral therapy (HAART) was 
also studied (Figure 2.1a). In this group, HIV genomes could be detected within CD34
+
 
cells from 40% of donors but Gag expression was only detectable after culturing the cells 
in GMCSF and TNF#, consistent with latent infection of this cell type (Carter et al. 
2010). In this group, we observed no correlation between bone marrow cellularity and 
year of diagnosis (Figure 2.1e) or between CD4 cell count and year of diagnosis (Figure 
2.1f).  These data provide in vivo support for a potent effect of HIV on the bone marrow 
that requires active viral replication. While this effect may be due to the chronic 
inflammation associated with unsuppressed HIV replication, it is also consistent with 
direct infection of multipotent HSPCs by HIV. 
 
X4-tropic Envs infect multipotent HSPCs. The conversion of HIV Env from R5-tropic to 
X4-tropic is associated with more rapid disease progression manifested as reduced CD4
+
 
T cell counts and a poor clinical prognosis (Connor et al. 1997, Daar et al. 2007, Karlsson 
et al. 1994, Scarlatti et al. 1997, Schuitemaker et al. 1992, Shepherd et al. 2008, Waters et 
al. 2008, Weiser et al. 2008, Yu et al. 1998, Zhou et al. 2008). To determine whether 
chemokine receptor expression influences the type of HSPC infected by HIV, we tested a 
panel of HIVs differing only in the Env they contained. These virus particles were 
generated by co-transfecting a GFP-expressing minimal HIV construct (HIV-7SF-GFP, 
Figure 2.2a (Yam et al. 2002)), which expresses GFP but no HIV proteins, along with a 
packaging-null/env-null HIV genome and an HIV env-expressing plasmid (Carter et al. 
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2010). The resulting virus particles thus contain unmodified HIV proteins, including Env, 
integrase, and reverse transcriptase. Once the HIV genome is integrated into the genome 
of the target cell, however, new HIV proteins are not transcribed and instead GFP is 
expressed from the constitutively active SFFV promoter. These viral supernatants were 
used to infect HSPCs isolated by magnetic sorting.  After infection, the cell surface 
phenotype of GFP-positive cells was determined by flow cytometry.  
 Remarkably, we found that both the X4-tropic Env HXB and the R5X4-tropic 
Env 89.6 were able to target various cell types, including cells with a surface phenotype 




) (Figure 2.2b-c). Infection 
occurred both when the cells were infected by spin infection and when cells were pulsed 
with virus for 2h at 37°C (Figure 2.3). In contrast, the R5 tropic Envs YU-2 (Figure 





 cells inefficiently; most infection was seen in cells with a surface 




). Similar results were 
observed in ten replicate experiments using three different CCR5-tropic Envs and sixteen 
replicates using three different CXCR4- or dual-tropic Envs (summarized in Fig 2.2d).   
 We performed additional experiments using full length HIVs encoding CXCR4-
tropic Env (NL4-3) or CCR5-tropic Env (94UG114.1.6), except that in this case we 
detected infection by expression of intracellular Gag. As shown in Figure 2.2e, we again 
found that CXCR4-tropic NL4-3 was able to infect cells with a surface phenotype 




). In contrast, CCR5-tropic 94UG114.1.6 only 





) (Figure 2.2e). Collectively, these findings indicate that wild type X4- 
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and R5-tropic HIVs target distinct subsets of HSPCs and that X4-tropic viruses have an 
increased capacity to target cells with surface markers characteristic of multipotent 
HSPCs.  
 
X4-tropic HIVs infect multipotent HSPC. To test whether X4-tropic HIVs were capable 
of infecting multipotent HSPCs, we asked whether the targeted cells formed multilineage 
colonies in culture. For these experiments, cord-blood derived HSPCs were infected with 
the minimal HIV construct HIV-7SF-GFP pseudotyped with HXB Env (X4-tropic) or 
YU-2 Env (R5-tropic) (Figure 2.4a). The use of this construct was critical for these 
experiments because wild type HIV kills actively infected HSPCs within a few days 
(Carter et al. 2010), making it difficult to determine the developmental capacity of the 
targeted cell type by colony formation as this assay takes weeks. 
 Three days after infection with HIV-7SF-GFP, the GFP
+
 cells were purified 
(>95% pure, Figure 2.4b), and 6000 GFP
+
 cells from each infection were plated in 
methylcellulose medium. After two weeks, colonies were analyzed for morphology and 
GFP expression. We found 140 erythroid (CFU-E), 158 myeloid (CFU-GM), and 30 
multilineage (CFU-GEMM) colonies generated from cells infected with HXB enveloped 
virus (Figure 2.4c-d). CFU-GEMM colonies form only from hematopoietic stem cells 
(HSCs), multipotent progenitor cells and common myeloid progenitors, indicating that 
the HXB envelope permitted entry into one of these immature HSPC types. In contrast, 
HSPCs infected with YU-2 enveloped virus gave rise to about ten-fold fewer colonies, 
primarily small granulocyte/macrophage colonies (Total of 14 CFU-E, 23 CFU-GM, and 
3 CFU-GEMM; Figure 2.4c-d).  
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 To determine whether the capacity to infect multipotent HSPCs was consistently 
associated with chemokine receptor use, we analyzed additional Envs (Figure 2.4d). In 
each case, we found X4-tropism or dual-tropism (NL4-3 and 92HT593) associated with 
infection of cells able to generate multilineage colonies. In contrast, cells infected using 
R5-tropic Env (BaL and 94UG114.1.6) largely lacked this capacity; we observed only 2 
CFU-GEMM colonies generated from cells infected with HIV-7SF-GFP pseudotyped 
with BaL Env and none from cells infected using 94UG114.1.6 Env (Figure 2.4d-f). 
These findings demonstrate that X4-tropic Envs have the capacity to infect multipotent 
HSPCs, whereas R5-tropic Envs primarily infect more mature HSPCs. 
 
CD4 and CXCR4 receptor use is required for infection of primitive HSPCs. We 
hypothesized that infection of primitive HSPCs with X4-tropic Envs occurred by the 
canonical mechanism, wherein HIV Env triggers membrane fusion after binding CD4 and 
CXCR4 on the target cell. While this is the most common scenario, numerous reports 
have documented HIV infection by CD4-independent mechanisms, usually involving the 
use of CXCR4 alone to facilitate entry (Endres et al. 1996, Hoxie et al. 1998, Liu et al. 
2004, Saha et al. 2005, Zerhouni et al. 2004). To explore this possibility, we treated cord-
blood derived HSPCs and CEM T cells with the CD4-blocking antibody L3T4 before 
infecting the cells with HIV-7SF-GFP pseudotyped with the dual tropic 89.6 Env. As 
expected, pre-treatment with CD4-blocking antibody substantially reduced infection of 
CEM T cells (Figure 2.5a). Pretreatment of HSPCs with CD4-blocking antibody 
inhibited infection even more robustly, causing a near-complete block in infection 
(Figure 2.5a). These data demonstrate that infection of HSPCs is strictly dependent on 
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CD4.  Moreover, CD4 antibody treatment blocked infection of all cells tested, those with 




) as well as more 
mature progenitors, suggesting that infection of all HSPCs is CD4-dependent (Figure 
2.5b). 
 As described above, infection of multipotent HSPCs by various HIVs correlates 
with their capacity to use CXCR4 for entry (Figure 2.4). These data likely reflect the 
expression pattern of chemokine receptors on multipotent HSPCs (i.e. that multipotent 
HSPCs express CXCR4 more widely than CCR5) (Carter et al. 2010). A less likely 
possibility was that some multipotent HSPCs express both chemokine receptors but that 
the X4-tropic Env is required for another function other than entry, or that signaling 
through CXCR4 is required for productive infection. To distinguish these possibilities, 
we asked whether blockade of CXCR4 would reduce infection of multipotent HSPCs by 
dual-tropic HIV Envs. We tested this approach using two related T cell lines: CEM-SS, 
which expresses only CXCR4, and CEM-R5, which expresses both CXCR4 and CCR5. 
These cells were treated with the small molecule CXCR4 antagonist AMD3100 
(Donzella et al. 1998) and infected with HIV-7SF-GFP pseudotyped with the dual-tropic 
Env 92HT593. As expected, AMD3100 blocked infection of CEM-SS cells almost 
completely but only partially blocked infection of CEM-R5 cells, demonstrating use of 
CCR5 by 92HT593 Env in these cells (Figure 2.5c).  
 We then treated cord blood-derived HSPCs with AMD3100 or maraviroc (CCR5-
blocking) and infected the cells with HIV-7SF-GFP pseudotyped with 89.6 Env. We 
found that not only did AMD3100 reduce the rate of infection in total HSPCs, it nearly 




 cells (Figure 2.5d). By contrast, maraviroc did 
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 cells by 89.6-pseudotyped HIV-7SF-GFP 
(Figure 2.5d) but did eliminate infection of HSPCs when we used the R5-tropic Env YU-
2 (Figure 2.5e). We further observed that when we infected HSPCs with HIV-7SF-GFP 





 cells to rates comparable to those observed with the R5-tropic 





 HSPCs express CXCR4 at higher levels than CCR5 (Figure 2.5g-h). 
We confirmed the low levels of CCR5 on these cells functionally with a calcium flux 
assay to assess response to CXCR4 and CCR5 ligands (Figure 2.6a-b) and with an acid 
wash to confirm that bound ligand was not masking CCR5 on these cells (Figure 2.6c). 
Finally, to assess whether crosslinking of CXCR4 could permit entry by CCR5-tropic 
virus, we infected CD133
+
 HSPCs with HIV-7SF-GFP pseudotyped with YU2 Env in the 
presence or absence of full-length NL4-3. We then examined GFP expression in the 
infected populations to determine which cell types were infected by the R5-tropic virus 




 Next, we treated cord-blood derived HSPCs with AMD3100 or maraviroc and 
infected with HIV-7SF-GFP pseudotyped with dual-tropic 89.6 Env. We sorted GFP
+
 
cells from AMD3100-treated, maraviroc-treated, and control-treated cultures and plated 
the cells in methylcellulose medium. Infected control-treated and maraviroc-treated cells 
formed numerous erythroid, myeloid and multilineage colonies (Figure 2.7a), whereas 
infection of AMD3100-treated colony-forming cells was dramatically reduced (Figure 
2.7b). Treatment with maraviroc (Figure 2.7c) or AMD3100 (Figure 2.7d) had no effect 
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on colony formation by uninfected cells. These data show that CXCR4 usage is necessary 
for the infection of multipotent HSPCs by HIV and that CCR5 cannot substitute.            
     
X4-tropic HIVs infect HSCs capable of multilineage reconstitution of 
immunocompromised mice. Having demonstrated that HIV can infect multipotent 
HSPCs, we next asked whether HIV could infect hematopoietic stem cells (HSCs) 
capable of stably engrafting irradiated NOD/SCID IL-2R"
null
 mice. Stable multilineage 
reconstitution in immunocompromised mice can be accomplished only by engraftment of 
hematopoietic stem cells, and thus this is a definitive assay for infection of HSCs 
(Christensen and Weissman 2001, Jones et al. 1990, Osawa et al. 1996, Uchida and 
Weissman 1992). Because we observed little infection of multipotent HSPCs with R5-
tropic HIV Envs, we used only X4-tropic Env for these experiments. We infected 
purified CD133
+
 cells with replication defective, minimal HIV (HIV-7SF-GFP) 
pseudotyped with X4-tropic HXB Env (Figure 2.8a, upper panel). Three days after 
infection, GFP
+
 cells were enriched to 40-70% purity (Figure 2.8a, lower panel) and 
intrafemorally injected into sublethally irradiated NOD/SCID IL-2R"
null
 mice. In all, 13 
animals were injected with infected CD133
+
 cells and 4 were injected with mock-




 cells for two 
reasons: first, to minimize loss of infected cells that would occur with more stringent 
purification; and second, to enable us to distinguish between mice that specifically failed 
to engraft infected (GFP
+
) cells and those that failed to engraft at all due to technical 
error. 
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 Because the HIV genome we used was not cytotoxic and expressed GFP from a 
constitutively active promoter, we were able to detect infected, mature peripheral blood 
cells that were the progeny of the originally infected HSPCs. The use of this construct 
thus enabled us to evaluate the developmental potential of all infected HSPCs, whereas 
we have previously shown that when HSPCs are infected with replication-competent 
HIV, the actively infected cells die rapidly (Carter et al. 2010).   
 Beginning 4 weeks after transplantation and continuing monthly for 20 weeks 
after transplantation, peripheral blood was collected from the mice and analyzed for GFP 





in the periphery of all four mice that received mock-infected transplants (animals 1-4 in 
Table 2.1 and Figure 2.9 and animals 1-2 in Figure 2.10). In addition, we detected 
human cells in 7 of 13 mice that received infected HPC transplants (animals 5-11 in 
Table 2.1 and Figure 2.10, animals 5-10 in Figure 2.8b, and animal 11 in Figure 2.9). 
Of the mice that engrafted, 71% (5/7) had GFP
+
 cells, indicating successful engraftment 
of cells infected with an HXB-Env bearing virus (animals 5-9 in Table 2.1, Figure 2.8b, 
and Figure 2.10). Two of the seven mice engrafted human cells that were all GFP-
negative (animals 10 and 11 in Table 2.1, Figure 2.8b, Figure 2.9, and Figure 2.10). An 
example of one of the six mice that failed to engraft human cells is also shown (animal 12 





 human cells, several animals (animals 5-7, 10-11) engrafted only GFP
+
 or only 
GFP
-
 human cells. This is because only a small fraction of the transplanted cells have the 
capacity to engraft in the mouse, and these few cells account for all of the human cells 
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found in the peripheral blood.  Because so few cells actually engraft, it is not surprising 
that in some mice, all of the engrafting cells were GFP
+
 or all were GFP
-
. 
 Although the frequency of human cells varied widely in the engrafted mice (0.1-
9.6% human leukocytes, Table 2.1, Figure 2.8b and Figure 2.9), all mice that engrafted 











) cells in the periphery for at least 20 weeks after transplantation. In all cases, the 
frequency of GFP
+
 human cells in the peripheral blood increased after 8-10 weeks post-
transplant (Figure 2.10). As only HSCs can maintain multilineage reconstitution for 
more than 4-6 weeks in vivo, the increasing frequency of GFP
+
 cells at later time points 
clearly demonstrates that infected HSCs have engrafted. 




engraftments, T lymphocytes (CD3
+
) were slow to 
appear in peripheral blood, consistent with prior reports that human thymopoiesis is 
inefficient in NOD/SCID/IL-2R"
null
 mice after stem-cell transplantation (Lan et al., 




 cells, whereas these 
cells were not apparent at an early time point (compare Figure 2.8c 20 week time point 
for animal 9 with 16 week time point shown in Figure 2.8b). Additionally, animal 6 was 
sacrificed 26 weeks after transplantation and the tissues were examined for T cell 
chimerism. As shown in Figure 2.8d, human CD3
+
 cells were present in both bone 
marrow and spleen. Thus, T cells were clearly present in at least 2 of 5 mice that stably 






 The identification and eradication of long-lived cellular reservoirs is necessary to 
cure HIV and eliminate the need for lifelong therapy. We have previously demonstrated 
that HIV can infect multipotent HSPCs, establishing both active and latent infections 
(Carter et al. 2010). Here we demonstrate that, similar to infection of T cells, infection of 
multipotent HSPCs depends on CD4. However, based on the panel of Envs we tested, 
robust infection of primitive HSPCs capable of generating multilineage colonies in soft 
agar only occurs with CXCR4- or dual-tropic viruses. Blockade of CXCR4 dramatically 
reduced infection of multipotent hematopoietic cells by dual-tropic HIVs. In contrast, the 
R5-tropic HIVs we tested had only minimal infectivity in multipotent HSPCs and 
blockade of CCR5 had no effect on infection of multipotent cells by dual-tropic HIVs.  
 The simplest explanation for the inability of CCR5-bearing viruses to infect 
multipotent HSPCs is that CCR5 is not expressed at high enough levels to support 
infection. An alternative hypothesis is that engagement of R5-tropic Envs with the CCR5 
chemokine receptor affects the ability of multipotent HSPC to form colonies or is toxic to 
the cells. This hypothesis is less likely because dual-tropic HIVs able to bind both 
CXCR4 and CCR5 can infect cells with a multipotent phenotype. In addition, we have 






 HIV infection of multipotent HSPCs could lead to the presence of viral genomes in 
multiple hematopoietic lineages. However, HIV is primarily detected in myeloid and T 
cells, but not in B cells. This apparent enigma may be explained by the fact that active 
infection of HSPCs leads to the upregulation of markers of apoptosis and rapid depletion 
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of infected cells from the culture (Carter et al. 2010). Thus, the lack of evidence for HIV 
genomes in B cells in infected people may be due to the fact that active HIV infection 
kills early HSPCs, preventing the development of infected cells in some lineages (Carter 
et al. 2010). Latent infection can also occur in HSPCs, but induction of differentiation 
may induce viral activation and subsequent cell death (Carter et al. 2010).  
 We have also determined that HIV infects HSCs that are capable of stable, 
multilineage engraftment in irradiated NOD/SCID IL-2R"
null
 mice. All of the mice that 
were successfully transplanted with infected HSPCs demonstrated multilineage 
engraftment of infected, GFP
+
 human cells. These results have significant implications 
for viral persistence because HSCs are capable of long-term self-renewal in vivo. Thus, 
latently infected HSCs would persist indefinitely, forming a long-term viral reservoir. 
Additionally, based on our prior results (Carter et al. 2010), active infection can trigger 
cell death in multipotent HSPCs. If a sufficient number of HSPCs were infected, the 
subsequent death of these cells could disrupt the entire hematopoietic cascade. Over 
many years, this disruption could impact the function of the bone marrow. Unfortunately, 
the toxicity of wild type HIV precluded us from generating sufficient numbers of infected 
cells to test whether wild type virus from patient samples infects cells in vivo that have 
the capacity to engraft. The experiments presented here were only possible with the use 
of replication defective HIV constructs that do not express additional cytotoxic HIV 
proteins following integration.  
 The findings in this study appear to conflict with previous reports indicating that 
HSCs are resistant to infection with HIV-1 as well as with lentiviral constructs 
pseudotyped with HIV Envs (Shen et al. 1999, Weichold et al. 1998, Zhang et al. 2007). 
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The mechanism by which HIV-1 infection of HSCs is purported to be blocked has been 
inconsistent: one study found that the block was solely at the level of entry due to 
insufficient expression of viral receptors and that VSVG-pseudotyped viral particles 
could efficiently infect HSCs (Shen et al. 1999), whereas another group found that there 
was a post-entry block to infection mediated by p21 (Zhang et al. 2007). The apparent 
difference between our findings and those of previous groups can be explained by low 
rates of infection (typically less than 2%) that rapidly decline over time because of the 
cytoxitcity of the virus. Such infection rates are too low to yield detectable infection with 
many of the non-flow cytometric assays used in previous studies, especially those that 
require that the cells be cultured for more than a couple days. The use of recently 
optimized culture conditions for HSPCs (Zhang et al. 2008) has allowed us to increase 
infection rates in these cells due to improved health of the cells. The previously described 
blocks to infection likely contribute to the low infection rates that we observe in HSPCs, 
but importantly, we show that these blocks are not absolute and that X4-tropic HIVs can 
infect HSCs at a low but significant rate. 
 In sum, we have shown that multipotent HSPCs and HSCs can be infected by 
HIV and that this infection is primarily accomplished by CXCR4-tropic HIVs. The 
infection and destruction of multipotent HSPCs may contribute to the more rapid decline 
in CD4 counts associated with CXCR4-tropic HIV isolate emergence. Alternatively, as 
infected HSCs could create an extremely long-lived reservoir of virus, preferential 
infection of these cells by CXCR4-tropic virus could provide a reservoir for the 
emergence of CXCR4-tropic isolates late in disease: as other viral reservoirs are depleted, 
CXCR4-tropic virus from the HSC and HSPC reservoir could begin to predominate. In 
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addition, our demonstration that HIV can infect cells capable of stably engrafting for 
months in the xenograft model indicates that HIV can infect HSCs that are capable of 
self-renewal and, if the integrated viral genome is latent, that it can be maintained and 
even expanded by cell division.  
 Based on these data, there should be a renewed focus on primitive hematopoietic 
progenitors as an important reservoir for HIV that will require eradication to improve the 
treatment of HIV-infected people. Our data suggesting that a subset of HSCs and other 
primitive hematopoietic progenitors could function as a latent reservoir for HIV raise the 
possibility that combining HIV therapies with approaches to activate HSCs might deplete 




Antibodies and reagents. Antibodies to the following proteins were used for flow 
cytometry: CD34 (FITC-conjugated, BD biosciences), CD34 (APC-conjugated, Caltag), 
CD34 (647-conjugated, eBioscience), CD133 (PE-conjugated, Miltenyi Biotech), CD133 
(biotin-conjugated with streptavidin-APC/Cy7 (eBioscience)), Gag (FITC-conjugated, 
Coulter), Gag (PE-conjugated, Coulter), CD45 (APC/Cy7-conjugated, BD Biosciences), 
CD33 (PE-conjugated, BD Biosciences), CD3 (PE/Cy5-conjugated, BD Biosciences), 
CD19 (APC-conjugated BD Biosciences), CD4 (BD Biosciences), CXCR4 (PE/Cy7–
conjugated, eBioscience), CCR5 (PE-conjugated, eBioscience), mouse IgG (FITC-
conjugated, Invitrogen). For receptor blocking experiments, functional grade antibody 
against CD4 was used (clone L3T4, eBioscience). 
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 The env gene expression plasmid pcDNA-89.6env was created as described 
(Carter et al. 2010). pcDNA-94UGenv was created by digesting p94UG114.1.6 with XbaI 
and SmaI. The resulting 3021-nucleotide fragment was then ligated to pcDNA3.1 (+), 
which had been digested with ApaI, blunted by Klenow treatment and digested with 
XbaI. We created the env gene expression plasmid pEBB-NLenv by digesting pNL4-3 
with SalI and NotI and blunting the resulting fragment by Klenow treatment. The 
resulting fragment was then ligated into pEBB that had been digested with NotI and 
blunted by Klenow treatment.  
 
Cell culture.  We obtained pre-existing umbilical cord blood lacking subject identifiers 
after scheduled cesarean section procedures. We obtained fresh whole bone marrow 
aspirates from a commercial source (AllCells Ltd.). We prepared BMMCs and UCB 
mononuclear cells by Ficoll-Paque density separation (GE Healthcare) according to the 
manufacturer's instructions. UCB-MNC were frequently cryopreserved in 10% DMSO in 





adherence-depleted mononuclear cells with commercially available kits (positive 
selection MACS, Miltenyi Biotech). After isolation we maintained HSPCs in STIF 
medium (StemSpan or Stemline II medium supplemented with 50ng/ml SCF, 50ng/ml 
TPO, 100ng/ml IGFBP-2, and 50ng/ml Flt3-L)
 
(Zhang et al. 2008).  
 We conducted methylcellulose colony-forming assays according to the 
manufacturer's recommendation (Methocult H4034, StemCell Technologies). Colonies 
were scored based on morphology using an inverted brightfield microscope at 40x or 
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100x magnification. CFU-GEMM morphology was verified at high power (200x). GFP 
expression was analyzed on an inverted epifluorescent microscope. 
 
HIV preparation.  We prepared infectious supernatants by transfection of proviral 
plasmids into 293T cells using polyethylenimine. For pseudotyped viruses, we 
concentrated supernatants with high-molecular-weight polyethylene glycol precipitation 




 the original volume of 
StemSpan medium and stored at -80°C. Virus infectivity was determined by infection of 
CEM-SS or CEM-R5 cells under identical conditions. MOI were calculated by applying 
the percent of infected CEM-SS cells to the formula MOI = -Ln (1-p) where p is the 
proportion of cells infected. We conducted HIV infections with a standard spin infection 
technique for primary cells (1048.6 x g for two hours at room temperature) or by 
incubating the cells with virus at 37°C for two hours. 
 
Flow cytometry.  We stained cells in FACS buffer (2% FBS, 1% human serum, 2mM 
HEPES, 0.025% NaN3/PBS) for 10-20 minutes on ice, washed and fixed them in 2% 
paraformaldehyde/PBS. For intracellular Gag staining, we then incubated the cells for 5 
min in 0.1% Triton X-100 in PBS at 25 °C. We incubated washed cells with anti-Gag 
antibody in FACS buffer for 30 minutes on ice. We analyzed the cells on a FACScan or 
FACSCanto flow cytometer. We excluded dead cells using 7AAD.  
 
For analysis of murine peripheral blood, we lysed erythrocytes with IO Test 3 lysis buffer 
(Beckman-Coulter) and we stained leukocytes as described above. We analyzed cells on 
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a FacsCantoII analyzer. We excluded dead cells from analysis by DAPI uptake and we 
excluded cell doublets using FSC-A/FSC-H ratio.  
 
We sorted cells with a FACSVantage SE or FACSAria cytometer (Becton Dickinson). 
For high-purity sorting, we used normal-R mode with a 1.0 sorted drop envelope. For cell 
enrichment, we sorted cells in enrich mode with a 1.0 sorted drop envelope.  
 
For the calcium flux assay, cells were suspended in cell loading media (RPMI with 2% 
FBS and 25mM HEPES) and loaded with 1.5µM Indo-1 AM. Cells were incubated at 
37°C for 45 minutes, then washed twice and resuspended in FACS buffer. Surface 
staining was conducted as described above. Following surface stain, cells were 
resuspended in cell loading media and equilibrated at 37°C for 30-60 minutes prior to 
analysis. EGTA was added 1 hour prior to analysis. Samples were analyzed using a 
FACSDiVa cyotmeter (BD). For the acid wash assay, cells were incubated in pH 2.7 
glycine buffer for 1 minute, then washed with 9 ml PBS and stained as above except that 
serum-free buffer (PBS + 0.1% BSA was used). 
 
Mice.  Nonobese diabetic severe combined immunodeficiency mice lacking the 
interleukin-2 gamma receptor (NOD/SCID IL-2R
null 
mice, strain NOD.CB17-Prkdcscid 
Il2rgtm1Wjl/Szj, (Jackson Laboratory)) were maintained at the University of Michigan 
by the Unit for Laboratory Animal Medicine. All experiments were conducted in 
accordance to with research protocols approved by the University Committee on the Use 
and Care of Animals. 
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Mouse transplantation. We cultured cord blood-derived CD133
+
 cells for 4 days in STIF 
medium to expand HSCs prior to infection. We then infected the cells with HIV-7SF-
GFP pseudotyped with HXB2 Env. After three days, we sorted GFP-positive cells, rested 
them overnight in STIF medium and then transplanted them into sublethally irradiated 
mice (340cGy). We used a Hamilton syringe fitted with a 27Ga needle to inject 25µL of 
cells in PBS into the femur. We gave the transplanted mice antibiotic water (1.1gl 




 cells from HIV-infected donors.  HIV
+
 individuals were recruited 
from the University of Michigan HIV/AIDS Treatment Program Outpatient Clinic. The 
human subjects protocol was approved by the Institutional Review Board and General 
Clinical Research Center and, as outlined in the protocol, all subjects signed informed 
consent documents. Using sterile procedure, a Jamshidi needle was used to aspirate one 
mL of marrow aspirate from the posterior iliac crest. The sample was evaluated for 
spicules to ensure adequate quality, and then ten ml of marrow aspirate was obtained in 
preservative free heparin. The subjects experienced no adverse events from the 
procedure. The bone marrow mononuclear cells were prepared by density separation 
using Ficoll-Paque (GE healthcare) according to the manufacturer’s instructions, and 
total mononuclear cells were counted. 
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Table 2.1.  Summary of murine xenotransplantation results.  Animals 1-4 were injected with mock-infected HPCs and successfully 
engrafted.  Animals 5-11 were injected with virus-treated HPCs and were successfully engrafted with human cells.  Animals 12-17 
were injected with virus-treated HPCs but did not successfully engraft.  Percents of human and GFP
+
 cells are percents of total 
peripheral blood leukocytes at 14-18 weeks after transplant.  *T cells present at 20 week time point (Figure 2.8c).  **T cells present in 
bone marrow (Figure 2.8d).  See also Figure 2.10. 
Animal Number of cells 
transplanted 
Condition % Human 
Leukocytes 
% of Human Leukocytes 
that are GFP+ 
% of GFP+ Human 
Leukocytes that are: 
     Myeloid B cells T cells 
1 50,000 Mock 0.6 0.0 - - - 
2 50,000 Mock 0.1 0.0 - - - 
3 100,000 Mock 0.1 0.0 - - - 
4 150,000 Mock 0.1 0.0 - - - 
5 50,000 7SF-GFP/HXB 0.1 98 16 78 0.0 
6 50,000 7SF-GFP/HXB 1.4 100 4.9 92 0.1* 
7 100,000 7SF-GFP/HXB 0.4 99 19 56 0.0 
8 150,000 7SF-GFP/HXB 9.6 16 6.9 88 0.0 
9 150,000 7SF-GFP/HXB 0.5 46 7.7 77 0.0** 
10 100,000 7SF-GFP/HXB 1.4 0.0 - - - 
11 100,000 7SF-GFP/HXB 0.6 0.0 - - - 
12-17 150,000 7SF-GFP/HXB 
(No engraftment) 
0.0-0.03 0.0 - - - 
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Figure 2.1. Total bone marrow mononuclear cells are correlated with year of diagnosis in 
HIV
+
 donors with high viral loads. (a) Complete blood count of HIV
+
 donors with high 
viral loads (1-6 and A1-A3, 61,000 to 202,000 copies/ml) and low viral loads (7-16, <48 
copies/ml). (b) The number of purified bone marrow cells versus year of diagnosis for 
high viral load donors.  (c) CD4 counts of high viral load donors at the time of bone 
marrow aspiration plotted as a function of year of diagnosis. (d) As (b), but with an 
outlier with a high mononuclear cell yield (Donor 5) removed. (e) The number of purified 
bone marrow cells versus year of diagnosis for low viral load donors. (f) CD4 counts of 









 HSPCs. (a) Schematic of 
HIV-7SF-GFP construct and generic HIV envelope plasmid used to construct viruses 
used in b-d. (b and c) Flow cytometric analysis of cord-blood derived CD133
+
 cells 
infected with a minimal HIV (HIV-7SF-GFP (Yam et al. 2002)) that lacked expression of 
HIV gene products and was pseudotyped with the indicated HIV Env. In this construct, 
GFP is expressed from a heterologous promoter (Yam et al. 2002). Cells were analyzed 
three days post-infection. The left panels show the GFP
+
 gating.  These events were 
overlaid in green on the right plots that also show staining of the total cell population in 
grey. Isotype control staining is shown in the top panel. The percentage of GFP
+





 is shown in the upper right hand corner (d), Summary plot of 
HIV-1 Env data. Results are compiled from ten experiments with CCR5-tropic Env 
proteins (94UG114.1.6, 8 replicates; YU-2, one experiment; ZM53M.PB12, one 
experiment) and sixteen experiments with CXCR4 and dual tropic Env proteins (HXB2, 
8 replicates; 89.6, 7 replicates; 92HT593, 1 experiment); error bars are standard error of 
the mean. ***p<0.0001.  (e) Upper panel, schematic of full-length HIV used in lower 
panel. Lower panel, flow cytometric analysis of cord-blood derived CD133
+
 cells three 
days post infection with full length, wild type HIVs. NL4-3 has an X4-tropic Env and 
94UG114.1.6 has an R5-tropic Env. Gag
+
 cells were gated on in the left panels, and these 
events (red dots) were overlaid on CD34 vs. CD133 plots in the right panels to determine 
the immunophenotype of the infected cells compared with the total cell population (grey 
















 cells without spin infection. Flow 
cytometric analysis of UCB-derived HPCs infected with HIV-7SF-GFP pseudotyped 
with the 89.6 dual-tropic HIV Env either by spin infection in the presence of polybrene 
for 2 hours at room temperature (Spin) or by incubation with virus for 2 hours at 37° 
(Pulse). The cells were analyzed three days after infection. GFP
+
 cells are shown on the 
left; in the right panel, the GFP
+
 cells were overlaid on plots of the total cell population. 
Numbers indicate the percentage of cells that are infected (left) or percent of infected 




Figure 2.4. CXCR4-tropic HIV Envs infect HSPCs with the capacity to form 
multilineage colonies. (a) Schematic of HIV-7SF-GFP construct and generic HIV 
envelope plasmid used to construct viruses used in b-e. (b) Flow cytometric analysis of 
cord-blood derived CD133
+
 cells infected with HIV-7SF-GFP pseudotyped with HXB 
(X4-tropic) or YU2 (R5-tropic) Env proteins, and purified by flow sorting. (c) Example 
colonies identified after culturing cells isolated as shown in part (b) for 14 days.  Phase 
contrast and epifluorescence microscopy are shown (erythroid, CFU-E; myeloid, CFU-
GM; or multilineage, CFU-GEMM). (d) Quantification of colony formation for the 
experiment shown in part (c) and for two similar experiments using other HIV Envs as 
indicated (erythroid, CFU-E; myeloid, CFU-GM; or multilineage, GFU-GEMM). The 
total number of colonies from 6 replicate wells is displayed. (e) Summary of colony 
formation results. Data were compiled from five independent experiments using six 
different Env proteins. The average normalized number of colonies observed with 
CXCR4- or dual-tropic Env versus CCR5-tropic Env is depicted. Error bars represent 
standard deviation and p-values were determined using the two-tailed Student’s T test 
(erythroid, CFU-E; myeloid, CFU-GM; or multilineage, GFU-GEMM). (f) Summary 













 HSPCs is dependent on CD4 and CXCR4. (a) 
Flow cytometric analysis of cord blood-derived CD133
+
 HSPCs or CEM T cells pre-
incubated with anti-CD4 antibody (L3T4, 20µg/mL) or control antibody and then 
infected with HIV-7SF-GFP pseudotyped with 89.6 Env. The cells were analyzed three 
days post-infection. The numbers in the right panels are fold inhibition of infection. (b) 
Flow cytometric analysis of cord blood-derived CD133
+
 HSPCs pre-incubated with 
control antibody or antibody to CD4 (L3T4, 20µg/mL) and then infected with HIV-7SF-
GFP pseudotyped with 89.6 Env. The cells were analyzed three days after infection. 
GFP
+
 (red) cells are overlaid on the total population (grey). (c) Flow cytometric analysis 
of CEM-SS (CXCR4-expressing) or CEM-R5 (CXCR4 and CCR5 expressing) cells 
treated with 10µg/mL AMD3100 or an equal volume of DMSO and then infected with 
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HIV-7SF-GFP pseudotyped with the dual tropic HIV Env 92HT593. The cells were 
analyzed three days post-infection. The percent GFP
+
 cells are shown in the numbers 
above each gate. Results are representative of two independent experiments. (d-f) Flow 
cytometric analysis of cord-blood derived CD133
+
 cells infected with HIV-7SF-GFP 
pseudotyped with the dual-tropic 89.6 (d) or 92HT (f) HIV Envs or the R5-tropic YU-2 
HIV env (e) in the presence and absence of 20µM maraviroc (R5-blocking) or 10µg/mL 
AMD3100 (X4-blocking). The cells were analyzed three days after infection. GFP
+
 cells 
(red) are overlaid on the total population (grey). (g) Flow cytometric analysis of CD133
+
 
UCB cells expanded 4-7 days in STIF media and then stained for the indicated cell 
surface markers. Samples stained with isotype control antibodies for CD133 and CD34 
(top) or with antibodies to CD133 and CD34 but isotype control antibodies for CD4, 
CXCR4, and CCR5 (middle) were included to determine gating. Numbers indicate the 





 cells that express both of the indicated receptors for three independent 










 cells. a. Flow cytometric analysis of 
Indo-1 violet (bound to calcium) normalized to Indo-1 blue (free Indo-1) in UCB CD133
+
 
cells loaded with Indo-1 AM calcium sensor dye and labeled with CD133-Pe.  Cytokines 
were added at the indicated time, each at 200ng/ml. b. Quantification of experiment 
shown in a. The fold increase in the Indo-1 Violet / Indo-1 Blue ratio at the peak of the 
calcium flux, normalized to EGTA-loaded samples (negative control) is shown. 
Ionomycin (1µg/ml) is a positive control for maximum calcium flux. c. Flow cytometric 
analysis of UCB CD133
+
 cells treated with acidic glycine buffer (pH 2.7) to remove 
bound ligand and stained for CD133, CD34, and CCR5 or isotype control in serum free 
buffer. 7AAD was used to exclude dead cells. CD133 vs. CD34 plots are shown on the 




 cells is shown on the 
right. d. Flow cytometric analysis of UCB CD133
+
 cells infected with HIV-7SF-GFP 
pseudotyped with R5-tropic YU2env, full length NL4-3 (X4-tropic), or both viruses 
simultaneously. Three days after infection, cells were analyzed for CD34, CD133, GFP, 
or HIV Gag (far right panel only). Plots show the total cell population with GFP
+
 cells 
(left 3 panels) or Gag
+
 cells (far right panel) overlaid. The results show no increase in 
entry of CCR5-tropic virus with CXCR4-tropic co-infection.
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Figure 2.7. Infection of multipotent cells requires CXCR4. (a and b) Colony formation 
by cord blood-derived HSPCs treated with 20µM maraviroc (a) 10µg/mL AMD3100 (b) 
or an equal volume of DMSO, infected with HIV-7SF-GFP pseudotyped with the dual 
tropic HIV Env 89.6 and purified by FACS. Two blinded counters analyzed the colonies 
14 to 18 days after plating in methylcellulose medium. Data are represented as number of 
colonies per 100 cells plated. The mean of the two scorers’ counts is shown. (c and d) 
Colony formation by CD133
+
 UCB mock-infected in the presence of 20µM maraviroc (c) 
or 10µg/mL AMD3100 (d) or an equal volume of DMSO and plated in methylcellulose 
three days after exposure. Colonies were scored after two weeks by two blinded counters. 






Figure 2.8. CXCR4-tropic HIV can infect HSCs that stably engraft and generate multiple 
lineages in NOD/SCID IL2!
null
 mice. (a) Upper panel, schematic of HIV-7SF-GFP and 
HXB envelope plasmid used to construct virus used in lower panel. Lower panel, flow 
cytometric analysis of cord blood derived CD133
+
 HPCs infected with HIV-7SF-GFP 
pseudotyped with HXB Env after three days in culture.  Cells in the right panel were 
sorted for GFP positivity. (b) Flow cytometric analysis of peripheral blood from 
transplanted mice 16-18 weeks post transplant. Leukocytes that were positive for human 
CD45 and negative for mouse CD45 were gated in the left panels. The right panels show 
staining of the indicated markers within this subpopulation. CD33, myeloid; CD3, T cell; 
CD19, B cell (c) Flow cytometric analysis of peripheral blood cells harvested 20 weeks 
post transplantation in animal 9. (d) Flow cytometric analysis of bone marrow and spleen 





Figure 2.9. Analysis of mice that did not engraft with GFP
+
 hematopoietic cells. Flow 
cytometric plots of peripheral blood from NOD/SCID IL2!null mice 14-18 weeks post-
transplant with mock-infected CD133
+
 cells or CD133
+
 cells infected with HIV-7SF-GFP 
pseudotyped with Hxb Env as described in the text. Peripheral blood was analyzed for 





 leukocytes were gated on in the left panels and GFP, CD33, CD3 and CD19 
expression were analyzed within this subpopulation.  Note that neither the mice 
transplanted with mock-infected cells nor mice 10, 11, or 12 transplanted with infected 










 human cells. 
The percentage of human cells in the peripheral blood of transplanted mice over time is 
shown. a. Mice that engrafted only GFP
-
 cells. Mice 1 and 2 were transplanted with 




 cells but 
engrafted only GFP
-
 cells. b. Mice that engrafted only GFP
+
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Latent HIV-1 Infection Occurs in Multiple Subsets of Hematopoietic Progenitor 
Cells and Is Reversed by NF-!B Activation5 
 
Abstract  
 The ability of HIV-1 to establish a latent infection presents a barrier to curing 
HIV.  The best-studied reservoir of latent virus in vivo is in resting memory CD4
+
 T 
cells, but it has recently been shown that CD34
+
 hematopoietic progenitor cells (HPCs) 
can also become latently infected by HIV-1 in vitro and in vivo.  CD34
+
 cells are not 
homogenous, however, and it is not yet known which types of CD34
+
 cells support a 
latent infection.  Furthermore, the mechanisms through which latency is established in 
this cell type are not yet known.  Here we report the development of a primary cell model 
for latent HIV-1 infection in HPCs.  We demonstrate that in this model, latent infection 
can be established in all subsets of HPCs examined, including HPCs with cell surface 
markers consistent with immature hematopoietic stem and progenitor cells.  We 
furthermore show that the establishment of latent infection in these cells can be reversed 
                                                
5
 This chapter has been published as: 
McNamara L, Ganesh J, and Collins K.  Latent HIV-1 Infection Occurs in Multiple 
Subsets of Hematopoietic Progenitor Cells and Is Reversed by NF-!B Activation.  J Virol 
2012; 86(17):9337-50. 
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by TNF-! through an NF-"B-dependent mechanism.  By contrast, we do not find 
evidence for a role of P-TEFb in the establishment of latent infection in HPCs.  Finally, 
we demonstrate that prostratin and suberoylanilide hydroxamic acid (SAHA), but not 
hexamethylene bisacetimide (HMBA) or 5-Aza-2’-deoxycytidine (Aza-CdR), reactivate 
latent HIV-1 in HPCs.  These findings illuminate the mechanisms through which latent 
infection can be established in HPCs and suggest common pathways through which latent 
virus could be reactivated in both HPCs and resting memory T cells to eliminate latent 
reservoirs of HIV-1. 
 
Introduction  
 Although highly active antiretroviral therapy (HAART) for HIV-1 suppresses 
viral replication and extends the lifespan of infected individuals, it cannot eliminate the 
virus (Finzi et al. 1999, Gulick et al. 1997, Hammer et al. 1997, Zhang et al. 1999).  A 
major barrier to viral eradication is the ability of HIV-1 to establish a latent infection 
(Finzi et al. 1999, Zhang et al. 1999).  Latent infection occurs when a replication-
competent HIV-1 provirus integrates into a host cell’s genomic DNA, but viral genes are 
not transcribed (reviewed in Geeraert et al. 2008).  Because no viral proteins are 
produced, the immune system cannot eliminate latently infected cells.  At any point, 
however, cellular changes can reactivate the latent virus, leading to the production of new 
viral particles and, in the absence of antiretroviral therapy, the infection of additional 
cells (reviewed in Trono et al. 2010).  Thus, reactivation of latent virus can lead to a 
resurgence of viremia in patients who have discontinued antiretroviral therapy. 
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 While reactivation of latent virus can lead to increased viremia, reactivating latent 
virus in a patient who is receiving HAART therapy could clear latent reservoirs while 
preventing new infection events.  Cells harboring reactivated virus would be eliminated 
because they produce viral proteins, leading to cell death through the action of the 
immune system or viral cytotoxic effects.  Reactivation of virus from latently infected 
cells has thus been proposed as a strategy to cure HIV-1. Unfortunately, efforts to use this 
strategy to eliminate HIV-1 infection have thus far been unsuccessful (reviewed in 
Geeraert et al. 2008).  There thus remains an urgent need for research to determine both 
the cell types that harbor latent virus as well as the mechanisms underlying the 
establishment and reactivation of latent infection in all latently infected cell types.  
 Although resting memory T cells are the best-studied and likely largest reservoir 
of latent HIV-1, several studies have found that not all viral genomes in the plasma can 
be matched to sequences in these cells (Bailey et al. 2006, Brennan et al. 2009, Sahu et al. 
2009).  These findings suggest that additional reservoirs of latent virus exist and 
contribute to residual plasma viremia.  Recently, we proposed that CD34
+
 hematopoietic 
progenitor cells (HPCs) in the bone marrow serve as a reservoir of HIV-1 and 
demonstrated that active and latent infection of these cells occur in vitro and in vivo 
(Carter et al. 2010).  These findings are supported by additional studies demonstrating 
that HPCs are infected by HIV-1 in vivo (Redd et al. 2007, Stanley et al. 1992).  
However, there are also conflicting studies reporting that HIV-1 genomes could not be 
detected in CD34
+
 cells in the bone marrow of patients with undetectable viral loads on 




 HPCs are rare cells, and only an extremely low rate of latent infection 
would be expected in most HAART-treated patients.  This is particularly true in patients 
with predominantly CCR5-tropic virus, as only CXCR4-utilizing HIV is able to infect 
immature HPCs (Carter et al. 2011).  In addition, it is difficult to rule out the possibility 
that contaminating CD4
+
 T cells in HPC samples contribute to the detection of HIV 
genomes in these cells.  Thus, it may be difficult to definitively show whether latent 
infection of HPCs occurs in a majority of individuals: indeed, disagreement on this point 
has persisted through more than two decades of study (reviewed in McNamara and 
Collins 2011).  However, latent infection can be readily established in HPCs in vitro 
(Carter et al. 2010), and thus in vitro systems can be used to assess which subtypes of 
HPCs become latently infected.  Such studies can illuminate the potential of HPCs to 
serve as a reservoir in vivo by demonstrating whether long-lived HPCs can be latently 
infected.  In addition, they can identify the HPC types most likely to harbor latent 
infection, suggesting cell types to selectively purify in future efforts to identify latent 
reservoirs in vivo.  Finally, in vitro studies can assess whether the mechanisms that 
promote the establishment and reactivation of latent infection in HPCs are comparable to 
those at work in CD4
+
 T cells, and thus whether both reservoirs might be targeted and 
eliminated with similar reactivation strategies.  For these reasons, an in vitro examination 
of latent infection of CD34
+
 HPCs provides valuable information to aid in both the search 
for latent reservoirs and the development of strategies to reactivate and eliminate latent 
virus in vivo. 
 CD34
+
 HPCs are not homogenous, and it is not clear which subsets of CD34
+
 
cells support latent HIV-1 infection.  The most immature HPCs are hematopoietic stem 
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cells (HSCs), which can differentiate into all blood cell lineages and have unlimited self-
renewal capacity.  HSCs differentiate into multipotent progenitor cells (MPPs), which 
also differentiate into all blood cell lineages but have reduced self-renewal capacity 
(Doulatov et al. 2010).  MPPs give rise to common myeloid progenitors (CMPs), which 
give rise to all myeloid lineages, and multilymphoid progenitors (MLPs), which generate 
the lymphoid lineages as well as monocytes and dendritic cells (Doulatov et al. 2010).  
These progenitors give rise to committed progenitor cells that eventually differentiate 
into mature blood cells.  While we recently showed that HIV-1 is capable of infecting 
multipotent HPCs, including hematopoietic stem cells, the ability of HIV-1 to establish a 
latent as opposed to active infection in these cells is unknown (Carter et al. 2011). 
 The mechanisms that promote latency in HPCs have not been investigated, but 
models of latent infection in T cells have identified mechanisms that promote latent 
infection in this cell type (Bosque and Planelles 2009, Lassen et al. 2012, Saleh et al. 
2007, Tyagi et al. 2010, Yang et al. 2009).  In T cells, epigenetic modifications result in a 
heterochromatic structure at the HIV-1 long terminal repeat (LTR) (Kauder et al. 2009, 
Tyagi et al. 2010).  Histone methylation and histone deacetylase (HDAC) recruitment 
contribute to the formation of this restricted transcriptional state (Tyagi et al. 2010).  
DNA methylation has also been associated with latent infection in both Jurkat and 
primary T cell models of latency (Blazkova et al. 2009, Kauder et al. 2009).  
Furthermore, resting memory T cells have restricted nuclear levels of nuclear factor !B 
(NF-!B) (Tyagi et al. 2010).  NF-!B, a key transcriptional regulator in many 
hematopoietic cells, is sequestered in the cytoplasm of resting cells by the inhibitor of !B 
(I!B) (reviewed in Vallabhapurapu and Karin 2009).  Upon T cell activation, 
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phosphorylation of I!B by I!B kinase (IKK) triggers the release of NF-!B from IkB and 
its translocation to the nucleus (Li et al. 1999, reviewed in Vallabhapurapu and Karin 
2009).  There, NF-!B can bind to the HIV-1 LTR, displacing inhibitory factors and 
recruiting histone acetyltransferases to relieve heterochromatic repression (Nabel and 
Baltimore 1987, Van Lint et al. 1996). 
 NF-!B activation alone is sufficient to reactivate latent virus in Jurkat cells 
(Duverger et al. 2009, Tyagi et al. 2010), but in primary resting memory T cells, 
activation of Positive Transcription Elongation Factor b (P-TEFb) is also required (Tyagi 
et al. 2010).  P-TEFb, a complex made up of the cyclin-dependent kinase 9 (CDK9) and 
Cyclin T1 (CycT1), is present only at low levels in resting CD4
+
 T cells, and much of the 
complex is sequestered by the 7SK small nuclear RNA and hexamethylene bisacetamide 
(HMBA)-induced protein (HEXIM1) (Nguyen et al. 2001, Yang et al. 2001, Yik et al. 
2003).  T cell activation results in increased P-TEFb mRNA transcription and protein 
translation (Herrmann et al. 1998) as well as the rapid phosphorylation of pre-existing 
CDK9 at Thr186 (Ramakrishnan et al. 2009) and dissociation of P-TEFb from 7SK RNA 
(Kim et al. 2011).  HIV-1 Tat assists in this process by competitively displacing HEXIM1 
to free P-TEFb from the inhibitory complex (Barboric et al. 2007, Sedore et al. 2007).  
Activated P-TEFb is then recruited to nascent HIV-1 transcripts, where it facilitates 
transcript elongation and thus reactivation of latent virus (Kim et al. 2011, Salerno et al. 
2007, Tyagi et al. 2010, Wei et al. 1998). 
 Compounds that counteract the factors promoting latency in T cells have been 
shown to reactivate latent virus in primary T cells or cell-line models.  Among these 
compounds are prostratin, which activates NF-!B through protein kinase C (Korin et al. 
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2002, Williams et al. 2004); HDAC inhibitors including suberoylanilide hydroxamic acid 
(SAHA) and valproic acid (VPA) (Contreras et al. 2009, Edelstein et al. 2009, Ylisastigui 
et al. 2004); the DNA methylation inhibitor 5-aza-2’-deoxycytidine (Aza-CdR) (Kauder 
et al. 2009); and hexamethylene bisacetamide (HMBA), a compound that appears to 
facilitate the release of P-TEFb from its inhibitory complex with 7SK and HEXIM1 
(Contreras et al. 2007).  Several of these compounds, notably SAHA, have been proposed 
as therapies to reactivate latent virus in vivo (Contreras et al. 2009, Edelstein et al. 2009, 
Ylisastigui et al. 2004).  However, if resting memory T cells are not the sole reservoir for 
latent virus, these compounds will be effective therapies only if they can reactivate virus 
in all additional HIV reservoirs as well. 
 In this paper, we develop an in vitro model system of latent HIV-1 infection in 
HPCs that permits detailed study of the factors promoting latency in these cells.  We use 
this model to show that HIV-1 is able to establish a latent infection in all subsets of HPCs 
examined, including cells with surface markers consistent with HSCs and MPPs.  We 
furthermore show that CD34
+
 HPCs have low nuclear levels of NF-!B and that NF-!B 
activation can reactivate latent virus in these cells.  Meanwhile, P-TEFb is readily 
detectable in the nuclei of unstimulated HPCs and is not increased under conditions that 
reactivate latent virus.  Finally, we assess the ability of compounds that reactivate latent 
virus in T cell systems to perform a similar function in HPCs.  We find that while 
prostratin and SAHA can reactivate latent infection in HPCs, HMBA and Aza-CdR 
cannot.  These findings enhance our understanding of the cellular factors required to 
establish a latent HIV-1 infection in HPCs and suggest common pathways in both HPCs 
and T cells that could be targeted to purge latent reservoirs. 
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Materials and Methods 
 
Cell Isolation and Culture. Whole umbilical cord blood (CB) was obtained from the New 
York Blood Center and whole bone marrow (BM) was obtained commercially (AllCells 
Ltd.); mononuclear cells were purified by Ficoll-Hypaque centrifugation and either 
frozen or used fresh.  Cells were adherence depleted for 1-2 hours at 37º C in StemSpan 
Media (STEMCELL Technologies), then CD133
+
 cells were isolated by magnetic 
separation (Miltenyi Biotech).  Isolated cells were cultured in STIF media (StemSpan 
supplemented with 100ng/ml SCF, 100ng/ml TPO, 100ng/ml Flt3L (all from 
STEMCELL Technologies), and 100ng/ml IGFBP-2 (R&D Systems)).  Pre-sorted 
CD133
+
 BM or CB cells were obtained commercially (AllCells Ltd.) and cultured as 
above. 
 Resting memory CD4
+
 T cells were purified from buffy coats obtained from the 
New York Blood Center.  Mononuclear cells were purified as above, then memory CD4
+
 
T cells were isolated by magnetic separation using the Memory CD4
+
 T Cell Isolation Kit 
(Miltenyi Biotech).  The resulting cells were incubated with biotinylated antibodies 
against the activation markers HLA-DR, CD69, and CD25 (eBioscience), then resting 
memory cells were isolated by negative selection using an anti-biotin magnetic separation 
kit (Miltenyi Biotech).  Resting memory CD4
+
 T cells were used immediately or cultured 
overnight with anti-CD3/anti-CD28 beads (Life Technologies). 
  U1 cells (Folks et al. 1987) and J-Lat clones 6.3, 8.4, and 9.2 (Jordan et al. 2003) 
were cultured in RPMI supplemented with 10% fetal bovine serum (FBS) and 2mM 
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penicillin, streptomycin, and glutamine (PSG).  293T cells were propagated in DMEM 
supplemented with 10% FBS and 2mM PSG. 
 
HIV-1 Virus Preparation and Transductions.  NL4-3-!GPE-GFP was generated by 
removing a SwaI-SwaI fragment from NL4-3-!E-GFP (Zhang et al. 2004) and religating. 
 Infectious supernatants were prepared by transfection of proviral plasmids into 
293T cells using polyethylenimine.  HXB-ePLAP (Chen et al. 1996) or NL4-3-!GPE-
GFP was cotransfected with a plasmid encoding either VSV-G or HXB envelope; the 
helper plasmid pCMV-HIV-1 (Gasmi et al. 1999) was additionally cotransfected to 
permit infectious particles to be formed with NL4-3-!GPE-GFP.  Viruses pseudotyped 
with HXB envelope were concentrated using high-molecular-weight polyethylene glycol 
precipitation as previously described (Kohno et al. 2002).   Pellets were resuspended in 
1/25 the original volume and used immediately.  Cells were infected by spin inoculation 
at 1048.6 " g for 2 hours at room temperature. 
 
Sorting and Stimulation of Latently Infected Cells.  Actively infected cells from HPCs 
infected with HXB-ePLAP were removed by magnetic sorting using a biotin-conjugated 
antibody to PLAP and anti-biotin beads (Miltenyi Biotech).  Actively infected cells were 
removed from samples infected with NL4-3-!GPE-GFP by flow cytometric sorting using 
a MoFlo XDP (Beckman Coulter), MoFlo Astrios (Beckman Coulter), or FACSAria (BD 
Biosciences) flow cytometer.  After sorting, cells were incubated in STIF or StemSpan 
with 8!M Raltegravir (Selleck Chemicals) alone or with one or more of the following: 
GM-CSF (R&D Systems), TNF-# (Biolegend), prostratin (Sigma), SAHA (Cayman 
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chemical), HMBA (Sigma), Aza-CdR (Sigma), IKK2 VI (Calbiochem), or functional 
grade anti-TNF-! (eBioscience). 
 
Time Course of Stimulation in Uninfected Cells.  Uninfected HPCs were cultured for 5 
days, then incubated in StemSpan with DMSO solvent control or TNF-!, prostratin, or 
SAHA for 3 days.  Images of cells under these conditions were acquired using a QICAM 
digital camera and Q-Capture Pro 7 software (QImaging).  Brightness and contrast of 
images were minimally adjusted using Canvas 8 (ACD Systems). 
 
Flow Cytometry and Antibodies. Antibodies to the following proteins were used for flow 
cytometry: CD133 (PE-conjugated, Miltenyi), CD3 (APC- or Alexa Fluor 647-
conjugated, eBioscience), CD34 (FITC, APC, Alexa Fluor 647, or biotin-conjugated, 
Miltenyi, eBioscience, and Invitrogen), CD45RA (PE-conjugated, eBioscience), CD38 
(PE-Cy7-conjugated, eBioscience), PLAP (Serotec) as provided or conjugated to biotin 
using EZ-Link Sulfo-NHS Biotinylation Kit (Pierce), and HIV-1 Gag (clone KC57, 
FITC-conjugated, Coulter).  Secondary reagents used were streptavidin (Alexa Fluor 488, 
PE, or Alexa Fluor 647-conjugated, Life Technologies) and antibody to mouse-IgG1 
(Alexa Fluor 647-conjugated, Invitrogen).  Cells were stained with 7-Aminoactinomycin 
D (7-AAD) to exclude dead cells.  Analysis was performed using a BD FacsCanto 
cytometer or BD FACScan with Cytek 6-color upgrade. 
 For staining cell surface proteins, cells were first incubated in FACS buffer (PBS 
with 2% FBS, 1% human serum, 2mM HEPES, and 0.025% NaN3) on ice for 10 minutes 
with directly conjugated antibodies, then washed and fixed in PBS with 2% 
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paraformaldeyde.  For stains utilizing antibodies against PLAP, cells were incubated in 
10% Fc receptor block (Accurate Chemical) in FACS buffer for 30 minutes, then 
incubated with antibodies against PLAP in FACS buffer with 10% Fc receptor block for 
15 minutes on ice.  Cells were then washed and stained with secondary antibody for an 
additional 5 (streptavidin) or 15 (anti-mouse-IgG1) minutes on ice.  For stains using 
antibodies against HIV Gag, cells were first fixed, then permeabilized with 0.1% Triton 
X-100 in PBS for five minutes at room temperature.  Cells were then washed and 
incubated with antibody against Gag for 30 minutes on ice. 
 
Transcription factor enzyme-linked immunosorbent assay (ELISA).  Nuclear and 
cytoplasmic extracts were prepared using a commercially available kit (Active Motif), 
then levels of activated nuclear NF-!B and AP-1 family members were determined using 
commercially available transcription factor ELISA assays (Active Motif).  Protein 
content of nuclear and cytoplasmic extracts was quantified and an equal amount of 
protein was plated for each condition.  Commercially obtained Raji nuclear cell extracts 
were used as a positive control for NF-!B activation and K-562 cells stimulated with 12-
O-tetradecanoylphorbol-13-acetate (TPA) were used as a positive control for AP-1 
activation (Active Motif).  Absorbance readings from blank wells were subtracted from 
all sample and positive control absorbance readings.  Then, readings were normalized to 
the positive control on each plate to control for differences in color development between 
plates.  Normalized absorbance in cytoplasmic extracts was subtracted from the 
absorbance in the nuclear extracts from each sample to control for non-specific binding.  
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These normalized differences were designated arbitrary units (AU) and used to compare 
samples.  In all cases, the signal from the positive control extract was set to 1 AU. 
 
Western blotting.  Nuclear extracts were collected as described above.  Antibodies to the 
following proteins were used for Western blot analysis: Cyclin T1 (Santa Cruz sc-8127); 
pCDK9 (Cell Signaling #2549), and Histone H1.4 (Sigma H7665). Secondary reagents 
used were rabbit antibodies directed against goat IgG and conjugated to horseradish 
peroxidase (HRP) (Zymed) and goat antibodies directed against rabbit IgG and 




Development of an in vitro model of HIV-1 latency in HPCs. Although latent infection of 
HPCs has been previously studied in vitro (Carter et al. 2010), the methods used required 
relatively long culture periods.  Because HPCs rapidly differentiate in culture, these 
methods did not permit the examination of latent infection in immature HPC subsets such 
as HSCs and MPPs.  To better assess latent infection in immature HPCs, we developed a 
short-term primary cell model of latency in CD133
+
 HPCs (Figure 3.1A).  This short 
term model allowed us to examine latent infection in immature HPCs, an important 
benefit as these cells are the most long-lived and thus the most likely to serve as a long-
term reservoir of virus in vivo.  However, the short culturing times required to study 
these cells in an undifferentiated state meant that while we could examine factors that are 
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important for the establishment of latency, we could not assess whether additional factors 
contribute to maintenance of proviral silencing at later time points. 
 In our model, primary HPCs were isolated on Day 0 from umbilical cord blood 
(CB) or bone marrow (BM) (Figure 3.1A).  Two days later, HPCs were infected with 
replication-defective HIV-1 reporter viruses, either HXB-ePLAP or NL4-3-!GPE-GFP 
(Figure 3.1B).  These viruses both have a deletion in the env gene while NL4-3-!GPE-
GFP has additional deletions in gag and pol, resulting in viruses that are capable of a 
single round of infection but not of continuing spread.  This feature of the viruses 
simplified our analysis by allowing us to distinguish reactivation of latent infection from 
stimulation of new infection events.  HXB-ePLAP encodes placental alkaline 
phosphatase (PLAP) as a reporter protein, which is expressed on the cell surface; NL4-3-
!GPE-GFP expresses EGFP (shortened to GFP throughout).  These viruses were 
pseudotyped with either VSV-G envelope or the HIV-1 envelope HXB (Figure 3.1B).  
Most experiments were conducted using VSV-G envelope to maximize the infection rate 
and increase the sensitivity of analysis, but major findings were confirmed using HXB 
envelope.  The CXCR4-tropic HXB envelope was selected for these experiments because 
we have previously shown that only HIV-1 envelopes able to use CXCR4 as a co-
receptor for entry can infect immature HPCs (Carter et al. 2011). 
 Three days after infection, actively infected cells expressing the reporter protein 
were removed by magnetic or flow cytometric sorting (Figure 3.1C); the remaining cells, 
a mixture of uninfected and latently infected cells, were resuspended in media with 8!M 
raltegravir (Figure 3.1A).  The integrase inhibitor raltegravir was routinely included in 
these experiments to ensure that increases in reporter gene expression would stem solely 
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from activation of integrated virus and not from new integration events.  Cells were then 
either incubated in STIF media, which contains a cocktail of cytokines that minimizes 
differentiation in culture, or were stimulated with GM-CSF and TNF-! or other 
compounds overnight.  Finally, samples were analyzed the next day by flow cytometry 




 at this time point were 
gated on so that only HPCs would be included in our analysis of latent infection. 
 We tested our model by stimulating latently infected cells with GM-CSF and 
TNF-!, which we have previously shown to be capable of reactivating latent virus in 
HPCs in vitro and ex vivo (Carter et al. 2010).  In agreement with our previous work, we 
found that overnight (13 hour) stimulation with GM-CSF and TNF-! resulted in a 2- to 
6-fold increase in reporter protein expression compared to unstimulated controls (Figure 
3.1D).  The rate of latent infection that could be reactivated with GM-CSF and TNF-! 
was comparable to the rate of active infection observed prior to sorting and stimulation 
(compare Figure 3.1C and D).  These results cannot be attributed to contamination of the 
culture with CD4
+
 T cells, as CD3
+
 cells are largely absent from our HPC cultures on the 
day of reactivation and are readily excluded by gating on CD34+ cells (Figure 3.1E). 
 
Latent Infection Occurs in Multiple HPC Subsets.  Although we have reported that HIV-1 
can infect multipotent HPCs, the ability of the virus to establish a latent infection in this 
cell subset was not established.  We therefore used our model to examine latent infection 
in HPCs expressing CD133, a cell surface marker found primarily on immature HPCs 
and associated with colony-forming capacity (Carter et al. 2011).  HPCs infected with 




 cells (Figure 3.1F), 
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then these cells were incubated overnight in STIF or GM-CSF and TNF-!.  Compared 
with the rate of infection in cells immediately post-sort (0.1%, Figure 3.1F), we observed 
spontaneous induction of active infection in a subset of cells (Figure 3.1G), which may 
result from spontaneous differentiation that occurs even in STIF.  Additionally, we 
observed a 2- to 4-fold increase in PLAP expression in CD133
+
 cells that were stimulated 
with GM-CSF and TNF-! compared to the STIF-treated control (Figure 3.1G-H), 
demonstrating that HIV-1 can establish a latent infection in CD133
+
 HPCs that can be 
reactivated by GM-CSF and TNF-! treatment. 
 To further define HPC populations in which latent HIV-1 infection occurs, we 
stained HPCs with antibodies against CD38 and CD45RA, cell surface markers for which 
expression on various HPC populations has recently been defined (Doulatov et al. 2010) 
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.  We infected and sorted the cells as 
described in Figure 1, then analyzed reactivation of latent virus in each of the populations 
defined by these cell surface antigens.  We found that we could reactivate latent virus in 






 subset that includes the most 
immature, long-lived HPCs (Figure 3.2B).  Similar results were obtained whether cells 
had been infected using VSV-G (Figure 3.2C and E) or HXB envelope (Figure 3.2B and 
D), and whether HPCs were derived from cord blood (Figure 3.2B-D) or bone marrow 
(Figure 3.2E).  These results demonstrate that latent infection does not occur in a specific 
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type of HPCs but rather in all cell subsets identified, including long-lived HSCs and 
MPPs with the potential to serve as a long-term reservoir for latent virus in vivo.  
 
Conditions that Reactivate Latent Virus in HPCs are Associated with Activation of NF-
!B but not AP-1.  We next assessed the cellular changes that occur when CD34
+
 HPCs 
are stimulated with GM-CSF and TNF-! to elucidate the mechanism by which these 
cytokines reactivate latent HIV-1.  We first examined whether nuclear levels of the 
transcription factors NF-"B or AP-1 are increased under these conditions.  We examined 
these factors because both have binding sites on the HIV-1 LTR, have been shown to 
promote HIV-1 transcription (Canonne-Hergaux et al. 1995, Nabel and Baltimore 1987, 
Richman et al. 1994, Roebuck et al. 1996, Van Lint et al. 1997, reviewed in Pereira et al. 
2000), and can be activated by TNF-! (reviewed in Aggarwall 2000 and Chen and 
Goeddel 2002). 
 Uninfected, cord blood-derived CD133
+
 HPCs were expanded in STIF media for 
5 days, then split into STIF vs. GM-CSF + TNF-! conditions for an overnight incubation.  
We isolated cytoplasmic and nuclear extracts from these cells and assessed levels of 
activated nuclear NF-"B and AP-1 transcription factor proteins by transcription factor 
enzyme-linked immunosorbent assay (ELISA).  We found that levels of activated nuclear 
NF-"B family members p65, p50, c-Rel, and RelB were all stimulated by overnight 
incubation with GM-CSF and TNF-! (Figure 3.3A), suggesting that these cytokines 
activate NF-"B through the classical pathway (reviewed in Vallabhapurapu and Karin 
2009).  In contrast, we found that nuclear NF-"B p52, which is mainly activated through 
the non-classical NF-"B pathway (reviewed in Vallabhapurapu and Karin 2009), was not 
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upregulated by GM-CSF and TNF-! stimulation (Figure 3.3A).  Additionally, no AP-1 
family member was upregulated by GM-CSF and TNF-! (Figure 3.3B).  Of the proteins 
studied, only AP-1 FosB and JunB could be consistently detected in the nuclei of HPCs 
incubated in STIF (Figure 3.3B).  The finding that NF-"B is usually undetectable in the 
nuclei of unstimulated HPCs suggests that NF-"B restriction promotes latent infection in 
this cell type. 
 
TNF-! Reactivates Latent Virus in HPCs through an NF-"B-Dependent Mechanism.  In 
other cell types, TNF-! has been reported to activate NF-"B through the classical 
pathway, which requires activation of the IKKß subunit of IKK (Li et al. 1999).  We 
therefore asked whether TNF-! alone could reactivate latent virus in HPCs and whether 
this reactivation required IKKß activity.  To test whether TNF-! alone was sufficient to 
reactivate latent virus, we incubated latently infected HPCs with STIF, GM-CSF alone, 
TNF-! alone, or GM-CSF + TNF-!.  We observed that while GM-CSF alone had no 
significant effect on viral gene expression, TNF-! was able to induce viral gene 
expression at the same level as the combination of the cytokines (Figure 3.4A).  We 
confirmed that this effect was specifically due to TNF-! by stimulating cells with TNF-! 
in the presence and absence of antibodies to TNF-!.  Induction of viral gene expression 
was substantially reduced in the presence of antibodies to TNF-! (Figure 3.4B). 
 To assess the dependence of TNF-!-induced viral reactivation upon activation of 
the classical NF-"B pathway, we stimulated latently infected HPCs with varying 
concentrations of TNF-! with and without an inhibitor of IKKß activity, IKK2 VI 
(Baxter et al. 2004).  While high doses of TNF-! overwhelmed the effect of IKK2 VI, at 
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moderate TNF-! doses IKK2 VI had a substantial inhibitory effect (Figure 3.4C). IKK2 
VI significantly counteracted TNF-!-induced reactivation of latent virus when cells were 
infected with HIV pseudotyped either with VSV-G (Figure 3.5A-B) or HIV (HXB) 
envelope (Figure 3.5C-D) and when either cord blood-derived (Figure 3.5A-D) or bone 
marrow-derived (Figure 3.5E-F) HPCs were used.  Using transcription factor ELISA to 
assess nuclear NF-"B p50 in these samples, we observed that in samples where IKK2 VI 
inhibited the ability of TNF-! to reactivate latent virus, IKK2 VI also blocked TNF-!-
induced NF-"B activation (Figure 3.5G).   
 In a majority of experiments, overnight incubation with IKK2 VI also reduced the 
level of active infection observed in cells cultured without TNF-! (Figure 3.4C, 3.5B-C, 
and 3.5F), indicating that a portion of the low-level spontaneous reactivation observed 
under these conditions was also due to activation of NF-"B.  This low-level spontaneous 
NF-"B activation is most likely a component of the spontaneous differentiation that 
occurs in HPCs under these culture conditions.  Such NF-"B activation has been reported 
as a component of the differentiation of more mature hematopoietic progenitor cells 
(Burkly et al. 1995, Zhang et al. 1998). 
 
Conditions that Reactivate Latent Virus in HPCs Do Not Alter P-TEFb expression.  We 
next asked whether restricted levels of P-TEFb contribute to the establishment of latency 
in HPCs.  To address this question, we analyzed nuclear CycT1 and phosphorylated 
CDK9 (pCDK9) in cord blood-derived HPCs incubated in STIF or stimulated overnight 
with GM-CSF and TNF-!.  We compared CycT1 and pCDK9 levels in these cells to 
those observed in resting memory T cells or resting memory T cells that had been 
 116 
stimulated overnight with anti-CD3/anti-CD28 beads.  As a positive control for CycT1 
and pCDK9 expression, we examined the levels of both proteins in Jurkat cells with or 
without TNF-! stimulation.  In agreement with previous findings (Herrmann et al. 1998, 
Kim et al. 2011, Ramakrishnan et al. 2009, Tyagi et al. 2010), Jurkat cells had high 
endogenous levels of CycT1 and pCDK9 that were not affected by TNF-! stimulation, 
while resting memory T cells had low levels of nuclear CycT1 and pCDK9 that increased 
dramatically following overnight incubation with anti-CD3/anti-CD28 beads (Figure 
3.6).  Finally, we observed that both CycT1 and pCDK9 were readily detectable in 
unstimulated HPCs and that levels of these proteins were not affected by incubation with 
GM-CSF and TNF-! (Figure 3.6).  This result demonstrates that the ability of these 
cytokines to induce HIV-1 gene expression in HPCs is not related to alterations in P-
TEFb expression. 
 
Prostratin and SAHA, but not HMBA, Can Reactivate Latent HIV-1 in HPCs.  We next 
asked whether compounds that reactivate latent virus in T cell systems had similar 
activity in our model of latent infection in HPCs.  We first tested prostratin, SAHA, and 
HMBA, and found that while prostratin and SAHA were able to induce viral gene 
expression, HMBA was not (Figure 3.7A).  A titration of prostratin demonstrated that 
prostratin effectively reactivated latent virus in HPCs only at high doses (1-5!M) (Figure 
3.7A).  Although the comparative efficacy of prostratin and TNF-! varied between 
experiments, prostratin was on average significantly less effective than TNF-! at 
reactivating latent virus from HPCs at a 13 hour time point (Figure 3.7B).  SAHA also 
reactivated latent virus only at high doses (2-10!M) (Figure 3.7A) and also induced 
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reactivation to a significantly lesser extent than TNF-! at 13 hours post-stimulation 
(Figure 3.7B).  Finally, although HMBA could induce expression of HIV-1 Gag in the 
latently infected U1 cell line (Figure 3.7C), we did not detect an effect of HMBA on 
viral gene expression in HPCs at any concentration assessed (Figure 3.7A).   
 Although SAHA and prostratin were less effective than TNF-! at 13 hours post-
stimulation, different results were obtained at 24 hours.  At this time point, we again 
found that SAHA, prostratin, and TNF-! were all able to induce a statistically significant 
reactivation of latent virus in HPCs (Figure 3.7D); however, there was no significant 
difference between the induction of active infection caused by TNF-! and that caused by 
prostratin or SAHA (Figure 3.7D).  HMBA still failed to induce significant reactivation 
at 24 hours (Figure 3.7D). The maximum reactivation achieved at 24 hours post-
stimulation was somewhat lower than that observed at 13 hours post-stimulation due to 
an increase in spontaneous reactivation in the solvent control.  Together, these results 
demonstrate that SAHA and prostratin, but not HMBA, are able to reactivate latent virus 
in HPCs; however, SAHA and prostratin reactivate virus with slower kinetics than does 
TNF-!. 
 Consistent with prostratin’s established ability to activate NF-"B through protein 
kinase C (Williams et al. 2004), we found that a 24 hour stimulation with prostratin 
resulted in an increase in nuclear NF-"B p50 activity to levels comparable to that 
observed with a high dose of TNF-! (Figure 3.7E).  By contrast, stimulation with 
HMBA or the histone deacetylase inhibitor SAHA had no effect on nuclear NF-"B 
activity, even though SAHA reactivated latent HIV-1 to the same extent as a 30pg/ml 
dose of TNF-! that did cause detectable NF-"B upregulation (Figure 3.7E). 
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 Although SAHA and prostratin reactivated latent virus in our model, both 
compounds had additional effects on HPCs.  We observed that incubating HPCs in media 
containing SAHA caused massive cell death after 48-72 hours (Figure 3.7F-G).  Similar 
cytotoxicity was observed at SAHA concentrations as low as 800nM (data not shown).  
Although prostratin was not cytotoxic to HPCs (Figure 3.7F), it caused rapid 
differentiation, resulting in adherent cells after as little as 24 hours of exposure (Figure 
3.7G).  By contrast, TNF-! did not induce cellular differentiation and although somewhat 
cytotoxic at 72h, it was substantially less so than SAHA (Figure 3.7F-G).  
 
Aza-CdR Does Not Reactivate Latent Infection in HPCs.  Finally, we examined whether 
the methylation inhibitor Aza-CdR could induce reactivation of latent virus in HPCs.  We 
first verified the activity of Aza-CdR in J-Lat cells, clones of Jurkat cells that are latently 
infected with a GFP-expressing HIV-1 reporter virus (Jordan et al. 2003).  In agreement 
with previous findings (Kauder et al. 2009), we observed that while Aza-CdR alone had 
minimal ability to induce viral gene expression in three J-Lat clones, it had a synergistic 
effect on reactivation when combined with TNF-! (Figure 3.8A).  However, we were 
unable to detect any effect of Aza-CdR on reactivation of latent virus in HPCs, either 
alone (Figure 3.8B) or in combination with TNF-! (Figure 3.8C). 
 
Discussion 
 In this study, we developed an in vitro model to study latency in immature HPCs, 
allowing us to investigate the types of HPCs that support latent infection and to study the 
factors that promote the establishment of latency. We found that HIV-1 could establish a 
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latent infection in all of the subsets of HPCs that we examined, including an immature 
population that includes hematopoietic stem cells and multipotent progenitors.  As 
hematopoietic stem cells and multipotent progenitors are long-lived cell types, this result 
has important implications for the ability of HPCs to serve as a latent reservoir in vivo.  
Hematopoietic stem cells in particular are capable of indefinite self-renewal, and thus 
latent infection in this cell type could result in a reservoir with an infinite half-life.  Such 
a reservoir has previously been proposed based on the decay kinetics of virus in the 
plasma (Palmer et al. 2008). 
 While our results suggest that many classes of progenitor cells might serve as 
short-term reservoirs of latent virus, immature progenitors are more likely to serve as 
latent reservoirs in patients treated with antiretroviral therapy.  The reason for this is that 
these cells have the greatest capacity to self-renew, as demonstrated by the fact that only 
HSCs are capable of sustaining long-term, multi-lineage engraftment in mice (Notta et al. 
2011).  Similarly, these immature cells are the most likely to persist in humans after 
months or years of treatment.  Thus, efforts to assess the extent of the latent reservoir in 
HPCs in patients on long-term antiretroviral therapy might be most successful if they 






 population of HPCs to maximize the 
chance of finding latently infected cells. 
 Our analysis revealed that TNF-!-induced activation of NF-"B in the absence of 
P-TEFb induction reactivates latent virus in HPCs.    This result differs from recent 
findings in resting memory T cells, where TNF-! is not sufficient to reactivate latent 
virus and induction of both NF-"B and P-TEFb activity appear to be required (Lassen et 
al. 2012, Tyagi et al. 2010, Yang et al. 2009) and is instead reminiscent of Jurkat cell line 
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models of latency (Duverger et al. 2009, Jordan et al. 2003, Kim et al. 2011).  Thus, our 
analysis suggests that HPCs may have fewer factors reinforcing latent infection than do 
resting memory T cells.  In vivo, this might result in a rate of latent infection in these 
cells that is lower than that observed in resting memory CD4
+
 T cells, where about 1 in 1 
million cells harbors replication-competent provirus in treated patients (Finzi et al. 1999). 
 In addition to TNF-!, which reactivated latent virus to the maximum level that we 
were able to achieve, we found that prostratin and SAHA can also reactivate latent virus 
in HPCs but with slower kinetics.  Prostratin, like TNF-!, efficiently induces NF-"B 
activation; however, the two compounds activate NF-"B through distinct pathways (Ea et 
al. 2006, Gaide et al. 2002, Hara et al. 2003, Hsu et al. 1996, Lucas et al. 2001, 
McAllister-Lucas et al. 2001, Micheau and Tschopp 2003, Pobezinskaya et al. 2008, 
Ruefli-Brasse et al. 2003, Ruland et al. 2001, Ting et al. 1996, Wang et al. 2002, Wu et 
al. 2006).  Thus, our finding that prostratin reactivates virus with slower kinetics than 
does TNF-! suggests that the pathway through which prostratin acts is less efficient in at 
least a subset of HPCs.  Alternatively, it is possible that in addition to NF-kB, TNF-! 
activates another factor that promotes reactivation in HPCs at early time points.  
However, as we found that TNF-! treatment of HPCs does not result in AP-1 activation, 
the identity of such an additional factor is not clear.  Overall, as TNF-! reactivates latent 
virus from HPCs more rapidly than prostratin does and without inducing the rapid 
cellular differentiation observed during prostratin stimulation, our results suggest that 
NF-"B activation may be a successful strategy for reactivating latent virus in HPCs but 
that prostratin may not be an ideal compound with which to initiate NF-"B activation in 
these cells. 
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 Consistent with SAHA’s function as a histone deacetylase inhibitor (Edelstein et 
al. 2009), we found that this compound reactivates latent virus in HPCs in the absence of 
NF-!B activation.  Reactivation occurred using SAHA concentrations that are 
comparable to those that are effective at reactivating latent virus in T cells (Contreras et 
al. 2009, Edelstein et al. 2009).  The relatively low efficacy of SAHA at 13 hours post-
stimulation compared to NF-!B activators TNF-" and prostratin suggests that although 
histone acetylation enhances HIV-1 transcription in HPCs, low NF-!B levels may still 
restrict rapid reactivation from latency.  In addition, although SAHA has been shown to 
be non-toxic to T cells even over long culture periods (Shan et al. 2012), we found that 
doses of SAHA that could reactivate latent virus were extremely toxic in HPCs.  This 
finding suggests that SAHA may not be effective in clearing latent virus from HPCs 
without significant detrimental effects on hematopoiesis. 
 Finally, we found that neither HMBA nor Aza-CdR could reactivate latent HIV-1 
in our system.  These findings are not surprising given the mechanisms of action of these 
compounds.  HMBA is believed to activate P-TEFb (Contreras et al. 2007); thus the 
inability of this compound to reactivate virus in HPCs confirms our finding that P-TEFb 
levels are not restricted in this cell type.  Finally, methylation has been shown to be a late 
event in the silencing of an HIV-1 provirus (Blazkova et al. 2009, Duverger et al. 2009, 
Kauder et al. 2009); as our model is designed to examine only early events in the 
establishment of latency in HPCs, it is not surprising that the methylation inhibitor Aza-
CdR would have no effect in this system. Unfortunately, the difficulty of maintaining 
HPCs in culture in an undifferentiated state precludes examination of whether 
methylation might similarly occur as a late event in proviral silencing in HPCs. 
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 To maximize HPC number, viability, and immaturity in our experiments, we 
cultured HPCs in STIF media, which contains the cytokines stem cell factor, 
thrombopoietin, IGFBP-2, and Flt3L.  In addition to maintaining HPCs in an immature 
state, this media also promotes the expansion of immature HPCs.  Of note, we found that 
latency could be established in HPCs in spite of the fact that these cells proliferated 
during the course of our assay with a mean doubling time of less than 48 hours (data not 
shown).  This observation parallels findings from resting memory T cells, where 
homeostatic proliferation does not reactivate latent virus and instead helps to maintain the 
latent reservoir (Bosque et al. 2011, Chomont et al. 2009).  Similarly, our observations 
suggest that self-renewal of HPCs in vivo would not reactivate latent virus, but instead 
would help to maintain this latent reservoir.  However, additional study is needed to 
better define the effects of cell cycling on latently infected HPCs. 
 While further research to understand the extent of the latent reservoir in HPCs in 
patients on antiretroviral therapy will be informative, the very low rate of infection 
anticipated in these cells may make it difficult to definitively determine the size of this 
reservoir in vivo.  Technical issues in culturing HPCs ex vivo may also contribute to the 
variable results that have been obtained when these cells are examined for infection; for 
instance, as active HIV infection is cytotoxic to HPCs (Carter et al. 2010), the 
reactivation of latent virus under differentiating culture conditions may result in cell 
death and false negative results.  Therefore, protocols that include a culturing step prior to 
cell purification may reduce their yield of provirus-containing cells (Durand et al. 2012).  




 cells may yield 
false negative cells as CD4 is required for infection of HPCs (Carter et al. 2011, 
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Josefsson et al. 2012).   Conversely, false positive results could be obtained if HPC 
samples are contaminated with CD4
+
 T cells.  Together, these factors may make it 
difficult to define the role of HPCs in viral persistence. 
 Further complicating the detection of infected HPCs is the fact that only CXCR4-
utilizing viruses can infect immature HPCs (Carter et al. 2011), which may result in 
widely varying infection rates in these cells in patients with different proportions of 
CXCR4- or dual-tropic virus.  Early in the course of infection most HIV isolates utilize 
CCR5 (Rieder et al. 2011, van’t Wout et al. 1994, Zhu et al. 1993); however, several 
recent reports have demonstrated that CXCR4-utilizing viral subpopulations are found in 
up to 10-50% of recently infected individuals (Abbate et al. 2011, Chalmet et al. 2012).  
In addition, CXCR4-utilizing viruses emerge in many patients later in the course of 
infection (Richman et al. 1994, Shankarappa et al. 1999).  A substantial fraction of HIV-
infected patients would thus be expected to harbor virus that is capable of infecting 
HPCs; however, patients for whom CXCR4-utilizing virus is a minority population 
would be expected to have only a very low rate of infection in these cells. Additional 
studies are needed to more fully understand these variables.  
 Nonetheless, an eradication strategy for HIV must reactivate latent virus from all 
latently infected cells to eliminate all reservoirs of virus in the body.  Thus, our 
observations on the mechanisms underlying the establishment and reactivation of latency 
in HPCs are of great utility in designing and evaluating eradication strategies, as they 
allow us to assess whether strategies that are effective in T cells will be equally effective 
in the proposed reservoir for latent virus in HPCs.  Our findings demonstrate that latent 
infection can occur in all HPC subsets studied, including cells with surface markers 
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consistent with long-lived, multipotent hematopoietic stem and progenitor cells.  We 
found that latent infection could be reversed by NF-!B activation but that nuclear P-
TEFb levels are not restricted in HPCs.  Finally, we observed that TNF-", prostratin, and 
SAHA are all capable of reactivating latent infection in HPCs, but that prostratin and 
SAHA also induce differentiation or death, respectively, in the HPC population.  
Together, these data show that immature HPCs have the potential to serve as a reservoir 
of latent virus and suggest that strategies that activate NF-!B can reactivate latent virus 
from these cells.  Proposed reactivation strategies can be assessed in this model of latent 
infection in HPCs in addition to models of latently infected resting memory T cells to 
assess the ability of different strategies to reactivate latent virus in both cell types and 
thus maximize the chance of eliminating all latent reservoirs in vivo. 
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Figure 3.1. A – D.  GM-CSF and TNF-! reactivate latent virus in a primary cell model 
for HIV-1 infection of CD34
+
 HPCs.  A. Time course for latency experiments.  B. 
Schematic diagrams of HIV-1 reporter viruses used for these studies.  Viruses were 
pseudotyped with VSV-G envelope (middle) or CXCR4-tropic HIV-1 envelope HXB 
(right).  The gray shading of vpr and vpu in HXB-ePLAP indicates that these genes are 
defective in full length HXB.  Black shading indicates genes that have been added or 
deleted compared to the wild type viral clone.  C. Flow cytometric analysis of cells sorted 
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for reactivation protocols.  Top, cord blood-derived HPCs infected with HXB-
ePLAP/VSV-G and PLAP
-
 cells isolated by magnetic sorting; bottom, cells infected with 
NL4-3-!GPE-GFP/VSV-G and GFP
-
 cells isolated by flow sorting. Numbers indicate the 




.  Live cells were gated using FSC and 
SSC parameters.  D. Flow cytometric analysis of cells shown in C after overnight 
incubation with STIF or GM-CSF (100ng/ml) and TNF-! (2.5ng/ml).  CD34+ cells are 
gated on at left, then PLAP (left) or GFP (right) expression in uninfected, STIF-treated, 
and GM-CSF and TNF-!-treated cells is shown at right. Numbers indicate the percent of 
cells within the labeled gate.  Live cells were gated based on FSC, SSC, and 7-AAD. E. 
CD3
+
 T cells are not present in the CD34
+
 HPC population.  Cord blood-derived HPCs 
were sorted and infected with NL4-3-"GPE-GFP/VSV-G as in A.  CD3 and CD34 
staining was assessed on day 6 following flow sorting and overnight incubation in STIF.  
Live cells were gated using FSC, SSC, and 7-AAD.  Data are representative of two 
independent experiments, one each using cord blood and bone marrow-derived HPCs.  F 
– H. Latent infection that can be reactivated with GM-CSF and TNF-! occurs in 
immature, CD133
+
 HPCs. F. Flow cytometric analysis of CD133
+
 cells treated with Hxb-
ePLAP/VSV-G and sorted to remove actively infected (PLAP
+
) cells.  Numbers indicate 
the percent of live cells in each quadrant.  Live cells were gated using forward scatter and 
side scatter.  G. Flow cytometric analysis of cells sorted as in F and then stimulated 
overnight with STIF or GM-CSF and TNF-!.   Live cells were defined by FSC, SSC, and 
7-AAD.  Numbers indicate the percent of cells falling within the indicated gate. H. 
Quantitation of reactivation in CD133
+
 cells (cells sorted for CD133 prior to stimulation) 
relative to cells incubated in STIF.  Mean and SE of 4 independent experiments are 




Figure 3.2.  Latent infection occurs in all subsets of CD34
+
 HPCs defined by CD38 and 
CD45RA expression. A. Diagram of hematopoiesis showing CD34, CD133, CD38 and 
CD45RA expression on each cell subset. HSC, hematopoietic stem cell; MPP, 
multipotent progenitor; MLP, multilymphoid progenitor; CMP, common myeloid 
progenitor; MEP, megakaryocyte/erythrocyte progenitor; GMP, granulocyte/monocyte 
progenitor; B-NK, B and NK cell progenitor.  B. Flow cytometric analysis of CD133
+
 
cells treated with HXB-ePLAP/HXB env, sorted to remove actively infected (PLAP
+
) 
cells, and stimulated overnight with STIF or TNF-!. Live cells were defined using FSC, 
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SSC, and 7-AAD, then analyzed for CD34, CD38, CD45RA, and PLAP expression.  
Numbers indicate the percent of total cells in each quadrant.  C. Summary of experiments 
similar to those shown in B except using HXB-ePLAP/VSV-G envelope to infect cells.  
Fold induction of active infection in cells treated with GM-CSF and TNF-! or TNF-! 
compared to cells incubated in media is shown.  Labels are colored to match cell types in 
A.  Mean and SE of 6 independent experiments are shown.  *p < 0.05, **p < 0.01, ***p < 
0.001, 1-sample t-test vs. expected fold increase of 1. Differences in the fold induction of 
active infection between cell subsets are not significant (1-way ANOVA, p = 0.26).  D. 
Summary of experiments shown in B. Fold induction of active infection in cells treated 
with GM-CSF and TNF-! or TNF-! vs. unstimulated cells is shown.  Mean and SE of 2 
independent experiments are shown.  *p<0.05, **p<0.01, 1-sample t-test vs. expected 
fold increase of 1.  Differences in the fold induction of active infection between cell 
subsets are not significant (1-way ANOVA, p = 0.53).  E.  Summary of experiments 
similar to those shown in B except using NL4-3-"GPE-GFP/VSV-G envelope to infect 
bone marrow cells. Fold induction of active infection in cells treated with TNF-! vs. 
unstimulated cells is shown.  Mean and SE of 2 independent experiments are shown.  
*p<0.05, 1-sample t-test vs. expected fold increase of 1.  Differences in the fold induction 




Figure 3.3. GM-CSF and TNF-!-treated HPCs have increased nuclear NF-"B DNA 
binding activity compared to STIF-treated cells.  A. Quantitation of transcription factor 
ELISA measuring NF-"B DNA-binding activity in nuclear lysates from HPCs incubated 
with STIF or GM-CSF + TNF-!.  Absorbance was normalized to the positive control on 
each plate, then non-specific activity (defined by activity obtained using cytoplasmic 
extracts) was subtracted from the nuclear absorbance and the difference graphed as 
arbitrary units (AU).  AU for the positive control, Raji nuclear cell extract, was set to 1.  
The mean and SE of 3 independent experiments are shown.  *p < 0.05, paired t-test.  B. 
Quantitation of transcription factor ELISA measuring AP-1 DNA-binding activity in 
nuclear lysates from HPCs incubated with STIF or GM-CSF + TNF-! overnight. Data 
were analyzed as described for part A except that nuclear extracts of K-562 cells 
stimulated with 12-O-tetradecanoylphorbol-13-acetate were used as the positive control.   
Mean and SE of 2 independent experiments are shown. AP-1 nuclear activity was not 
significantly elevated by GM-CSF and TNF-! treatment (p > 0.2 for all subunits, paired t 
test); however, JunB expression in STIF-treated cells (p < 0.05) and FosB (p < 0.01) and 
Fra-1 (p < 0.05) expression in GM-CSF and TNF-!-treated cells were significantly 




Figure 3.4. TNF-! reactivates latent infection in HPCs via an NF-"B-dependent 
pathway.  A. TNF-! is sufficient to reactivate latent virus.  Flow cytometric analysis of 
CD133
+
 cells treated with NL4-3-!GPE-GFP/VSV-G, sorted to remove actively infected 
cells, and incubated overnight with the indicated cytokines.  Numbers show the percent 
of cells falling within the indicated gate.  Live cells were gated using FSC, SSC, and 7-
AAD.  B.  Quantitative analysis of reactivation in cells treated as described in part A and 
incubated with ten-fold dilutions of TNF-! in the presence or absence of antibody to 
TNF-!.  Mean fold increase in the percentage of cells expressing GFP compared to cells 
incubated in STIF alone is shown.  Error bars represent SE of two independent 
experiments.  C. Quantitation of reactivation in cells treated as described in part B except 
that cells were treated with HXB-ePLAP/VSV-G and reactivated with and without the 
classical NF-"B pathway inhibitor IKK2 VI (10µM).  Mean fold increase in the 
percentage of cells expressing PLAP compared to the STIF+DMSO condition is shown.  




Figure 3.5. NF-!B inhibitor IKK2 VI counteracts TNF-"-induced reactivation of latent 
virus in HPCs.  A, C, and E. Flow cytometric analysis of CD133
+
 cells using the 
indicated envelope, sorted to remove actively infected cells, and stimulated overnight as 
indicated.  Live cells were gated using FSC, SSC, and 7-AAD; numbers indicate the 
percent of cells within each gate.  Results are representative of 4 (A) or 2 (C and E) 
independent experiments.  B, D, and F. Summary of reactivation for parts A, C, and E, 
respectively.  Fold increase in the percentage of cells expressing PLAP compared to the 
STIF+DMSO condition was calculated.  Mean and SE of 4 (B) or 2 (D or F) independent 
experiments are shown.  *p < 0.01 (B), 0.02 (D), or 0.03 (F) by paired t-test.  G. 
Quantitation of nuclear NF-kB p50 DNA binding activity for cells treated as for part A 




Figure 3.6. Nuclear P-TEFb in HPCs is not increased by stimulation with GM-CSF and 
TNF-!.  Western blot analysis of CyclinT1 and pCDK9 in nuclear extracts from CD133+ 
HPCs (CB) incubated for 5 days in STIF media and then treated with STIF or GM-CSF 
(10ng/ml) plus TNF-! (2.5ng/ml).  Controls were nuclear extracts from resting memory 











 cells, lysed immediately or after stimulation with 
CD3/CD28 antibody beads overnight, and nuclear extracts from Jurkat cells incubated 
overnight in media or 3ng/ml TNF-!.  Results are representative of two independent 





Figure 3.7. Prostratin and SAHA reactivate latent virus in CD34
+
 HPCs. A. Quantitation 
of viral reactivation in CD133
+
 cells treated with prostratin, SAHA, or HMBA for 13 
hours.  Reactivation was measured using the latency reactivation assay described in Fig 1 
after infection with NL4-3-!GPE-GFP/VSV-G or HXB-ePLAP/VSV-G.  Mean fold 
increase in the percentage of live, CD34
+
 cells expressing PLAP or GFP compared to 
solvent control is shown.  Error bars represent standard error of 3 (Prostratin, SAHA) or 2 
(HMBA) independent experiments.  *p < 0.05, 1-sample t-test vs. expected fold increase 
of 1. B. Quantitation of reactivation by cells treated with prostratin (5µM, left) and 
SAHA (10"M, right) for 13 hours using the reactivation assay described in Fig 1.  Mean 
and SE of 7 independent experiments in cord blood (6) or bone marrow (1) are shown.  
*p<0.05, **p<0.01, paired t-test.  C. Quantitation of reactivation by U1 cells stimulated 
for 48h with 5mM HMBA or solvent control (H2O) and analyzed by flow cytometry to 
assess induction of HIV-1 Gag expression.  Mean and standard error of three replicates is 
shown.  D. Quantitation of reactivation by cells treated with TNF-!, prostratin, SAHA, or 
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HMBA for 24 hours using the reactivation assay described in Fig. 1.  Mean and SE of 6 
(TNF-!), 5 (HMBA), or 4 (prostratin or SAHA) independent experiments is shown.  *p < 
0.03, 1-sample t-test vs. expected fold increase of 1.  Induction of active infection with 
Prostratin, SAHA, and HMBA is not significantly different from induction with TNF-! 
stimulation.  E. Quantitation of transcription factor ELISA measuring nuclear NF-"B 
DNA binding activity in nuclear extracts from HPCs infected with NL4-3-#GPE-
GFP/VSV-G and stimulated for 24h with the indicated compounds.  ELISA data was 
analyzed as described in Fig 4A. Mean and standard deviation of two replicates are 
shown.  Fold increase in percent of cells expressing GFP compared to solvent control is 
indicated under the graph.  Results are representative of two independent experiments 
using cells from separate donor pools.  F. Time course of HPC survival when cultured 
with TNF-! (3ng/ml), prostratin (5!M), or SAHA (10!M).  CD133+ HPCs were isolated 
from cord blood and cultured in STIF for 5 days, then split into solvent control or the 
conditions shown for an additional 3 days.  Cells remaining as a percentage of cells 
remaining in the solvent control are displayed as a function of time.  Mean and SE of 3 
independent experiments are shown.  *p<0.05, **p<0.01, ***p<0.001, 1-sample t-test vs. 
expected cell count of 100% of solvent.  G.  Images of the cells analyzed in F obtained 
with light microscopy at 400x magnification.  Images were collected at the indicated 




Figure 3.8. Aza-CdR does not reactivate latent virus in CD34
+
 HPCs. A. Quantitation of 
reactivation in J-Lat cells treated with the indicated compounds and assayed by GFP 
expression by flow cytometry. J-Lat cells treated with 30ng/ml TNF-! and/or 1µM Aza-
CdR for 24h were assayed for GFP expression (reporter for HIV-1 LTR activity) by flow 
cytometry after an additional 48h.  Mean and SE of results from three J-Lat clones (J-Lat 
8.4, J-Lat 9.2, and J-Lat 6.3) are shown.  *p<0.05, **p<0.01, paired t-test.  B.  
Quantitation of reactivation of viral gene expression in CD133
+
 HPCs using the 
reactivation assay shown in Fig 1 following treatment with the indicated concentrations 
of Aza-CdR.  Mean fold increase in the percentage of cells expressing GFP compared to 
solvent control is shown.  Error bars represent standard error of 2 independent 
experiments.  C. Quantitation of reactivation of viral gene expression in CD133
+
 HPCs 
using the reactivation assay shown in Fig 1 following treatment with TNF-! and either 
Aza-CdR or DMSO solvent control.  Fold increase in the percentage of cells expressing 
GFP compared to solvent control was calculated.  Mean and standard error of 2 
independent experiments are shown.
 137 
References  
Abbate I, Vlassi C, Rozera G, et al.  Detection of quasispecies variants predicted to use 
CXCR4 by ultra-deep pyrosequencing during early HIV infection.  AIDS 2011; 
25:611-7. 
Aggarwal B.  Tumour necrosis factors receptor associated signalling molecules and their 
role in activation of apoptosis, JNK and NF-!B.  Ann Rheum Dis 2000; 59(suppl 
I):i6-16. 
Bailey J, Sedaghat A, Kieffer T, et al.  Residual Human Immunodeficiency Virus Type 1 
Viremia in Some Patients on Antiretroviral Therapy is Dominated by a Small 
Number of Invariant Clones Rarely Found in Circulating CD4
+
 T Cells.  J Virol 
2006; 80(13):6441-57. 
Barboric M, Yik J, Czudnochowski N, et al.  Tat competes with HEXIM1 to increase the 
active pool of P-TEFb for HIV-1 transcription.  Nucleic Acids Res 2007; 
35(6):2003-12. 
Baxter A, Brough S, Cooper A, et al.  Hit-to-lead studies: the discovery of potent, orally 
active, thiophenecarboxamide IKK-2 inhibitors.  Bioorg Med Chem Lett 2004; 
14:2817-22. 
Blazkova J, Trejbalova K, Gondois-Rey F, et al.  CpG methylation controls reactivation 
of HIV from latency.  PLoS Pathog 2009; 5(8):e1000554. 
Bosque A, Famiglietti M, Weyrich A, et al.  Homeostatic Proliferation Fails to Efficiently 
Reactivate HIV-1 Latently Infected Central Memory CD4
+
 T Cells.  PLoS Pathog 
2011; 7(10):e1002288. 
Bosque A, and Planelles V.  Induction of HIV-1 latency and reactivation in primary 
memory CD4
+
 T cells.  Blood 2009; 113(1):58-65. 
Brennan T, Woods J, Sedaghat A, et al.  Analysis of Human Immunodeficiency Virus 
Type 1 Viremia and Provirus in Resting CD4
+
 T Cells Reveals a Novel Source of 
Residual Viremia in Patients on Antiretroviral Therapy.  J Virol 2009; 
83(17):8470-81. 
Burkly L, Hession C, Ogata L, et al.  Expression of relB is required for the development 
of thymic medulla and dendritic cells.  Nature 1995; 373:531-6. 
Cannone-Hergaux F, Aunis D, and Schaeffer E.  Interactions of the transcription factor 
AP-1 with the longe terminal repeat of different human immunodeficiency virus 
type 1 strains in Jurkat, glial, and neuronal cells.  J Virol 1995; 69(11):6634-42. 
Carter C, McNamara L, Onafuwa-Nuga A, et al.  HIV-1 Utilizes the CXCR4 Chemokine 
Receptor to Infect Multipotent Hematopoietic Stem and Progenitor Cells.  Cell 
Host & Microbe 2011; 9:223-34. 
Carter C, Onafuwa-Nuga A, McNamara L, et al.  HIV-1 infects multipotent progenitor 
cells causing cell death and establishing latent cellular reservoirs.  Nat Med 2010; 
16(4):446-51. 
Chalmet K, Dauwe K, Foquet L, et al.  Presence of CXCR4-Using HIV-1 in Patients 
With Recently Diagnosed Infection: Correlates and Evidence for Transmission.  J 
Infect Dis 2012; 205:174-84. 
Chen B, Gandhi R, and Baltimore D.  CD4 down-modulation during infection of human 
T cells with human immunodeficiency virus type 1 involves independent 
activities of vpu, env, and nef.  J Virol 1996; 70(9):6044-53. 
 138 
Chen G, and Goeddel D.  TNF-R1 Signaling: A Beautiful Pathway.  Science 2002; 
296:1634-5. 
Chomont N, El-Far M, Ancuta P, et al.  HIV reservoir size and persistence are driven by 
T cell survival and homeostatic proliferation.  Nat Med 2009; 15(8):893-900. 
Contreras X, Barboric M, Lenasi T, et al.  HMBA Releases P-TEFb from HEXIM1 and 
7SK snRNA via PI3K/Akt and Activates HIV Transcription.  PLoS Pathog 2007; 
3(10):e146. 
Contreras X, Schweneker M, Chen C-S, et al.  Suberoylanilide Hydroxamic Acid 
Reactivates HIV from Latently Infected Cells.  J Biol Chem 2008; 284(11):6782-
9. 
Doulatov S, Notta F, Eppert K, et al.  Revised map of the human progenitor hierarchy 
shows the origin of macrophages and dendritic cells in early lymphoid 
development.  Nat Immunol 2010; 11(7):585-93. 
Durand CM, Ghiaur G, Siliciano JD, et al.  HIV-1 DNA Is Detected in Bone Marrow 
Populations Containing CD4
+
 T Cells but Is not Found in Purified CD34
+
 
Hematopoietic Progenitor Cells in Most Patients on Antiretroviral Therapy.  J 
Infect Dis 2012; 205(6):1014-8. 
Duverger A, Jones J, May J, et al.  Determinants of the Establishment of Human 
Immunodeficiency Virus Type 1 Latency.  J Virol 2009; 83(7):3078-93. 
Ea C-K, Deng L, Xia Z-P, et al.  Activation of IKK by TNF! requires site-specific 
ubiquitination of RIP1 and polyubiquitin binding by NEMO.  Mol Cell 2006; 
22:245-57. 
Edelstein L, Micheva-Viteva S, Phelan B, et al.  Short Communication: Activation of 
Latent HIV Type 1 Gene Expression by Suberoylanilide Hydroxamic Acid 
(SAHA), an HDAC Inhibitor Approved for Use to Treat Cutaneous T Cell 
Lymphoma.  AIDS Res Hum Retroviruses 2009; 25(9):883-7. 
Finzi D, Blankson J, Siliciano J, et al.  Latent infection of CD4
+
 T cells provides a 
mechanism for lifelong persistence of HIV-1, even in patients on effective 
combination therapy.  Nat Med 1999; 5(5):512-7. 
Folks T, Justement J, Kinter A, et al.  Cytokine-induced expression of HIV-1 in a 
chronically infected promonocyte cell line.  Science 1987; 238:800-2. 
Gaide O, Favier B, Legler D, et al.  CARMA1 is a critical lipid raft-associated regulator 
of TCR-induced NF-"B activation.  Nat Immunol 2002; 3(9):836-43. 
Gasmi M, Glynn J, Jin M, et al.  Requirements for efficienct production and transduction 
of human immunodeficiency virus type 1-based vectors.  J Virol 1999; 
73(3):1828-34. 
Geeraert L, Kraus G, and Pomerantz R.  Hide-and-seek: the challenge of viral persistence 
in HIV-1 infection.  Annu Rev Med 2008; 59:487-501. 
Gulick R, Mellors J, Havlir D, et al.  Treatment with indinavir, zidovudine, and 
lamivudine in adults with human immunodeficiency virus infection and prior 
antiretroviral therapy.  N Engl J Med 1997; 337(11):734-9. 
Hammer S, Squires K, Hughes M, et al.  A controlled trial of two nucleoside analogues 
plus indinavir in persons with human immunodeficiency virus infection and CD4 
cell counts of 200 per cubic millimeter or less.  N Engl J Med 1997l 337(11):725-
33. 
 139 
Hara H, Wada T, Bakal C, et al.  The MAGUK family protein CARD11 is essential for 
lymphocyte activation.  Immunity 2003; 18: 763-75. 
Herrmann C, Carroll R, Wei P, et al.  Tat-associated kinase, TAK, activity is regulated by 
distinct mechanisms in peripheral blood lymphocytes and promonocytic cell lines.  
J Virol 1998; 72(12):9881-8. 
Hsu H, Shu H-B, Pan M-G, et al.  TRADD-TRAF2 and TRADD-FADD interactions 
define two distinct TNF receptor 1 signal transduction pathways.  Cell 1996; 
84:299-308. 
Jordan A, Bisgrove D, and Verdin E.  HIV reproducibly establishes a latent infection 
after acute infection of T cells in vitro.  EMBO J. 2003; 22:1868-77. 
Josefsson L, Eriksson S, Sinclair E, et al.  Hematopoietic Precursor Cells Isolated from 
Patients on Long Term Suppressive HIV Therapy Did Not Contain HIV-1 DNA.  
J Infect Dis 2012; 206(1):28-34. 
Kauder S, Boque A, Lindqvist A, et al.  Epigenetic Regulation of HIV-1 Latency by 
Cytosine Methylation.  PLoS Pathog 2009; 5(6):e1000495. 
Kim Y-K, Mbonye U, Hokello J, et al.  T-Cell Receptor Signaling Enhances 
Transcriptional Elongation from Latent HIV Proviruses by Activating P-TEFb 
through an ERK-Dependent Pathway.  J Mol Biol 2011; 410:896-916. 
Kohno T, Mohan S, Goto T, et al.  A new improved method for the concentration of 
HIV-1 infective particles.  J Virol Methods 2002; 106:167-73. 
Korin Y, Brooks D, Brown S, et al.  Effects of prostratin on T-cell activation and human 
immunodeficiency virus latency.  J Virol 2002; 76(16):8118-23. 
Lassen K, Hebbeler A, Bhattacharyya D, et al.  A Flexible Model of HIV-1 Latency 
Permitting Evaluation of Many Primary CD4 T-Cell Reservoirs.  PLoS ONE 
2012; 7(1):e30176. 
Li S, Chu W, Hu Y, et al.  The IKKß Subunit of I!B Kinase (IKK) is Essential for 
Nuclear Factor !B Activation and Prevention of Apoptosis.  J Exp Med 1999; 
189(11):1839-45. 
Lucas P, Yonezumi M, Inohara N, et al.  Bcl10 and MALT1, Independent Targets of 
Chromosomal Translocation in MALT Lymphoma, Cooperate in a Novel NF-!B 
Signaling Pathway.  J Biol Chem 2001; 276(22):19012-9. 
McAllister-Lucas L, Inohara N, Lucas P, et al.  Bimp1, a MAGUK Family Member 
Linking Protein Kinase C Activation to Bcl10-mediated-NF-!B Induction.  J Biol 
Chem 2001; 276(33):30589-97. 
McNamara L and Collins K.  Hematopoietic stem/precursor cells as HIV reservoirs.  Curr 
Opin HIV AIDS 2011; 6:43-8. 
Micheau O and Tschopp J.  Induction of TNF receptor I-mediated apoptosis via two 
sequential signaling complexes.  Cell 2003; 114:181-90. 
Nabel G and Baltimore D.  An inducible transcription factor activates expression of 
human immunodeficiency virus in T cells.  Nature 1987; 326:711-3. 
Nguyen V, Kiss T, Michels A, et al.  7SK small nuclear RNA binds to and inhibits the 
activity of CDK9/cyclin T complexes.  Nature 2001; 414:322-5. 
Notta F, Doulatov S, Laurenti E, et al.  Isolation of Single Human Hematopoietic Stem 
Cells Capable of Long-Term Multilineage Engraftment.  Science 2011; 333:218-
21. 
 140 
Palmer S, Maldarelli F, Wiegand A, et al.  Low-level viremia persists for at least 7 years 
in patients on suppressive antiretroviral therapy.  Proc Natl Acad Sci 2008; 
105(10):3879-84. 
Pereira L, Bentley K, Peeters A, et al.  A compilation of cellular transcription factor 
interactions with the HIV-1 LTR promoter.  Nuc Acid Res 2000; 28(3):663-8. 
Pobezinskaya Y, Kim Y-S, Choksi S, et al.  The function of TRADD in signaling through 
tumor necrosis factor receptor 1 and TRIF-dependent Toll-like receptors.  Nat 
Immunol 2008; 9(9):1047-54. 
Ramakrishnan R, Dow E, and Rice AP.  Characterization of Cdk9 T-loop 
phosphorylation in resting and activated CD4
+
 T lymphocytes.  J Leukocyte Biol 
2009; 86:1345-50. 
Redd A, Avalos A, and Essex M.  Infection of hematopoietic progenitor cells by HIV-1 
subtype C, and its association with anemia in southern Africa.  Blood 2007; 
110(9):3143-9. 
Richman D and Bozzette S.  The Impact of the Syncytium-Inducing Phenotype of Human 
Immunodeficiency Virus on Disease Progression.  J Infect Dis 1994; 169(5):968-
74. 
Rieder P, Joos B, Scherrer A, et al.  Characterization of Human Immunodeficiency Virus 
Type 1 (HIV-1) Diversity and Tropism in 145 Patients With Primary HIV-1 
Infection.  Clin Infect Dis 2011; 53(12):1271-9. 
Roebuck K, Brenner D, and Kagnoff M.  Identification of c-fos-responsive elements 
downstream of TAR in the long terminal repeat of human immunodeficiency 
virus type-1.  J Clin Invest 1993; 92(3):1336-48. 
Roebuck K, Gu D, and Kagnoff M.  Activating protein-1 cooperates with phorbol ester 
activation signals to increase HIV-1 expression.  AIDS 1996; 10(8):819-26. 
Ruefli-Brasse A, French D, and Dixit V.  Regulation of NF-!B-Dependent Lymphocyte 
Activation and Development by Paracaspase.  Science 2003; 302:1581-4. 
Ruland J, Duncan G, Elia A, et al.  Bcl10 Is a Positive Regulator of Antigen Recptor-
Induced Activation of NF-!B and Neural Tube Closure.  Cell 2001; 104:33-42. 
Sahu G, Paar D, Frost S, et al.  Low-level plasma HIVs in patients on prolonged 
suppressive highly active antiretroviral therapy are produced mostly by cells other 
than CD4 T-cells.  J Med Virol 2009; 81:9-15. 
Saleh S, Solomon A, Wightman F, et al.  CCR7 ligands CCL19 and CCL21 increase 
permissiveness of resting memory CD4
+
 T cells to HIV-1 infection: a novel 
model of HIV-1 latency.  Blood 2007; 110(13):4161-4. 
Salerno D, Hasham M, Marshall R, et al.  Direct inhibition of CDK9 blocks HIV-1 
replication without preventing T-cell activation in primary human peripheral 
blood lymphocytes.  Gene 2007; 405:65-78. 
Sedore S, Byers S, Biglione S, et al.  Manipulation of P-TEFb control machinery by HIV: 
recruitment of P-TEFb from the large form by Tat and binding of HEXIM1 to 
TAR.  Nucleic Acids Res 2007; 35(13):4347-58. 
Shan L, Deng K, Shroff N, et al.  Stimulation of HIV-1-Specific Cytolytic T 
Lymphocytes Facilitates Elimination of Latent Viral Reservoir after Virus 
Reactivation.  Immunity 2012; 36:491-501. 
 141 
Shankarappa F, Margolick J, Gange S, et al.  Consistent viral evolutionary changes 
associated with the progression of human immunodeficiency virus type 1 
infection.  J Virol 1999; 73(12):10489-502. 
Stanley S, Kessler S, Justement J, et al.  CD34
+
 bone marrow cells are infected with HIV 
in a subset of seropositive individuals.  J Immunol 1992; 149(2):689-97. 
Ting A, Pimentel-Muiños F, and Seed B.  RIP mediates tumor necrosis factor receptor 1 
activation of NF-!B but not Fas/APO-1-initiated apoptosis.  EMBO J 1996; 
15(22):6189-96. 
Trono D, Lint C, Rouzioux C, et al.  HIV Persistence and the Prospect of Long-Term 
Drug-Free Remissions for HIV-Infected Individuals.  Science 2010; 329:174-80. 
Tyagi M, Pearson R, and Karn J.  Establishment of HIV Latency in Primary CD4
+
 Cells 
Is due to Epigenetic Transcriptional Silencing and P-TEFb Restriction.  J Virol 
2010; 84(13):6425-37. 
Vallabhapurapu S and Karin M.  Regulation and function of NF-!B transcription factors 
in the immune system.  Annu Rev Immunol 2009; 27:693-733. 
Van Lint C, Amella C, Emiliani S, et al.  Transcription factor binding sites downstream 
of the human immunodeficiency virus type 1 transcription start site are important 
for virus infectivity.  J Virol 1997; 71(8): 6113-27. 
Van Lint C, Emiliani S, Ott M, et al.  Transcriptional activation and chromatin 
remodeling of the HIV-1 promoter in response to histone acetylation.  EMBO J 
1996; 15(5):1112-20. 
van't Wout A, Kootstra N, Mulder-Kampinga G, et al.  Macrophage-tropic variants 
initiate human immunodeficiency virus type 1 infection after sexual, parenteral, 
and vertical transmission.  J Clin Invest 1994; 94:2060-7. 
Wang D, You Y, Case S, et al.  A requirement for CARMA1 in TCR-induced NF-!B 
activation.  Nat Immunol 2002; 3(9):830-5. 
Wei P, Gargber M, Fang S-M, et al.  A novel CDK9-associated C-type cyclin interacts 
directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to 
TAR RNA.  Cell 1998; 92:451-62. 
Williams S, Chen L-F, Kwon H, et al.  Prostratin Antagonizes HIV Latency by 
Activating NF-!B.  J Biol Chem 2004; 279(40):42008-17. 
Wu C-J, Conze D, Li T, et al.  NEMO is a sensor of Lys 63-linked polyubiquitination and 
functions in NF-!B activation.  Nat Cell Biol 2006; 8(4):398-406. 
 Yang H-C, Xing S, Shan L, et al.  Small-molecule screening using a human primary cell 
model of HIV latency identifies compounds that reverse latency without cellular 
activation.  J Clin Invest 2009; 119(11):3473-86. 
Yang Z, Zhu Q, Luo K, et al.  The 7SK small nuclear RNA inhibits the CDK9/cyclin T1 
kinase to control transcription.  Nature 2001; 414:317-22. 
Yik J, Chen R, Nishimura R, et al.  Inhibition of P-TEFb (CDK9/Cyclin T) kinase and 
RNA polymerase II transcription by the coordinated actions of HEXIM1 and 7SK 
snRNA.  Mol Cell 2003; 12:971-82. 
Ylisastigui L, Archin N, Lehrman G, et al.  Coaxing HIV-1 from resting CD4 T cells: 
histone deacetylase inhibition allows latent viral expression.  AIDS 2004; 
18(8):1101-8. 
 142 
Zhang H, Zhou Y, Alcock C, et al.  Novel Single-Cell-Level Phenotypic Assay for 
Residual Drug Susceptibility and Reduced Replication Capacity of Drug-
Resistant Human Immunodeficiency Virus Type 1.  J Virol 2004; 78:1718-29. 
Zhang L, Ramratnam B, Tenner-Racz K, et al.  Quantifying residual HIV-1 replication in 
patients receiving combination antiretroviral therapy.  N Engl J Med 1999; 
340(21):1605-13. 
Zhang M-Y, Sun S-C, Bell L, et al.  NF-!B transcription factors are involved in normal 
erythropoiesis.  Blood 1998; 91:4136-44. 
Zhu T, Mo H, Wang N, et al.  Genotypic and phenotypic characterization of HIV-1 








HIV genomes in CD133
+
 hematopoietic progenitors in optimally treated people with 
long-term viral suppression cannot be explained by CD3
+




Background.  Hematopoietic progenitor cells (HPCs) in the bone marrow of HIV
+
 
individuals have been proposed as a persistent reservoir of virus.  However, some studies 
have suggested that HIV genomes detected in HPCs arise from T cell contamination.   
 
Methods.  CD133-sorted HPCs and CD133-depleted bone marrow cells were purified 
from 11 antiretroviral-treated donors with a viral load of <48 copies per ml for at least 6 
months.   CD133 and CD3 expression on the cells was assessed by flow cytometry.  HIV 
DNA was quantified by real time PCR.   
 
Results. HIV genomes were detected in CD133-sorted samples from 6 donors, including 
two with undetectable viral loads for more than 8 years.  CD3
+
 cells represented less than 
1% of cells in all CD133-sorted samples.   For 5 of 6 CD133-sorted samples with 
detectable HIV DNA, the HIV genomes could not be explained by contaminating CD3
+
 
cells.  Donors with detectable HIV DNA in HPCs were diagnosed significantly more 
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recently than the remaining donors but had had undetectable viral loads for similar 
periods of time.   
 
Conclusions. HIV genomes can be detected in CD133-sorted cells from a subset of 






 Latent HIV infection represents a major barrier to curing HIV (Finzi et al. 1999, 
Zhang et al. 1999).  When HIV establishes a latent infection within a cell, the DNA 
provirus integrates into the host cell’s genome but viral genes are not transcribed 
(reviewed in Geeraert et al. 2008).  As a result, the latently infected cell is 
indistinguishable from an uninfected cell and cannot be targeted by the immune system 
or current antiretroviral therapies.  The HIV provirus can persist in this state for the 
lifetime of the cell; however, it can also be reactivated if cellular conditions change, 
leading to the production of new virions and potentially new infection events (reviewed 
in Trono et al. 2010).  Thus, HIV replication will resume if antiretroviral therapy is 
discontinued unless all latent reservoirs of virus are eliminated. 
 Although resting memory CD4
+
 T cells are a well-studied reservoir for latent 
HIV, not all HIV sequences in the plasma of many successfully treated HIV
+
 donors can 
be matched to sequences in peripheral blood CD4
+
 T cells (Bailey et al. 2006, Brennan et 
al. 2009, Sahu et al. 2009).  These data suggest that additional reservoirs of virus exist 
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and contribute to residual viremia during treatment as well as to viral rebound upon 
treatment interruption (Sahu et al. 2009). 
 Recently, we proposed that hematopoietic progenitor cells (HPCs) in the bone 
marrow serve as a reservoir for latent HIV.  We assessed HIV-1 infection in CD34
+
 
HPCs from nine HIV-infected donors with undetectable viral loads on highly active 
antiretroviral therapy (HAART) for at least 6 months (Carter et al. 2010).  In four of nine 
donors, we detected HIV-1 proviral genomes in CD34-sorted cells at a frequency of 3-40 
HIV genomes per 10,000 cells (Carter et al. 2010), suggesting that these cells could serve 
as a reservoir of virus in optimally treated individuals.  Comparable amounts of HIV 
DNA were not observed in bone marrow cells immunodepleted for CD34 (Carter et al. 
2010).  However, subsequent studies have not detected HIV genomes in CD34
+
 HPCs 
from donors with undetectable viral loads (Durand et al. 2012, Josefsson et al. 2012) and 
have instead suggested that HIV genomes in CD34
+
 samples may be due to 
contamination with CD3
+
 T cells (Durand et al. 2012). 
 In addition to detecting HIV genomes in CD34
+
 cells ex vivo, we have shown that 
CD34
+
 cells can be infected by CCR5- and CXCR4-tropic HIV in vitro (Carter et al. 
2010).  We also demonstrated that HPCs expressing CD133, a marker for an immature 
subset of CD34
+
 HPCs, can only be infected by CXCR4-utilizing HIV-1 in vitro (Carter 
et al. 2011). However, HIV infection of CD133
+
 cells in vivo has not been assessed. 
 To investigate whether CD133
+
 HPCs are a reservoir for HIV-1 in vivo, we 
quantified HIV proviral genomes in CD133
+
 HPCs from 11 HIV
+
 donors with plasma 




 T cells in each sample to assess the possibility that HIV genomes 





Clinical Samples.  The donor samples analyzed in this study are a consecutive subset of 
our cohort, excluding two donors where the CD133-sorted sample did not meet our cutoff 
of 80% overall purity and two donors where samples had been used up in prior 
experiments (1 sample) or lost (1 sample).  We recruited HIV
+
 donors currently on 
antiretroviral therapy from the University of Michigan HIV-AIDS Treatment Program 
and obtained informed consent according to a protocol approved by the University of 
Michigan Institutional Review Board.  At the time of aspiration, all donors were over the 
age of 18, had normal white blood cell counts, and had had a plasma viral load of <48 
copies per ml for at least 6 months.  Twenty ml of bone marrow was aspirated from the 
posterior iliac crest of each donor, collected in preservative-free heparin, and processed 
immediately. 
 
Isolation of CD133-sorted and CD133-depleted cells.  Bone marrow mononuclear cells 
(BMMC) were isolated by Ficoll-Paque density separation (GE Healthcare).  Adherent 
cells were depleted by incubation in serum-free StemSpan media (STEMCELL 
Technologies) for two hours at 37ºC, then CD133
+
 cells were isolated by positive 
selection using a commercially available magnetic sorting kit (Miltenyi Biotec).  Cells 
were sequentially sorted on two columns to increase purity of the CD133-sorted 
population.  BMMCs that flowed through the first column were collected as the CD133-
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depleted fraction.  Samples were cryopreserved in 10% DMSO in fetal bovine serum 
until analysis. 
 
Flow cytometric analysis.  A fraction of each clinical sample was stained with R-
phycoerythrin-conjugated anti-CD133 (Miltenyi Biotec), allophycocyanin-conjugated 
anti-CD3 (eBioscience), and 7-Aminoactinomycin D (7-AAD).  BMMCs from a healthy 
donor (AllCells) were stained with R-phycoerythrin-conjugated anti-CD133, R-
phycoerythrin-Cy7-conjugated anti-CD34 (BD), and 7-AAD.  Samples were analyzed on 
a BD FACSCanto. 
 
DNA amplification.  Cells were lysed in MagNA Pure DNA Lysis/Binding Buffer 
(Roche) and DNA extracted using a MagNA Pure Compact System (Roche).  HIV-1 
DNA was quantified using a two-step real-time PCR assay.  In the first round, 5!l of 
DNA was amplified in each of 6 to 18 25!l reactions containing 2.5!l 10x Expand Long 




(702-714 in HXB2) and 2
nd
-LTR-F-univ (5’-GTGTIGAAAATCTCTAGCAGTGGC-3’) 
(616-639), and 500!M dNTPs. In some reactions, 400nM of ß-actin primers ß-actin-F 
(5’-CCTTTTTTGTCCCCCAACTTG-3’) and ß-actin-R (5’-TGGCTGCCTCCACCCA-
3’) were also added. The 13 bases at the 3’ end of the 1
st
-Gag-R primer are homologous 
to HIV-1 Gag, while the remaining bases form a tag used in the second round of the PCR. 
 DNA from ACH-2 cells (Clouse et al. 1989) diluted in DNA from uninfected 
primary HPCs or peripheral blood mononuclear cells (PBMCs) to a concentration of 10 
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HIV genomes per !l or 0.2 genomes per !l were used as a positive control and a control 
for sensitivity, respectively. DNA from uninfected HPCs or PBMCs was used as a 
negative control.  Thermocycling was conducted using a thermocycler preheated to 93ºC 
with the following cycling conditions: 93ºC for 2 minutes; 12 cycles of 93ºC for 15 
seconds, 60ºC for 30 seconds, 68ºC for 1 minute; and a final 1 minute at 68ºC. 
 Second round quantitative PCR reactions were conducted in triplicate, each using 
2!l of the first round reaction in a 50!l reaction.  Reactions contained 25!l FastStart 





-Tag-R (5’-CAATATCATACGCCGAGAGTGC-3’), and 250nM Gag-probe-2 (5’-
FAM-CGCTTCAGCAAGCCGAGTCCTGC-BHQ-1-3’) (Biosearch Technologies).  
Reactions were run and analyzed on an Applied Biosystems 7300 thermocycler (Applied 
Biosystems) with the following cycling conditions: 95ºC for 10 minutes, then 45 cycles 
of 95ºC for 15 seconds followed by 60ºC for 60 seconds. 
 Second round quantitative PCR reactions to amplify ß-actin were conducted to 
validate sample cell counts.  Conditions were identical to those listed for the HIV-1 
quantitative PCR except that the ß-actin-F and ß-actin-R primers and a ß-actin probe (5’-
FAM-CCCAGGGAGACCAAAAGCCTTCATACA-BHQ-1-3’) (Biosearch 
Technologies) were used. 
 
DNA sequencing.  All positive qPCR reactions were run on a 2% agarose gel, then the 
amplicon was excised from the gel and the DNA extracted using the QIAquick Gel 
Extraction Kit (Qiagen).  Amplicons were sequenced by Sanger dideoxy sequencing and 
analyzed using 4Peaks (Mekentosj), EditSeq (DNAStar), and MEGA 5.05. 
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Statistical analysis. 95% confidence intervals for cell counts were generated using Excel 





 were generated using a 95% confidence interval generator for binomial 
distributions (statpages.org/confint.html).  Fisher’s exact test was performed using an 
online calculator (www.langsrud.com/fisher.htm).  The Mann Whitney test was 
performed using GraphPad Prism version 5.0a. 
 
Results 
Donor characteristics.  The 11 donors included in this study had been diagnosed with 
HIV infection for an average of 11.9 years (standard deviation [s.d.] 8.1 years, range 3 – 
24 years) (Table 4.1).  Donors had viral loads of less than 48 copies per ml for at least 6 
months (mean 4.1 years, s.d. 2.7 years, range <1 – 8.4 years) and were being treated with 
at least 3 active antiretroviral agents at the time of bone marrow aspiration (Table 4.1). 
 
Magnetic sorting for CD133 minimizes contamination with CD3
+
 T cells.  Bone marrow 
mononuclear cells (BMMC) from each donor were subjected to magnetic sorting for 
CD133 (Figure 4.1A), a cell surface marker found on a subset of CD34
+
 cells (Figure 
4.1B).  CD133 and CD3 expression was analyzed on the CD133-sorted and CD133-
depleted populations by flow cytometry (Figure 4.1C).  Although the purity of the 
CD133-sorted populations varied from 84.4 – 98.9% for different donors, less than 1% of 
the cells in each CD133-sorted sample were positive for CD3 (Figure 4.1C and Table 
4.2).  By contrast, CD133-depleted samples contained 36-82% CD3
+
 cells.   
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HIV DNA is detected in CD133-sorted BMMCs.  We used a two-step, quantitative PCR 
assay to determine the frequency of HIV genomes in CD133-sorted and CD133-depleted 
samples. Donor samples were at limiting dilution as prepared, with no more than 1/3 of 
reactions yielding HIV amplification for any sample.  HIV-1 DNA was detected in 
CD133-sorted samples for 6 of 11 donors and in CD133-depleted samples for 6 of 11 
donors with between 0 and 2 total copies of HIV DNA detected per sample (Table 4.2).  
The frequency of cells containing HIV DNA varied from 0 to 42 per 100,000 cells for 
CD133-sorted samples and from 0 to 49 per 100,000 cells for CD133-depleted samples 




 T cells are unlikely to account for HIV DNAin CD133-sorted samples.  If the HIV 
genomes detected in our samples derived from CD3
+
 T cells, we would expect to observe 
many more HIV genomes in the CD133-depleted samples, which contain 36-82% CD3
+
 
cells, than in the CD133-sorted samples, which contain less than 1% CD3
+
 cells.  
However, we instead observed that the frequency of HIV genomes in the CD133-sorted 
samples was higher than the frequency of HIV genomes in the CD133-depleted samples 
for 4 of 11 donors (Table 4.2).  To further assess the possibility that contamination with 
CD3
+
 cells accounted for the HIV genomes observed in CD133-sorted samples, we 
calculated what the frequency of HIV genomes in the CD3
+
 cells in each CD133-sorted 
and CD133-depleted sample would be if all genomes detected derived from CD3
+
 cells 
(Figure 4.2A).  If all of the HIV genomes were derived from CD3
+
 cells, then we would 
expect these calculated frequencies to be similar in the CD133-depleted and CD133-
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sorted samples for each donor. Instead, we found that for each donor where an HIV 
genome was detected in the CD133-sorted sample, the calculated frequency of HIV 
genomes in the CD3
+
 cells from the CD133-sorted sample was much higher than the 
calculated frequency of HIV genomes in the CD3
+
 cells from the CD133-depleted sample 
(Figure 4.2A).  Using Fisher’s exact test, we found that the calculated frequency of HIV 
genomes in the CD3
+
 cells in the CD133-sorted sample was significantly greater than the 
calculated frequency of HIV genomes in the CD3
+
 cells in the CD133-depleted sample 
for donors 304000, 305000, 312101, 313212, and 315214 (p < 0.01 using mean estimates 
of CD3
+
 cell number, p < 0.01 (donors 305000 and 312101) or p < 0.05 (donors 304000, 
313212, and 315214) using conservative estimates; see legend for Figure 4.2A) (Figure 
4.2A).  For donor 311000 the same trend was observed but statistical significance was not 
achieved (p = 0.066 using mean estimates) (Figure 4.2A).  We therefore conclude that 
for at least 5 of the 6 donors with detectable HIV DNA in CD133-sorted cells, it is 
unlikely that the HIV DNA we detected in the sorted samples comes from T cell 
contamination. 
   We used an analogous calculation to determine whether total contaminating 
CD133
-
 cells could account for the HIV DNA observed in CD133-sorted samples.  For 
this analysis, we calculated what the frequency of HIV genomes in the CD133
-
 cells from 
the CD133-sorted and CD133-depleted samples would be if all genomes derived from 
CD133
-
 cells.  Using this analysis, we found that the frequencies of HIV genomes 
calculated to be present in the CD133
-
 cells in the CD133-sorted and CD133-depleted 
samples were significantly different for donors 305000 and 312101 (p < 0.05) (Figure 
4.2B).  For donors 313212 and 315214, a significant difference was observed using mean 
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estimates (p < 0.05) but not conservative estimates (p = 0.0506 or 0.136, respectively) of 
CD133
-
 cell number (see Figure 4.2A legend).  Donors 304000 and 311000 
demonstrated the same trend, but statistical significance was not achieved (p = 0.096 
(donor 31025) or 0.105 (donor 31031) using mean estimates) (Figure 4.2B).  We 
therefore conclude that total CD133
-
 contaminants are unlikely to be the source of HIV 
genomes in the CD133-sorted samples from donors 305000 and 312101.  Furthermore, 
for donors 304000, 313212, and 315214 we were able to rule out CD3
+
 T cell 
contamination as the source of the HIV genomes in the CD133-sorted samples, making 
CD133
+
 progenitors the most likely source of the genomes detected based on current 
knowledge of the cell types that can serve as long-lived reservoirs for HIV. 
 
HIV sequencing and assessment of contamination.  To assess whether the HIV DNA 
detected may have arisen from laboratory contamination, amplicons from the quantitative 
PCR reaction were separated from the primers and probe on a 2% agarose gel.  In all 
cases, a distinct band of approximately 120 base pairs was observed, confirming 
successful amplification (Figure 4.3A).  PCR products were extracted from the gel and 
sequenced, then aligned to the positive control (HXB2 DNA, Figure 4.3B).   An analysis 
of HXB2 DNA from three single copy reactions amplified alongside the donor samples 
revealed that all three sequences were identical and agreed with the HXB2 reference 
sequence.  In contrast, no two donors samples yielded identical sequences. 
Unsurprisingly, we did observe identical sequences within the CD133-sorted and CD133-
depleted fractions from the same donor (311000 and 315214).  Compared with the HXB2 
reference sequence, the number of differences we observed was similar to that observed 
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in samples from the Los Alamos database (Figure 4.3C).  Thus, it is unlikely that the 
positive results we obtained are due to contamination by the positive control template. 
 
Stability of HIV DNA in HPCs over time.  As noted in Table 4.1, four donors had donated 
samples for prior published studies (Carter et al. 2010, Carter et al. 2011).  At the time of 
the previous donation, two of these donors had high viral loads (>50,000 copies/ml; 
donors 308103 and 312101) and subsequently started therapy. The other repeat donors 
had undetectable viral loads at the time of previous donation (donors 313212 and 
315214).  In the prior study, HIV DNA was detected in HPC samples from both of these 
donors (previously referred to as donors 12 and 14, respectively (Carter et al. 2010)).  In 
concordance with these results, we also detected HIV DNA in the current HPC samples, 
which were collected after an additional 3.3 years of suppressive therapy.  Thus, HIV 
infection of HPCs can be consistently detected in the same donors after years of 
suppressed viral replication. 
 
Year of diagnosis is associated with detection of HIV DNA in CD133-sorted cells. In our 
prior study we had noted that of the 9 total donors, all 4 donors with detectable HIV DNA 
in progenitor cells were diagnosed relatively recently (in 2001 or later) whereas all three 
donors that had been diagnosed prior to 2001 were PCR negative.  We assessed whether 
this trend held in our current cohort and observed that donors with a positive PCR result 
were diagnosed significantly more recently than donors that did not have detectable 
provirus in CD133-sorted samples (p < 0.02, t-test) (Figure 4.4A).   One sample from a 
recently diagnosed donor was negative in the current study (308103).  However, only 
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14,000 cells could be analyzed from this donor (Table 4.2) and thus this may be a false 
negative result. The association between infection of HPCs and year of diagnosis does 
not result from differences in the duration of time these donors had received fully 
suppressive HAART (p = 0.49, t-test) (Table 4.1 and Figure 4.4B) or from differences in 




 Because reservoirs of latent virus represent a barrier to curing HIV, it is essential 
to identify all sources of persistent virus.  We have previously shown that CD34
+
 HPCs 
may serve as a persistent reservoir of virus in donors with HIV viral loads of <48 copies 
per ml (Carter et al. 2010); however, subsequent studies suggested that contamination 
with CD3
+
 cells may account for our positive results (Durand et al. 2012) or that HIV 
genomes in HPCs may not persist during years of therapy (Josefsson et al. 2012).  In the 
current study, we extend our previous findings by showing that HIV can be detected in 
the immature, CD133
+
 subset of HPCs from donors with undetectable viral loads, 
including two donors where we had detected HIV DNA in CD34
+
 HPCs in samples 
donated for our previous study 3 years earlier (Carter et al. 2010).  We furthermore 
demonstrate that for 5 of 6 CD133-sorted samples where HIV genomes were detected, 
CD3
+
 cell contamination does not provide a good explanation for our positive results.  
Finally, we demonstrate that HIV DNA can be detected in HPCs from antiretroviral-
treated patients who have had suppressed viral loads for up to 8 years.  Together, these 
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findings demonstrate that HPCs, including CD133
+
 HPCs, are a persistent reservoir of 
HIV DNA during therapy. 
The mean reported frequencies of HIV DNA in the CD34
+
 cells examined in our 
prior study (Carter et al. 2010) were higher than those reported for the CD133
+
 cells 
examined here.  However, the 95% confidence intervals for the true frequency of 
genomes in these cell populations are overlapping in the two donors who donated 
samples in both studies (data not shown).  These 95% confidence intervals are very broad 
because of the low number of detectable genomes. To better quantify the number of 
genomes in each cell population and to permit comparison with the frequency of HIV 
genomes in peripheral blood resting memory T cells, additional studies are needed that 
use larger cell numbers and that simultaneously compare HIV proviral DNA frequencies 
in all of these cell populations from the same donor.   
We report here that donors with evidence of infected HPCs were diagnosed 
significantly more recently than donors without evidence of infection.  This result cannot 
be explained by a shorter period of suppressive therapy or by the number of 
contaminating CD3
+
 cells.  Instead, we hypothesize that individuals with high levels of 
HIV infection in HPCs are less likely to have survived or maintained low viral loads until 
the present if they were diagnosed prior to the advent of HAART.  This reduced survival 
might be due to higher levels of CXCR4-tropic virus, which we have previously shown to 
be required for infection of immature HPCs in vitro (Carter et al. 2011) and which is 
associated with more rapid disease progression (Connor et al. 1997, Karlsson et al. 1994, 
Scarlatti et al. 1997, Shepherd et al. 2008, Waters et al. 2008, Weiser et al. 2008, Yu et al. 
1998), or to an as-yet uncharacterized factor. 
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In a recent study by Durand et al., which failed to detect evidence of infection of 
HPCs in optimally treated donors, 10 of 11 total donors were diagnosed prior to 2001 and 
5 of 11 donors were diagnosed during the 1980s (Durand et al. 2012).   Based on the 
results reported here, it is not surprising that positive results were not achieved in this 
study. In addition, the protocol used by Durand et al. included an overnight incubation in 
serum-containing media whereas our one-day protocol utilized media optimized to 
maintain progenitors in an undifferentiated state that preserves latent infection 
(McNamara et al. 2012). 
A second study authored by Josefsson et al., also failed to detect evidence of HIV 
infection of HPCs in eight optimally treated donors who were more recently diagnosed.  
However, methodological differences may have contributed to these negative results.  




 cells from the HPC population studied 
(Josefsson et al. 2012).  Because we have previously shown that CD4 expression on 





 cells would exclude the CD34
+
 cell population most likely to contain HIV 
genomes.  Furthermore, the primers used in our PCR analysis are substantially more 
conserved than those used by Josefsson and colleagues (data not shown), which could 
limit the sensitivity of their assay to detect variable donor HIV sequences.  
 In vitro, CD133
+
 HPCs are almost exclusively infected by HIV-1 envelopes that 
use CXCR4 as a coreceptor (Carter et al. 2011).  We would therefore expect that at least 
a minor population of CXCR4-tropic virus exists in the 6 donors for whom we detected 
HIV DNA in CD133-sorted cells.  This is consistent with studies showing that isolates 
predicted to use CXCR4 can be detected as a minor population in 12-50% of recently-
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infected patients (Abbate et al. 2011, Chalmet et al. 2012, Daar et al. 2007); furthermore, 
CXCR4-utilizing virus persists in patients on suppressive therapy (Seclén et al. 2012, 
Soulie et al. 2007) and may become more prevalent during therapy in some patients 
(Delobel et al. 2005, Hunt et al. 2006).  Further study to assess HIV envelope tropism in 
our cohort is needed to confirm the role of HIV envelope tropism in the infection of 
HPCs in vivo.   
 Our results demonstrate that HIV genomes can be detected in CD133
+
 HPCs from 
a subset of donors with undetectable viral loads and that the genomes detected are not 
explained by contamination with CD3
+
 T cells.  While these findings do not prove that 
HPCs serve as a reservoir for HIV in these donors, as the genomes detected may be 
defective, they do indicate that HPCs can retain HIV DNA during years of successful 
antiretroviral therapy.  We are currently investigating the contribution of HIV genomes in 
HPCs to residual viremia in treated donors.  Meanwhile, strategies to reactivate latent 
virus from HPCs should be considered alongside strategies that reactivate virus in resting 
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Time on ART with 
VL < 50 copies per 
ml (years) 
CD4 count 












303000 1990 1.0 1026 4.5 15.9 No 
304000 2004 3.3 533 4.8 9.35 No 
305000 2007 > 0.5 1421 6.4 15.4 No 
306000 1986/1987 3.4 1039 9.4 11.4 No 
307000 1992 5.8 829 8.0 20.7 No 
308103 2008 1.6 852 5.3 5.05 Yes (3) 
311000 1999 8.2 564 7.2 6.25 No 
312101 2006 2.2 812 7.5 8.75 Yes (1) 
313212 2002 8.4 466 4.0 9.00 Yes (12) 
314000 Late 1980’s 5.1 543 7.6 4.22 No 
315214 2006 5.0 850 6.3 4.11 Yes (14) 
1
Number in parentheses indicates the donor number in Carter et al. 2010.   
Note: VL = viral load; WBC = white blood cells; BMMC = bone marrow mononuclear 
cells.
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Table 4.2.  Purity of samples and frequency of HIV genomes detected 
Donor identifier 10
4
 Cells analyzed 
(95% CI) 
% CD133+ cells 
(95% CI) 
%CD3+ cells (95% CI) HIV genomes 
detected 
Frequency of HIV genomes 
per 10
5
 cells in vivo (95% CI) 
CD133-sorted samples      
303000 14 (9.7 – 17) 98.8 (98.4 – 99.0) 0.05 (0.01 – 0.14) 0 <0.71 (0 – 3.8) 
304000 2.7 (2.4 – 3.0) 84.4 (81.6 – 86.9) 0.80 (0.29 – 1.7) 1 3.7 (0.084 – 23) 
305000 6.0 (5.6 – 6.4) 94.1 (93.3 – 94.9) 0.59 (0.36 – 0.89) 1 1.7 (0.040 – 9.9) 
306000 5.4 (4.8 – 6.0) 94.3 (93.5 – 95.0) 0.62 (0.39 – 0.94) 0 <1.9 (0 – 7.7) 
307000 12 (11 – 13) 93.2 (92.5 – 93.8) 0.22 (0.12 – 0.38) 0 <0.83 (0 – 3.3) 
308103 1.4 (1.0 – 1.7) 92.1 (90.2 – 93.8) 0.23 (0.03 – 0.82) 0 <7.1 (0 – 37) 
311000 4.1 (3.6 – 4.5) 97.7 (97.1 – 98.3) 0.83 (0.51 – 1.3) 1 2.5 (0.057 – 15) 
312101 8.4 (5.9 – 11) 98.9 (98.7 – 99.1) 0.06 (0.02 – 0.15) 1 1.2 (0.023 – 9.5) 
313212 5.4 (4.3 – 6.5) 98.4 (98.0 – 98.7) 0.29 (0.16 – 0.48) 1 1.9 (0.039 – 13) 
314000 0.96 (0.83 – 1.1) 85.8 (81.4 – 89.5) 0.65 (0.08 – 2.3) 0 <10.4 (0 – 44) 
315214 0.48 (0.35 – 0.61) 92.4 (89.4 – 94.8) 0.76 (0.16 – 2.2) 2 42 (4 – 210) 
CD133-depleted samples      
303000 18 (13 – 23) 5.0 (4.0 – 6.2) 36 (34 – 38) 2 1.1 (0.11 – 5.7) 
304000 4.0 (3.6 – 4.3) 0.18 (0.01 – 1.5) 61 (56 – 66) 0 <2.5 (0 – 10) 
305000 17 (14 – 20) 0.13 (0.03 – 0.43) 52 (50 – 54) 0 <0.59 (0 – 2.7) 
306000 1.8 (1.7 – 2.0) 0.31 (0.08 – 1.1) 73 (70 – 76) 0 <5.6 (0 – 22) 
307000 13 (12 – 14) 1.6 (1.0 – 2.4) 43 (40 – 46) 1 0.77 (0.017 – 4.8) 
308103 1.1 (0.90 – 1.2) 0 (0 – 0.69) 75 (71 – 79) 2 19 (2.0 – 80) 
311000 2.5 (2.1 – 2.9) 0 (0 – 0.74) 58 (54 – 63) 2 8.1 (0.84 – 35) 
312101 5.4 (4.7 – 6.0) 0 (0 – 1.1) 44 (38 – 49) 0 <1.9 (0 – 7.8) 
313212 3.1 (2.4 – 3.8) 0 (0 – 0.55) 59 (55 – 63) 0 <3.2 (0 – 15) 
314000 0.54 (0.42 – 0.66) 0 (0 – 0.76) 82 (78 – 85) 1 19 (0.38 – 130) 






 cells isolated by magnetic sorting are minimally contaminated with 
CD3
+
 T cells.  A, Purification protocol.  CD133
+
 hematopoietic progenitor cells (HPCs) 
were isolated from total bone marrow mononuclear cells (BMMC) using anti-CD133-
conjugated magnetic beads.  Cells were sequentially sorted on two columns to maximize 
the purity of the CD133-sorted population.  Bone marrow cells not expressing CD133, 




 HPCs, were collected in the CD133-depleted 
fraction.  B, Example of CD133 and CD34 staining on adherence-depleted bone marrow 
cells from a healthy donor.  Live cells were gated based on forward scatter (FSC), side 
scatter (SSC), and 7-aminoactinomycin D (7-AAD) uptake.  Numbers indicate the 
percent of the population falling into each quadrant.  The percentage of BMMCs that are 
CD34
+
 ranges from 0.1 to 5% between donors.  C, Flow cytometric analysis of CD133 
and CD3 expression in CD133-sorted and CD133-depleted samples.  Live cells were 
gated based on FSC, SSC, and 7-AAD uptake.  Numbers indicate the percent of the 




Figure 4.2. HIV genomes detected in CD133-sorted samples are not attributable to 
contamination with CD3
+
 cells for a majority of samples.  A, Comparison of the 
frequency of HIV genomes in CD3
+
 cells from CD133-depleted samples (round symbols) 
with the frequency (square symbols) of HIV genomes in CD3
+
 cells in CD133-sorted 
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samples under the assumption that all HIV genomes are found in CD3
+
 cells.  Error bars 
indicate 95% confidence intervals for the frequency of HIV genomes in these cells.  For 
these calculations, the total number of HIV genomes detected in each sample was divided 
by the total number of CD3
+
 cells analyzed in each sample (= (total number of cells 
analyzed) X (fraction of cells that are CD3
+
)).   Fisher’s exact test was used to compare 
these calculated frequencies using (1) a mean estimate of the number of CD3
+
 cells 
analyzed as well as (2) a conservative estimate.  The conservative estimate used the upper 
bounds of the 95% confidence intervals for the observed number of CD3
+
 cells analyzed 
in the CD133-sorted samples and the lower bounds of the 95% confidence intervals for 
the number of CD3
+
 cells analyzed in the CD133-depleted samples.  * p < 0.01 by (1), p 
< 0.05 by (2); ** p < 0.01 by (1) and (2).  B, As A, except that it was assumed that all 
genomes were found in total CD133
-
 cells.  Mean (1) and conservative (2) estimates of 
the total number of CD133
-
 cells in each sample were calculated as in A.  * p < 0.05 by 




Figure 4.3. Sequence analysis of PCR products does not suggest contamination with 
HXB2 DNA.  A, Example of agarose gel analysis and purification of qPCR products.  S, 
CD133-sorted sample from the listed donor; FT, CD133-depleted (flowthrough); NT, no-
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template PCR control; HXB2, single copy of HXB2 HIV-1 DNA amplified from ACH-2 
cells.  B, Alignment of donor sequences with HXB2.  Numbers indicate coordinates in 
the HXB2 reference sequence.  The HXB2 sequence was obtained by sequencing 3 
single-copy qPCR reactions of HXB2 genomes from ACH-2 cells.  All 3 sequences were 
identical to the HXB2 reference sequence.  N’s in the 315214 Sort 2 sequence are due 
largely to double peaks, suggesting that more than one HIV genome was present.  C, 
Comparison of the number of differences from HXB2 in our donor sequences and the 
number of differences from HXB2 in all subtype B isolates in the Los Alamos database 
that have been sequenced through the region of our 61 nucleotide qPCR amplicon (n = 
378, 1 sequence per patient).  Each base pair change, insertion, and deletion was counted 
as 1 difference.  Box plots indicate median, first and third quartiles, and minimum and 
maximum excluding outliers; outliers are indicated with dots.  The 315214 Sort 2 
sequence was excluded due to the ambiguities in the sequence.  The median number of 





Figure 4.4. Donors with detectable HIV DNA in CD133-sorted samples were diagnosed 
significantly more recently than donors without detectable HIV DNA in CD133-sorted 
cells.  A, Comparison of the mean year of diagnosis of donors with or without detectable 
HIV DNA in CD133-sorted cells.  * p < 0.02, t-test.  Lines indicate mean and standard 
error; symbols indicate individual values.  Conservative estimates of the year of diagnosis 
were used in cases where the year of diagnosis was not known precisely (1987 for donor 
306000 and 1989 for donor 314000).  B, Comparison of the mean length of time that viral 
load in the plasma has been undetectable in donors with or without detectable HIV DNA 
in CD133-sorted cells.  The difference between the two groups is not significant (p = 
0.49, t-test).  Lines indicate the mean and standard error; symbols indicate individual 
values.  A conservative estimate of 0.5 years for time that the viral load in the plasma had 
been undetectable was used for donor 305000.
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 Latent HIV infection establishes reservoirs of virus that are a barrier to curing 
HIV.  In addition to the well-characterized reservoir in resting memory CD4
+
 T cells, we 
have proposed that hematopoietic progenitor cells (HPCs) in the bone marrow also serve 
as a reservoir for HIV (Carter et al. 2010).  In this dissertation, we have characterized this 
potential reservoir by examining the viral and cellular characteristics that promote active 
and latent HIV infection in HPCs as well as the extent of infection in HPCs from HIV-
infected donors.  In chapter 2, we demonstrated that CXCR4- and dual- but not CCR5-
tropic HIV can infect immature, multipotent HPCs.  We furthermore showed that 
CXCR4-tropic HIV was capable of infecting the most immature HPCs, hematopoietic 
stem cells (HSCs).  In chapter 3, we found that active as well as latent HIV infection 
could be established in HPCs with cell surface markers of multipotent cells, and that this 
latent infection could be reactivated by activation of the transcription factor NF-!B or by 
inhibition of histone deacetylases (HDACs).  Finally, in chapter 4, we demonstrated that 
HIV DNA can be detected in the immature, CD133
+
 subset of HPCs from donors who 
have had undetectable viral loads for up to 8 years.  Together, these findings demonstrate 
that immature HPCs have the potential to serve as a persistent reservoir of virus in vivo. 
 In this chapter, we will discuss the implications of these findings and situate them 
within the body of research on HIV pathogenesis and persistence during therapy.  We 
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will then explore new questions that are raised by these findings and discuss how they 
can be addressed in further studies.  Ultimately, this discussion will clarify how the data 
presented in this dissertation can contribute to the search for a cure for HIV. 
 
Summary of findings 
 
Multipotent HPCs are infected almost exclusively by CXCR4-using virus.  In chapter 2, 
we demonstrated that although CCR5-, dual-, and CXCR4-tropic HIV-1 envelopes all 
permit the infection of CD34
+




 HPCs can be readily 
infected only by CXCR4-using envelopes.  We confirmed that infection of these cells 
required use of the CXCR4 co-receptor through receptor-blocking experiments and 
demonstrated that CXCR4 is expressed on a larger fraction of CD133
+
 HPCs than is 
CCR5.  Together, these findings suggest that the more rapid disease progression 
associated with the emergence of CXCR4-using HIV isolates (Connor et al. 1997, Daar et 
al. 2007, Karlsson et al. 1994, Richman and Bozzette 1994, Schuitemaker et al. 1992, 
Shepherd et al. 2008, Waters et al. 2008, Weiser et al. 2008, Yu et al. 1998) could be 
related to the improved ability of these isolates to infect HPCs.  Possible mechanisms 
through which CXCR4-mediated infection of HPCs could contribute to disease 
progression are explored later in this chapter. 
 The finding that CCR5-tropic HIV has only a limited ability to infect immature 
HPCs suggests that these cells may not be a major target of viral infection in individuals 
who harbor only CCR5-tropic virus.  However, it is not clear how common it is for 
CXCR4-using virus to be entirely absent from an infected individual.  Although CCR5-
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tropic virus is more common than CXCR4-utilizing virus among recently infected 
individuals, new data suggest that 12-50% of recently infected individuals harbor at least 
minor populations of CXCR4-using virus (Abbate et al. 2011, Chalmet et al. 2012, Daar 
et al. 2007).  Furthermore, CXCR4-using virus often emerges later in the course of 
disease in patients who initially appear to harbor only CCR5-tropic strains (Karlsson et 
al. 1994, Scarlatti et al. 1997, Shankarappa et al. 1999).  Finally, the HIV Env protein can 
switch from CCR5- to CXCR4- or dual-tropic with a change of only one to two amino 
acids (De Jong et al. 1992, Raymond et al. 2008), and thus it would not be surprising if 
very small populations of CXCR4-using virus exist even in patients where only CCR5-
tropic virus is detected.  Thus, CXCR4-mediated infection of HPCs is expected to be 
relevant for a large proportion of HIV-infected individuals; however, the rates of 
infection in vivo would be expected to vary widely based on the prevalence of CXCR4-
using virus in each person.  This is consistent with the heterogeneity of infection rates in 
HPCs observed in our previous study (Carter et al. 2010) and in chapter 4. 
 
HSCs can be infected with CXCR4-tropic HIV.  We also showed that using a CXCR4-
tropic HIV envelope, we were able to infect HSCs capable of stable, multilineage 
engraftment in irradiated mice.  This finding may be of key importance to understanding 
HIV persistence: as HSCs can live for the lifetime of a person, a latent infection in this 
cell could create a reservoir of virus with an essentially infinite half-life.  The presence of 
such a reservoir was suggested by a recent analysis of the decay kinetics of low-level 
viremia in HAART-treated patients (Palmer et al. 2008).  Furthermore, active HIV 
infection and killing of HSCs could explain why HIV infection is associated with 
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depletion of multiple blood cell lineages, including many that are not targets of HIV 
infection (Adetifa et al. 2006, Dikshit et al. 2009, Meira et al. 2005, Mlisana et al. 2008, 
Redd et al. 2007a, Redd et al. 2007b). 
 Although several studies have reported HIV infection of HPCs (Carter et al. 2010, 
Davis et al. 1991, Folks et al. 1998, Neal et al. 1995, Redd et al. 2007a, Ruiz et al. 1998, 
Slobold et al. 1996, Stanley et al. 1992, Von Laer et al. 1990, Zauli et al. 1992), previous 
studies that focused specifically on HIV infection of HSCs were unable to detect HIV 
infection in this cell type (Shen et al. 1999, Weichold et al. 1998, Zhang et al. 2007).  
There are a number of methodological differences that could account for the negative 
results of previous studies, including different culturing conditions and different assays 
for HIV infection.  Due to the very low rates of infection that are possible in HSCs, 
highly sensitive assays for HSC infection, such as the flow cytometric assays that we 
employed, are essential to permit the detection of infected cells.  In addition, our cycling 
conditions promote the proliferation of HSCs whereas at least one prior study focused 
only on non-cycling cells (Shen et al. 1999); this could be an important factor in the 
discrepancy in our results if HSCs are more readily infected when they are cycling rather 
than quiescent.  Finally, it is important to note that previous studies have also conflicted 
with each other as to the mechanism by which HIV infection of HSCs is blocked.  One 
previous study reported solely an entry-level block that was overcome when virions were 
pseudotyped with VSV-G envelope (Shen et al. 1999), whereas another study suggested 
that the block to infection of these cells occurs at integration (Zhang et al. 2007).  
Although our data clearly demonstrate that these blocks to infection are not absolute, they 
may still contribute to the low rates of infection that we observe in HSCs and other types 
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of HPCs.  Indeed, we do observe much higher rates of infection in HPCs when we use 
virions pseudotyped with VSV-G envelope. 
 
Latent HIV-1 infection occurs in diverse HPC subsets.  While the findings presented in 
chapter 2 showed that immature HPCs, including HSCs, could be infected by HIV, it was 
not clear whether a latent HIV infection could be established in these cells.  In chapter 3, 
we expanded upon the findings of chapter 2 by demonstrating that HIV can establish a 















 cells are an HPC subset that contains stem cells and multipotent 







 subset has recently been shown to consist primarily of 
stem cells and MPPs (Doulatov et al. 2010).  Thus, our findings demonstrate that latent 
HIV infection can occur in HPCs that have the cell surface markers of immature, 
multipotent cells. 
 An interesting aspect of our findings is that both active and latent infection could 
be established in the same HPC population with no indication that active or latent 
infection occurred preferentially in a specific HPC type.  This finding suggests that the 
establishment of latency in our model depends to some extent on stochastic factors, such 
as the integration site of the virus (Jordan et al. 2003) or variation in the level of Tat 
produced immediately following integration (Weinberger et al. 2005).  Further studies to 
evaluate the impact of exogenous Tat on the establishment or maintenance of latency in 
this system or to identify the integration sites of active vs. latent HIV genomes would 
clarify the role of stochastic factors in latent infection of HPCs. 
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 A limitation of our findings in chapter 3 is that we were unable to determine 
whether latent HIV infection could occur specifically in bona fide HSCs.  Although 
several cell surface markers have recently been proposed to more specifically identify 
human HSCs, notably Thy-1 (Majeti et al. 2007) and CD49f (Notta et al. 2011), we were 
unable to detect sufficient expression of these markers in our CD34
+
 HPCs to analyze in 
our study (data not shown).  The stability of these markers in culture has not been 
demonstrated and in our experiments the expression of these markers seemed to change 
substantially over our 6-day culture period.  We found that initially detectable Thy-1 
declined to undetectable levels while CD49f became highly expressed on the more 
differentiated cells in our culture, as assessed by (lack of) CD34 staining and colony-
forming ability (data not shown).  Thus, it presently does not seem feasible to identify 
HSCs by cell surface markers under our culture conditions. 
 The ability of HIV to establish a latent infection in HSCs might be better assessed 
via a xenograft assay. HPCs could be infected with a non-cytotoxic reporter virus 
expressing GFP under the control of the HIV-1 LTR, then the GFP
-
 subset that contains 
both uninfected and latently infected cells could be sorted out and transplanted into mice.  
Mature peripheral blood cells could then be screened for GFP expression or, as we have 
not confirmed that lymphoid differentiation results in the reactivation of latent HIV, HIV 
genomes could be detected by PCR.  Long-term reconstitution of both the myeloid and 
lymphoid lineages with human GFP
+
 or HIV DNA-containing cells would indicate the 
engraftment of a latently infected stem cell in the mouse, thereby clarifying the ability of 
HIV to establish a latent infection in this cell type. 
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Latent HIV-1 infection in HPCs can be reversed by NF-!B activation or histone 
deacetylase inhibition.  In HPC populations that supported the establishment of latent 
HIV infection, we found that levels of nuclear NF-!B family members were uniformly 
low whereas positive transcription elongation factor b (P-TEFb) was readily detected.  
Furthermore, conditions that reactivated latent virus resulted in a distinct upregulation of 
most NF-!B family members in the nucleus but did not affect P-TEFb expression.  These 
findings contrast with observations in resting T cells, where TNF-"-induced NF-!B 
activation is insufficient to reactivate latent virus while upregulation of both nuclear NF-
!B and P-TEFb through T cell receptor signaling reactivates latent virus efficiently 
(Tyagi et al. 2010). 
 The finding that P-TEFb restriction is not associated with the establishment of 
latency in HPCs may indicate that there are fewer factors reinforcing latency in this cell 
type than in T cells.  This reduced reinforcement of latent infection could potentially 
result in more frequent reactivation of latent virus in these cells.  Such an increased rate 
of reactivation might lead to reduced stability and more rapid decay of this reservoir.  
Alternatively, if the reservoir is maintained through HPC proliferation in spite of 
increased rates of reactivation, this reactivation might lead this reservoir to contribute 
disproportionately to the residual viremia detected in HAART-treated patients.  This 
latter possibility is consistent with studies demonstrating that most viral sequences in the 
plasma of many HAART-treated patients cannot be matched to sequences found in 
peripheral blood resting memory T cells (Bailey et al. 2006, Brennan et al. 2009, Lopez 
et al. 2010, Sahu et al. 2009), and might suggest that HPCs could contribute 
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disproportionately to residual viremia even if very few HPCs harbor latent viral genomes 
in vivo. 
 We found that NF-!B activation by both prostratin and TNF-" reactivated latent 
virus in our HPC model system.  Prostratin was not toxic to our cells but did induce 
substantial differentiation that could have negative consequences in vivo.  TNF-" was 
also non-toxic to our cells and, unlike prostratin, did not induce cell differentiation; 
however, this cytokine has been associated with significant toxicity in vivo (reviewed in 
Beutler and Cerami 1986).  Interestingly, it has been shown that activation of the heat 
shock response in mice can reduce TNF-"-related toxicity without negating this 
cytokine’s anti-tumor effects (Van Molle et al. 2002, Van Molle et al. 2007).  If a similar 
strategy can reduce TNF-"-related toxicity in humans, TNF-" could potentially be used 
therapeutically to reactivate latent virus in HPCs and eliminate this viral reservoir.  
However, the ability of the heat shock response to modify TNF-" toxicity in humans has 
not yet been investigated and it is not clear how this response could be safely and 
effectively induced. 
 We also found that the histone deacetylase inhibitor suberoylanilide hydroxamic 
acid (SAHA) reactivates latent virus in HPCs whereas hexamethylene bisacetimde 
(HMBA) and the methylation inhibitor 5-aza-2’-deoxycytidine (Aza-CdR) does not.  The 
findings that HMBA and Aza-CdR are unable to reactivate latent virus in HPCs may not 
be surprising.  HMBA is purported to act by activating P-TEFb (Contreras et al. 2007), 
which is not restricted in HPCs.  Methylation, meanwhile, is thought to be a late event in 
the maintenance of viral latency (Blazkova et al. 2009, Duverger et al. 2009, Kauder et al. 
2009); however, our short-term model system could examine only early factors in latency 
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establishment.  Nevertheless, our findings suggest that as in T cells, histone deacetylases 
may be recruited to the latent HIV LTR in HPCs; thus, inhibition of histone deacetylases 
may provide a common mechanism whereby latent infection could be eliminated in both 
cell types.  Unfortunately, we observed that SAHA was toxic to HPCs at doses that 
reactivated latent virus, suggesting that this compound could not be effective in vivo 
without significant toxicity.  Further research is required to determine whether other 




 HPCs are a reservoir for HIV DNA in patients with undetectable viral loads.  
Finally, in chapter 4 we investigated whether CD133
+
 HPCs harbor HIV DNA in 
HAART-treated donors who have had clinically undetectable viral loads for at least 6 
months.  In 6 out of 11 donors, we were able to detect HIV DNA in CD133-sorted 
samples at a frequency of 1.2 - 42 genomes per 100,000 cells.  Furthermore, we were able 
to demonstrate that for at least 5 of these 6 donors, contamination with CD3
+
 T cells was 
not a good explanation for the genomes detected in the sample.  These results confirm our 
previous finding that HPCs from HAART-treated donors contain HIV-1 DNA (Carter et 
al. 2010) and extend these findings to demonstrate that the immature, CD133
+
 subset of 
HPCs also harbors HIV-1 DNA after up to 8 years of viral suppression. 
 We also found that the mean year of diagnosis for donors where we were able to 
detect HIV genomes in CD133-sorted samples was significantly more recent than the 
mean year of diagnosis for donors where we could not detect HIV genomes in these cells.  
This association could not be explained by the decay of this viral reservoir during 
treatment, as the mean length of time that donors had had undetectable viral loads was 
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similar in the two groups.  Although it is not yet clear why year of diagnosis would be 
associated with infection of HPCs, this finding may partially explain the discrepancy 
between our results and those recently reported by Durand and colleagues, who were 
unable to detect HIV DNA in HPC samples from a cohort of 11 HAART-treated donors 
(Durand et al. 2012).  Six of the 11 donors in this cohort had been diagnosed in 1990 or 
earlier, and thus based on the association we observed it may not be surprising that these 
donors did not show evidence for HIV infection in HPCs.   
 Another recent study was also unable to detect HIV DNA in hematopoietic 
progenitor cells.  This study focused on 8 donors, of whom 5 had been treated during 
acute HIV infection (Josefsson et al. 2012).  Such donors would be expected to have very 
low levels of HIV DNA in any cell type; furthermore, the observation that CXCR4-tropic 
virus usually constitutes a relatively small fraction of the total virus found in recently-
infected donors (Abbate et al. 2011) suggests that infection rates in HPCs would be even 
lower than those in T cells.  Although such a low infection rate could still be 
physiologically relevant, as a single latently infected HSC could serve as a lifelong viral 
reservoir, it would be extremely difficult to detect HIV infection of HPCs in these donors. 
 The negative results from the remaining donors in these two studies might be 
explained in part by heterogeneity in the frequency of HIV infection in HPCs in different 
donors, which we have observed to vary widely (chapter 4 and Carter et al. 2010).  
Furthermore, methodological differences between these studies and ours could impact the 
detection of HPCs.  In particular, Josefsson and colleagues isolated CD34
+
 HPCs through 
a sorting protocol that specifically eliminated CD4
+
 cells from the CD34-sorted 
population (Josefsson et al. 2012).  However, as we showed in chapter 2, CD4 is required 
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for infection of HPCs by HIV; thus this sorting protocol may have removed those HPCs 
most likely to contain HIV DNA from the samples analyzed.  In addition, the primers 
used by Josefsson et al. to detect HIV DNA are less conserved in subtype B HIV isolates 
than those we used (data not shown), which may also have decreased the sensitivity of 
their assay.  Finally, Durand and colleagues cultured their cells in serum-containing 
medium overnight prior to sorting.  The effects that this protocol might have on the 
survival or CD34 expression of HIV-infection HPCs are unknown. 
 A final possible explanation for the discrepancy between our results and those of 
other groups is that some of the genomes detected in our CD133-sorted samples are due 
to contaminating cell types.  Although we showed that CD3
+
 T cell contamination is 
unlikely to explain the HIV DNA detected in 5 out of 6 of our positive CD133-sorted 
samples, we were able to rule out total contamination as an explanation for the HIV DNA 
detected for only 2 of 6 samples.  It is possible that long-lived macrophages or mast cells 
in the bone marrow could contain HIV DNA.  As these cells express Fc receptors, they 
might non-specifically bind the antibodies used in our sorting protocols and thus end up 
in our CD133-sorted populations.  However, bone marrow macrophages or mast cells 
have never been reported to harbor HIV genomes in donors with undetectable viral loads.  
Furthermore, if contamination were the explanation for the detection of HIV DNA in our 
sorted samples, we would expect to see an association between sample purity and 
genome detection in our cohort; however, we did not detect such an association.  Finally, 
it should be noted that the samples analyzed by Josefsson et al. were only 76.7% pure on 
average (Josefsson et al. 2012) whereas all of the CD133-sorted samples analyzed in our 
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study were more than 80% CD133
+
.  Thus, it is unlikely that contamination would serve 
as a source of HIV genomes in our HPC samples but not in theirs. 
 In sum, there are many possible explanations for the discrepancies between our 
findings and those observed by other groups.  Hopefully, additional research on this topic 
will clarify the reasons that other studies have not detected HIV genomes in HPCs and 
will allow us to better understand the importance of this potential viral reservoir in vivo.  
 
Future directions 
 The studies described in this dissertation raise exciting new questions about the 
role of HPCs in HIV pathogenesis and persistence.  In this section, we will outline some 
of these questions and discuss how they might be addressed in future studies.  
Specifically, we will discuss how infection of HPCs might contribute to the more rapid 
disease progression associated with the emergence of CXCR4-tropic virus.  We will also 
discuss additional factors that may affect the establishment or maintenance of latent HIV 
infection in HPCs and examine how we can develop strategies that may be able to 
reactivate latent virus in this potential viral reservoir.  Finally, we will discuss possible 
explanations for the heterogeneous rates of HIV infection observed in HPCs in vivo and 
outline the additional research that is needed to understand the role of these cells in the 
persistence of HIV during treatment.  Through these additional studies, some of which 
are already ongoing in our lab, we will enhance our understanding of latent infection of 
HPCs and move one step closer to a cure for HIV. 
 
 181 
Contribution of HPC infection to disease progression associated with the emergence of 
CXCR4-tropic virus.  It is not yet clear whether our finding that only CXCR4-tropic HIV 
is able to infect immature HPCs may contribute to the association between the emergence 
of CXCR4-using virus and more rapid disease progression (Connor et al. 1997, Daar et 
al. 2007, Karlsson et al. 1994, Richman and Bozzette 1994, Schuitemaker et al. 1992, 
Shepherd et al. 2008, Waters et al. 2008, Weiser et al. 2008, Yu et al. 1998).  The 
enhanced ability of CXCR4-tropic HIV to infect immature HPCs suggests that one 
explanation for the association between the emergence of CXCR4-tropic virus and 
disease progression could be the infection and destruction of immature HPCs.  By killing 
HPCs, CXCR4-tropic virus could hasten disease progression by diminishing production 
not only of CD4
+
 T cells, but also of the CD8
+
 T cells and other immune system cells that 
help to control viral replication. 
 This possibility is supported by data showing that the emergence of CXCR4-
tropic virus is associated not only with a more rapid decline in CD4
+
 T cell counts 
(Connor et al. 1997, Daar et al. 2007, Karlsson et al. 1994, Richman and Bozzette 1994), 
but also with a loss of T cell homeostasis that results in a decline in total T cell numbers 
(Maas et al. 2000, Shankarappa et al. 1999, Shepherd et al. 2008), including CD8
+
 T cells 
(Hazenberg et al. 2003, Yu et al. 1998).  A decline only in CD4
+
 T cell counts could be 
explained by the enhanced infection rate and cytotoxicity of CXCR4-using virus in these 
cells (Grivel and Margolis 1999, Grivel et al. 2000, Jekle et al. 2002, Jekle et al. 2003, 
Kreisberg et al. 2001, Schramm et al. 2000, Schuitemaker et al. 1992), but the observed 
decline in CD8
+
 T cells, which do not express CD4, cannot be explained by direct 
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infection of the mature lymphocytes.  Infection of hematopoietic progenitor cells could 
account for the loss of both T cell subsets. 




 T cells could also be accounted for by 
infection and killing of committed T-cell progenitors in the thymus, some of which have 
been reported to express high levels of CXCR4 (Berkowitz et al. 1998).  Indeed, HIV-
induced apoptosis of thymocyte progenitors by CXCR4-tropic HIV has been reported 
(Choudhary et al. 2006, Su et al. 1995), and one study has suggested that CXCR4-tropic 
virus replication in the thymus depletes thymic progenitors to a greater extent than 
CCR5-tropic virus does (Berkowitz et al. 2000).  By contrast, depletion of more 
immature HPCs by CXCR4-tropic virus should result in a loss of additional mature blood 
cell types.  Although numerous hematological abnormalities have been associated with 
HIV infection, including anemia, neutropenia, thrombocytopenia, leucopenia, and 
depletion of bone marrow B cells (Adetifa et al. 2006, Dikshit et al. 2009, Meira et al. 
2005, Mlisana et al. 2008, Redd et al. 2007a, Redd et al. 2007b), the association of these 
hematologic abnormalities with viral envelope tropism was addressed only in one study 
in which the frequency of patients with CXCR4-tropic virus was too low to draw 
definitive conclusions (Calis et al. 2008).  One additional study did observe an 
association between hematopoietic progenitor infection and anemia, but in this study viral 
envelope tropism was not assessed (Redd et al. 2007a).  Additional studies assessing viral 
envelope tropism, hematologic abnormalities, and infection rates in hematopoietic 
progenitors in treatment-naïve, HIV-infected individuals would clarify how CXCR4-
mediated infection of HPCs might contribute to cytopenias in vivo.  
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Finding new ways to reactivate latent HIV.  Using the assay for reactivation of latent 
virus in HPCs that we developed in chapter 3, we are continuing to screen additional 
compounds for the ability to reactivate latent virus in this cell type.  Thus far our efforts 
have focused on disulfiram, an FDA-approved compound that reactivates latent virus in a 
T cell model (Xing et al. 2011), as well as several HDAC inhibitors that might be more 
active or less toxic than SAHA (Nakajima et al. 1998, Rai et al. 2008, Thomas et al. 
2008).  We also plan to investigate whether inhibitors of specific histone deacetylases 
might reactivate latent virus with reduced cytotoxicity.  A recent study demonstrated that 
specific inhibition of Class II HDACs reactivated latent virus in the ACH-2 latently 
infected T cell line (Clouse et al. 1989, Palmisano et al. 2012) and that the toxicity of this 
treatment was less than that of pan-HDAC inhibition with trichostatin A (Palmisano et al. 
2012).  Inhibition of Class II HDACs did not reactivate latent virus in the latently 
infected pro-monocytic U1 cell line (Folks 1987, Palmisano et al. 2012), however, 
highlighting the importance of investigating whether different components of the 
chromatin modification machinery contribute to HIV latency in different cell types.  We 
will thus continue to use our assay to screen compounds that have been demonstrated to 
reactivate latent HIV in other cell types as well as to test novel compounds for the ability 
to reactivate latent HIV. 
 Although the use of primary HPCs ensures that our model of latent infection 
accurately reflects HPC-specific factors that impact latency in this cell type, the use of 
primary cells also limits the speed with which we can screen novel compounds for the 
ability to reactivate virus.  Because of this, we have attempted to develop a cell-line 
model for latency in HPCs using the CD34
+
 KG-1 and KG-1a cell lines.  Unfortunately, 
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we were not able to establish a latent HIV infection in these cells.  However, additional 
CD34
+
 cell lines exist (Lorenzana et al. 1993, Rajotte et al. 1996, Simmons et al. 1992) 
and may be more permissive to the establishment of latent infection.  The identification 
of an HPC-like cell line in which latent HIV infection could be established would allow 
us to perform high-throughput screening to identify novel compounds that reactivate HIV 
in this cell type.  The activity of these compounds in primary cells could then be verified 
in our existing model.  The combination of these two methods could provide a powerful 
way to identify new compounds that reactivate latent HIV in HPCs. 
 
Impact of HPC cycling on the establishment and maintenance of latency.  In our model of 
latent infection in HPCs, we were able to establish a latent infection in spite of the fact 
that the cells were cycling during the course of our assays with a mean doubling time of 
24-48 hours (data not shown).  However, we also observed spontaneous reactivation in a 
proportion of latently infected cells.  This low-level spontaneous reactivation is likely 
related to the ongoing differentiation that unavoidably occurs in cultures of immature 
HPCs; additionally, it could be related to the proliferation of the cells.  Such low-level 
reactivation of latent virus has been observed in latently infected T cells induced to 
proliferate via IL-7 stimulation (Bosque et al. 2011). 
 Based on this observation, we are currently investigating the role of cell cycling in 
the establishment and maintenance of latent infection in HPCs.  Our initial approach to 
this question is to determine whether the rates of active or latent infection or of 
spontaneous reactivation are altered when HPCs are cultured with or without cytokines 
that induce proliferation.  We will also use carboxyfluorescein succinimidyl ester (CFSE) 
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to track cell cycling and investigate whether latency or spontaneous reactivation occurs 
specifically in dividing or non-dividing cells.  These studies will not only help us to better 
understand the factors controlling the establishment and maintenance of latent infection 
in our model, they will further our understanding of HIV infection of HSCs, which are 
found predominantly in a non-cycling state in vivo (Cheng et al. 2000). 
 
Impact of HPC differentiation on latent HIV.  Although we have demonstrated that 
induction of myeloid differentiation with the cytokines GM-CSF and TNF-! results in 
reactivation of latent virus (Carter et al. 2010), we have not evaluated the impact of 
lymphoid differentiation on latently infected HPCs.  B and T cell differentiation both 
involve the activation of NF-"B (Liou et al. 1994, Voll et al. 2000), which we have 
shown to reactivate latent virus in HPCs.  Thus, we would expect differentiation along 
these pathways to reactivate latent virus, resulting in cell death and an absence of HIV-
infected B cells in the periphery.  The importance of NF-"B in natural killer (NK) cell 
differentiation is not as well understood.  Although activated NF-"B is present in 
immature NK cells, levels of NF-"B are relatively low compared to those found in B 
cells (Samson et al. 2004).  Furthermore, the differentiation of NK cells appears to be less 
sensitive to NF-"B levels than is B or T cell differentiation (Samson et al. 2004).  As a 
result, it is not clear whether inducing HPCs to differentiate down the NK cell lineage 
would result in reactivation of latent virus. 
 Conditions to differentiate CD34
+
 HPCs into NK cells in vitro have been 
developed (Grzywacz et al. 2011) and could be integrated with our reactivation assay to 
assess whether NK cell differentiation reactivates latent HIV.  Investigating the fate of 
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latently infected HPCs induced to differentiate into NK cells would illuminate whether 
these cells might be expected to harbor HIV genomes in vivo, a topic which has not been 
directly addressed.  Furthermore, if latent infection is reactivated during NK cell 
differentiation, the mechanism of this reactivation may differ from that observed during 
myeloid differentiation.  Thus, studying the effects of NK cell differentiation on latently 
infected HPCs may allow us to identify novel mechanisms through which latent virus can 
be reactivated in these cells. 
 
Heterogeneity in the frequency of HIV infection in HPCs in vivo.  As noted above, we 
found an association between year of diagnosis and detection of HIV genomes in HPC 
samples in our donor cohort.  This association could not be explained by the decay of the 
viral reservoir during treatment, as there was no difference in the length of time that 
donors had had suppressed viral loads between donors for whom we could detect HIV 
genomes in HPCs and donors for whom we could not.  An alternative explanation is that 
donors with high rates of HIV infection in HPCs who were diagnosed prior to the advent 
of combination antiretroviral therapy in 1995-6 (Hogg et al. 1997) may have been less 
likely to survive to the present day or to maintain suppressed viral loads.  We 
demonstrated in chapter 2 that CXCR4-tropic viruses, which are associated with more 
rapid disease progression (Connor et al. 1997, Daar et al. 2007, Karlsson et al. 1994, 
Richman and Bozzette 1994, Schuitemaker et al. 1992, Shepherd et al. 2008, Waters et al. 
2008, Weiser et al. 2008, Yu et al. 1998), have a greatly enhanced ability to infect 
immature HPCs compared to CCR5-tropic HIV.  Thus, donors with high levels of 
CXCR4-tropic virus would be expected to be more likely to both harbor HIV DNA in 
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HPCs and to experience mortality if they were diagnosed prior to the advent of HAART.  
Further research to assess the envelope tropism of the virus in our donors could reveal 
whether the presence of CXCR4-using virus in the plasma or in HPCs is associated with 
HPC infection in vivo. 
 A second possibility is that inflammation induces HSC cycling that results in 
increased HIV infection in these cells.  Biomarkers of inflammation are increased among 
HIV-infected patients with higher viral loads (Eastburn et al. 2011, Kuller et al. 2008), 
and higher viral loads are associated with more rapid disease progression (Mellors et al. 
1995, Mellors et al. 1996).  Thus, HIV-infected individuals with high levels of 
inflammation might again be less likely to have survived until the present if they were 
diagnosed prior to the development of HAART.  Meanwhile, HSCs have been shown to 
proliferate in response to inflammation (Baldridge et al. 2010, Essers et al. 2009, 
Takizawa et al. 2011), which might alter how permissive these cells are to HIV infection.  
The role of HPC cycling in HIV infection and latency will be investigated through the 
experiments described above.  In addition, the possible role of inflammation in the 
infection of HPCs in vivo could be assessed by measuring viral loads, markers of 
inflammation, and levels of HIV DNA and protein in HPCs in untreated HIV-infected 
patients.  If an increased viral load and increased inflammation promotes infection of 
HPCs, as proposed here, an increased infection rate in these cells would be observed in 
donors with increased viral loads and biomarkers for inflammation.  This investigation 
would shed light on the observed association between year of diagnosis and HIV 
infection in HPCs and would help to explain the heterogeneous rates of infection 
observed in this cell subset. 
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Do HIV genomes in HPCs contribute to residual viremia in treated patients?  To truly 
understand the role of HIV-infected HPCs in the persistence of HIV, it is essential to 
determine whether HIV genomes found in HPCs contribute to residual viremia during 
HAART.  To assess this question, we will amplify HIV sequences from plasma, 
peripheral blood resting memory T cells, and purified HPC populations at limiting 
dilution so that we can assess the variation among sequences within each compartment.  
We will then use a phylogenetic analysis to assess whether there are viral sequences in 
the plasma that are more related to the sequences found in HPCs than to those in T cells.  
As previously noted, a large proportion of residual viral sequences in the plasma of 
HAART-treated individuals are not closely related to those found in peripheral blood T 
cells (Bailey et al. 2006, Brennan et al. 2009, Lopez et al. 2010, Sahu et al. 2009).  Thus, 
the finding that some or all of the sequences that cannot be matched to those in resting 
memory T cells are similar to those found in HPCs would provide strong evidence for a 
role of HPC infection in the persistence of HIV during HAART. 
 It is also possible that the genomes detected in HPCs will be highly similar to 
those found in CD4
+
 T cells.  This finding would demonstrate that there must be yet 
another, as yet uncharacterized reservoir for latent HIV in HAART-treated patients that 
contributes substantially to residual viremia.  Either way, the results of this study will 
provide important new information on the source of residual virus in effectively treated 
patients, which will allow us to better assess which cell types need to be targeted to 





 In this dissertation, we have investigated the role of HPCs in the pathogenesis and 
persistence of HIV infection.  We found that CXCR4- but not CCR5-tropic HIV is able to 
infect immature, multipotent hematopoietic progenitor cells.  We furthermore showed 
that even extremely long-lived HSCs are susceptible to infection with CXCR4-tropic 
HIV, providing a mechanism for lifelong persistence of HIV in vivo.  In addition, we 
demonstrated that immature, CD133
+
 HPCs could be latently infected by HIV in vitro 
and that these cells may serve as a reservoir for latent HIV in vivo that persists through at 
least 8 years of suppressive antiretroviral therapy.  An updated model of HIV infection in 
HPCs that incorporates these findings is shown in Figure 5.1. 
 These findings suggest that we need to look beyond T cells when developing 
approaches to eradicate reservoirs of latent HIV.  Through the development of a primary 
cell model for latent HIV infection in HPCs, we have provided the first data on strategies 
that may eliminate latent virus from this cell type.  We found that both activation of NF-
!B and inhibition of histone deacetylases reactivate latent virus from these cells.  In 
combination with strategies that reactivate latent virus from T cells, modulation of these 
cellular factors might provide a means of eliminating latent reservoirs of virus from HIV-
infected people.  The findings described in this dissertation thus provide a foundation for 
further research that will lead us closer to a cure for HIV. 
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Figure 5.1. Updated model of HIV-1 infection in hematopoietic progenitor cells.  
Modifications to the model based on the work shown in this dissertation are highlighted 
in green.  Immature, CD133
+
 hematopoietic stem and progenitor cells (HSPCs) can be 
infected by CXCR4-utilizing HIV-1 (chapter 2), leading either to active infection, cell 
death, and virion release, or to latent infection (chapter 3).  Latently infected HSPCs with 
self-renewal capacity can continue to self-renew, generating an expanded reservoir of 
latent HIV-1 in these cells that persists for at least 8 years during highly active 
antiretroviral therapy (chapter 4).  If the latently infected HSPC is induced to differentiate 
or stimulated with compounds that activate NF-!B or inhibit histone deacetylases 
(HDAC), the latent virus can reactivate (chapter 3), leading to cell death and virion 
release. Modified from Collins and McNamara 2011. 
 191 
References 
Abbate I, Vlassi C, Rozera G, et al.  Detection of quasispecies variants predicted to use 
CXCR4 by ultra-deep pyrosequencing during early HIV infection.  AIDS 2011; 
25:611-7. 
Adetifa I, Temiye E, Akinsulie A, et al.  Haematological abnormalities associated with 
paediatric HIV/AIDS in Lagos.  Annals of Tropical Paediatrics 2006; 26:121-125. 
Bailey J, Sedaghat A, Kieffer T, et al.  Residual human immunodeficiency virus type 1 
viremia in some patients on antiretroviral therapy is dominated by a small number 
of invariant clones rarely found in circulating CD4+ T cells.  J Virol 2006; 
80(13):6441-6457. 
Baldridge M, King K, Boles N, et al.  Quiescent haematopoietic stem cells are activated 
by IFN-! in response to chronic infection.  Nature 2010; 465:793-7. 
Berkowitz R, Beckerman K, Schall T, et al.  CXCR4 and CCR5 expression delineates 
targets for HIV-1 disruption of T cell differentiation.  J Immunol 1998; 161:3702-
3710. 
Berkowitz R, Alexander S, and McCune J.  Causal Relationships between HIV-1 
Corecptor Utilization, Tropism, and Pathogenesis in Human Thymus.  AIDS Res 
Hum Retroviruses 2000; 16(11): 1039-45. 
Beutler B and Cerami A.  Cachectin and tumour necrosis factor as two sides of the same 
biological coin.  Nature 1986; 320:584-8. 
Blazkova J, Trejbalova K, Gondois-Rey F, et al.  CpG methylation controls reactivation 
of HIV from latency.  PLoS Pathog 2009; 5(8):e1000554. 
Bosque A, Famiglietti M, Wyrich A, et al.  Homeostatic Proliferation Fails to Efficiently 
Reactivate HIV-1 Latently Infected Central Memory CD4+ T Cells.  PLoS Pathog 
2011; 7(10):e1002288. 
Brennan T, Woods J, Sedaghat A, et al.  Analysis of human immunodeficiency virus type 
1 viremia and provirus in resting CD4+ T cells reveals a novel source of residual 
viremia in patients on antiretroviral therapy.  J Virol 2009; 83(17):8470-8481. 
Calis J, Phiri K, Faragher E, et al.  Severe anemia in Malawian children.  N Engl J Med 
2008; 358(9):888-899. 
Carter C, Onafuwa-Nuga A, McNamara L, et al. HIV-1 infects multipotent progenitor 
cells causing cell death and establishing latent cellular reservoirs.  Nat Med 2010; 
16:446-451. 
Chalmet K, Dauwe K, Foquet L, et al.  Presence of CXCR4-Using HIV-1 in Patients with 
Recently Diagnosed Infection: Correlates and Evidence for Transmission.  J 
Infect Dis 2012; 205:174-84. 
Cheng T, Rodrigues N, Shen H, et al.  Hematopoietic Stem Cell Quiescence Maintained 
by p21cip1/waf1.  Science 2000; 287:1804-8. 
Choudhary S, Walker R, Powell D, et al.  CXCR4 tropic human immunodeficiency virus 
type 1 induces an apoptotic cascade in immature infected thymocytes that 
resembles thymocyte negative selection.  Virology 2006; 352:268-84. 
Clouse K, Powell D, Washington I.  Monokine regulation of human immunodeficiency 
virus-1 expression in a chronically infected human T cell clone.  J Immunol 1989; 
142(2):431-8. 
 192 
Connor R, Sheridan K, Ceradini D, et al.  Change in coreceptor use correlates with 
disease progression in HIV-1-infected individuals.  J Exp Med 1997; 185(4):621-
8. 
Contreras X, Barboric M, Lenasi T, et al.  HMBA Releases P-TEFb from HEXIM1 and 
7SK snRNA via PI3K/Akt and Activates HIV Transcription.  PLoS Pathog 2007; 
3(10):e146. 
Daar E, Kesler K, Petropoulos C, et al.  Baseline HIV Type 1 Coreceptor Tropism 
Predicts Disease Progression.  Clin Infect Dis 2007; 45(5):643-9. 
Davis B, Schwartz D, Marx J, et al.  Absent or rare human immunodeficiency virus 
infection of bone marrow stem/progenitor cells in vivo.  J Virol 1991; 65(4):1985-
1990. 
De Jong J, De Ronde A, Keulen W, et al.  Minimal requirements for the human 
immunodeficiency virus type 1 V3 domain to support the syncytium-inducing 
phenotype: analysis by single amino acid substitution.  J Virol 1992; 66(11):6777-
80. 
Dikshit B, Wanchu A, Sachdeva R, et al.  Profile of hematological abnormalities of 
Indian HIV infected individuals.  BMC Blood Disorders 2009; 9:5. 
Doulatov S, Notta F, Eppert K, et al.  Revised map of the human progenitor hierarchy 
shows the origin of macrophages and dendritic cells in early lymphoid 
development. Nature Immunol 2010; 11(7):585-93. 
Durand C, Ghiaur G, Siliciano J, et al.  HIV-1 DNA is detected in bone marrow 
populations containing CD4
+
 T cells but is not found in purified CD34
+
 
hematopoietic progenitor cells in most patients on antiretroviral therapy.  J Infect 
Dis 2012; 205:1014-8. 
Duverger A, Jones J, May J, et al.  Determinants of the Establishment of Human 
Immunodeficiency Virus Type 1 Latency.  J Virol 2009; 83(7):3078-93. 
Eastburn A, Scherzer R, Zolopa A, et al.  Association of Low Level Viremia with 
Inflammation and Mortality in HIV-Infected Adults.  PLoS ONE 2011; 
6(11):e26320. 
Essers M, Offner S, Blanco-Bose W, et al.  IFN! activates dormant haematopoietic stem 
cells in vivo.  Nature 2009; 458:904-8. 
Folks T, Justement J, Kinter A, et al.  Cytokine-induced expression of HIV-1 in a 
chronically infected promonocyte cell line.  Science 1987; 238:800-2. 
Folks T, Kessler S, Orenstein J, et al.  Infection and replication of HIV-1 in purified 
progenitor cells of normal human bone marrow.  Science 1988; 242(4880): 919-
922. 
Grivel J-C and Margolis L.  CCR5- and CXCR4-tropic HIV-1 are equally cytopathic for 
their T-cell targets in human lymphoid tissue.  Nature Med 1999; 5(3):3344-6. 
Grivel J-C, Penn M, Eckstein D, et al.  Human immunodeficiency virus type 1 coreceptor 
preferences determine target T-cell depletion and cellular tropism in human 
lymphoid tissue.  J Virol 2000; 74(11):5347-51. 
Gryzwacz B, Kataria N, Kataria N, et al.  Natural killer-cell differentiation by myeloid 
progenitors.  Blood 2011; 117(13):3548-58. 
Hazenberg M, Otto S, Hamann D, et al.  Depletion of naïve CD4 T cells by CXCR4-
using HIV-1 variants occurs mainly through increased T-cell death and activation.  
AIDS 2003; 17(10):1419-24. 
 193 
Hogg R, O’Shaughnessy M, Gataric N, et al.  Decline in deaths from AIDS due to new 
antiretrovirals.  Lancet 1997; 349:1294. 
Jekle A, Keppler O, De Clercq E, et al.  In vivo evolution of human immunodeficiency 
virus type 1 toward increased pathogenicity through CXCR4-mediated killing of 
uninfected CD4 T cells.  J Virol 2003; 77(10): 5846-54. 
Jekle A, Schramm B, Jayakumar P, et al.  Coreceptor phenotype of natural human 
immunodeficiency virus with nef deleted evolves in vivo, leading to increased 
virulence.  J Virol 2002; 76(14):6966-73. 
Jordan A, Bisgrove D, and Verdin E.  HIV reproducibly establishes a latent infection 
after acute infection of T cells in vitro.  EMBO J 2003; 22(8):1868-77. 
Josefsson L, Eriksson S, Sinclair E, et al.  Hematopoietic Precursor Cells Isolated From 
Patients on Long-term Suppressive HIV Therapy Did Not Contain HIV-1 DNA.  J 
Infect Dis 2012; 206:28-34. 
Karlsson A, Parsmyr K, Sandström E, et al.  MT-2 cell tropism as prognostic marker for 
disease progression in human immunodeficiency virus type 1 infection.  J Clin 
Microbiol 1994; 32(2):364-70. 
Kauder S, Bosque A, Lindqvist A, et al.  Epigenetic Regulation of HIV-1 Latency by 
Cytosine Methylation.  PLoS Pathog 2009; 5(6):e1000495. 
Kreisberg J, Kwa D, Schramm B, et al.  Cytopathicity of human immunodeficiency virus 
type 1 primary isolates depends on coreceptor usage and not patient disease 
status.  J Virol 2001; 75(18):8842-7. 
Kuller L, Tracy R, Belloso W, et al.  Inflammatory and Coagulation Biomarkers and 
Mortality in Patients with HIV Infection.  PLoS Med 2008; 5(10):e203. 
Liou H, Sha W, Scott M, et al.  Sequential Induction of NF-!B/Rel Family Proteins 
during B-Cell Terminal Differentiation.  Mol Cell Biol 1994; 14(8):5349-59. 
Lopez C, Vazquez M, Hill M, et al.  Characterization of HIV-1 RNA forms in the plasma 
of patients undergoing successful HAART.  Arch Virol 2010; 155:895-903. 
Lorenzana A, McCabe N, Goodell W, et al.  Characterization of a CD34+ Cell Line 
Established from a Child with Large Cell Cutaneous Lymphoma.  Cancer 1993; 
72(3):931-7. 
Maas J, Gange S, Schuitemaker H, et al.  Strong association between failure of T cell 
homeostasis and the syncytium-inducing phenotype among HIV-1-infected men 
in the Amsterdam Cohort Study.  AIDS 2000; 14:1155-61. 
Majeti R, Park C, and Weissman I.  Identification of a hierarchy of multipotent 
hematopoietic progenitors in human cord blood.  Cell Stem Cell 2007; 1:635-45. 
Meira D, Lorand-Metze I, Toro A, et al.  Bone marrow features in children with HIV 
infection and peripheral blood cytopenias.  Journal of Tropical Pediatrics 2005; 
51(2):114-119. 
Mellors J, Kingsley L, Rinaldo C, et al.  Quantitation of HIV-1 RNA in plasma predicts 
outcome after seroconversion.  Ann Intern Med 1995; 122:573-9. 
Mellors J, Rinaldo C, Gupta P, et al.  Prognosis in HIV-1 infection predicted by the 
quantity of virus in plasma.  Science 1996; 272:1167-70. 
Mlisana K, Auld S, Grobler A, et al.  Anaemia in acute HIV-1 subtype C infection.  PLoS 
ONE 2008; 3(2):e1626. 
Moses A, Nelson J, and Bagby G.  The influence of human immunodeficiency virus-1 on 
hematopoiesis.  Blood 1998; 91(5):1479-1495. 
 194 
Nakajima H, Kim Y, Terano H, et al.  FR901228, a potent antitumor antibiotic, is a novel 
histone deacetylase inhibitor.  Exp Cell Res 1998; 241:126-33. 
Neal T, Holland H, Baum C, et al.  CD34+ progenitor cells from asymptomatic patients 
are not a major reservoir for human immunodeficiency virus-1.  Blood 1995; 
86(5):1749-1756. 
Notta F, Doulatov S, Laurenti E, et al.  Isolation of Single Human Hematopoietic Stem 
Cells Capable of Long-Term Multilineage Engraftment.  Science 2011; 333:218-
21. 
Palmer S, Maldarelli F, Wiegand A, et al.  Low-level viremia persists for at least 7 years 
in patients on suppressive antiretroviral therapy.  Proc Natl Acad Sci 2008; 
105(10):3879-3884. 
Palmisano I, Chiara G, D’Ambrosio R, et al.  Amino acid starvation induces reactivation 
of silenced transgenes and latent HIV-1 provirus via down-regulation of histone 
deacetylase 4 (HDAC4).  Proc Natl Acad Sci 2012; E2284-93. 
Rai M, Soragni E, Jenssen K, et al.  HDAC Inhibitors Correct Frataxin Deficiency in a 
Friedreich Ataxia Mouse Model.  PLoS ONE 2008; 3(4):e1958. 
Rajotte D, Sadowski H, Haman A, et al.  Contribution of both STAT and SRF/TCF to c-
fos promoter activation by granulocyte-macrophage colony-stimulating factor.  
Blood 1996; 88(8):2906-16. 
Raymond S, Delobel P, Mavigner M, et al.  Correlation between genotypic predictions 
based on V3 sequences and phenotypic determination of HIV-1 tropism.  AIDS 
2008; 22(14):F11-6. 
Redd A, Avalos A, and Essex M.  Infection of hematopoietic progenitor cells by HIV-1 
subtype C, and its association with anemia in southern Africa.  Blood 2007a; 
110(9):3143-3149. 
Redd A, Avalos A, Phiri K, and Essex M.  Effects of HIV type 1 infection on 
hematopoiesis in Botswana.  AIDS Research and Human Retroviruses 2007b; 
23(8):996-1003. 
Richman D and Bozzette S.  The Impact of the Syncytium-Inducing Phenotype of Human 
Immunodeficiency Virus on Disease Progression.  J Infect Dis 1994; 169(5). 
Ruiz M, Cicala C, Arthos J, et al.  Peripheral Blood-Derived CD34
+
 Progenitor Cells: 
CXC Chemokine Receptor 4 and CC Chemokine Receptor 5 Expression and 
Infection by HIV.  J Immunol 1998; 161(8):4169-76. 
Sahu G, Paar D, Frost S, et al.  Low-level plasma HIVs in patients on prolonged 
suppressive highly active antiretroviral therapy are produced mostly by cells other 
than CD4 T-cells.  J Med Virol 2009; 81(1):9-15. 
Samson S, Mémet S, Vosshenrich C, et al.  Combined deficiency in I!B" and I!B# 
reveals a critical window of NF-!B activity in natural killer cell differentiation.  
Blood 2004; 103(12):4573-80. 
Scarlatti G, Tresoldi E, Björndal A, et al.  In vivo evolution of HIV-1 co-receptor usage 
and sensitivity to chemokine-mediated suppression.  Nature Med 1997; 
3(11):1259-65. 
Schramm B, Penn M, Speck R, et al.  Viral Entry through CXCR4 Is a Pathogenic Factor 
and Therapeutic Target in Human Immunodeficiency Virus Type 1 Disease.  J 
Virol 2000; 74(1):184-92. 
 195 
Schuitemaker H, Koot M, Kottstra N, et al.  Biological phenotype of human 
immunodeficiency virus type 1 clones at different stages of infection: progression 
of disease is associated with a shift from monocytotropic to T-cell-tropic virus 
population.  J Virol 1992; 66(3):1354-60. 
Shankarappa R, Margolick J, Gange S, et al.  Consistent viral evolutionary changes 
associated with the progression of human immunodeficiency virus type 1 
infection.  J Virol 1999; 73(12):10489-502. 
Shen H, Cheng T, Preffer F, et al.  Intrinsic human immunodeficiency virus type 1 
resistance of hematopoietic stem cells despite corectpro expression.  J Virol 1999; 
73(1): 728-37. 
Shepherd J, Jacobson L, Qiao W, et al.  Emergence and Persistence of CXCR4-Tropic 
HIV-1 in a Population of Men from the Multicenter AIDS Cohort Study.  J Infect 
Dis 2008; 198(8):1104-12. 
Simmons D, Satterthwaite A, Tenen D, et al.  Molecular cloning of a cDNA encoding 
CD34, a sialomucin of human hematopoietic stem cells.  J Immunol 1992; 
148(1):267-71. 
Slobold K, Bennett T, Freiden P, et al.  Mobilization of CD34+ progenitor cells by 
granulocyte colony-stimulating factor in human immunodeficiency virus type 1-
infected adults.  Blood 1996; 88(9):3329-3335. 
Stanley S, Kessler S, Justement J, et al.  CD34+ bone marrow cells are infected with HIV 
in a subset of seropositive individuals.  J Immunol 1992; 149(2):689-697. 
Su L, Kaneshima H, Bonyhadi M, et al.  HIV-1-induced thymocyte depletion is 
associated with indirect cytopathogenicity and infection of progenitor cells in 
vivo.  Immunity 1995; 2;25-36. 
Takizawa H, Regoes R, Boddupalli C, et al.  Dynamic variation in cycling of 
hematopoietic stem cells in steady state and inflammation.  J Exp Med 2011; 
208(2):273-84. 
Thomas E, Coppola G, Desplats P, et al.  The HDAC inhibitor 4b ameliorates the disease 
phenotype and transcriptional abnormalities in Huntington’s disease transgenic 
mice.  Proc Natl Acad Sci 2008; 105(40:15564-9. 
Tyagi M, Pearson R, and Karn J.  Establishment of HIV Latency in Primary CD4
+
 Cells 
Is due to Epigenetic Transcriptional Silencing and P-TEFb Restriction.  J Virol 
2010; 84(13):6425-37. 
Van Molle W, Van Roy M, Van Bogaert T, et al.  Protection of Zinc against Tumor 
Necrosis Factor Induced Lethal Inflammation Depends on Heat Shock Protein 70 
and Allows Safe Antitumor Therapy.  Cancer Res 2007; 67(15):7301-7. 
Van Molle W, Wielockx B, Mahieu T, et al.  HSP70 protects against TNF-induced lethal 
inflammatory shock.  Immunity 2002; 16(5):685-95. 
Voll R, Jimi E, Phillips R, et al.  NF-!B Activation by the Pre-T Cell Receptor Serves as 
a Selective Survival Signal in T Lymphocyte Development.  Immunity 2000; 
13(5): 677-89. 
Von Laer D, Hufert F, Fenner T, et al.  CD34+ hematopoietic progenitor cells are not a 
major reservoir of the human immunodeficiency virus.  Blood 1990; 76(7):1281-
1286. 
 196 
Waters L, Mandalia S, Randell P, et al.  The Impact of HIV Tropism on Decreases in 
CD4 Cell Count, Clinical Progression, and Subsequent Response to a First 
Antiretroviral Therapy Regimen.  Clin Infect Dis 2008; 46(10):1617-23. 
Weichold F, Zella D, Barabitskaja O, et al.  Neither human immunodeficiency virus-1 
(HIV-1) nor HIV-2 infects most-primitive human hematopoietic stem cells as 
assessed in long-term bone marrow cultures.  Blood 1998; 91(3):907-15. 
Weinberger L, Burnett J, Toettcher J, et al.  Stochastic gene expression in a lentiviral 
positive-feedback loop: HIV-1 Tat fluctuations drive phenotypic diversity.  Cell 
2005; 122(2):169-82. 
Weiser B, Philpott S, Klimkait T, et al.  HIV-1 coreceptor usage and CXCR4-specific 
viral load predict clinical disease progression during combination antiretroviral 
therapy.  AIDS 2008; 22(4):469-79. 
Xing S, Bullen C, Shroff N, et al.  Disulfiram Reactivates Latent HIV-1 in a Bcl-2-
Transduced Primary CD4
+
 T Cell Model without Inducing Global T Cell 
Activation.  J Virol 2011; 85(12):6060-64. 
Yin A, Miraglia S, Zanjani E, et al.  AC133, a novel marker for human hematopoietic 
stem and progenitor cells.  Blood 1997; 90(12):5002-12. 
Yu X, Wang Z, Vlahov D, et al.  Infection with dual-tropic human immunodeficiency 
virus type 1 variants associated with rapid total T cell decline and disease 
progression in injection drug users.  J Infect Dis 1998; 178(2):388-96. 
Zauli G, Re M, Davis B, et al.  Impaired in vitro growth of purified (CD34+) 
hematopoietic progenitors in human immunodeficiency virus-1 seropositive 
thrombocytopenic individuals.  Blood 1992; 79(10):2680-2687. 
Zhang J, Scadden D, and Crumpacker C.  Primitive hematopoietic cells resist HIV-1 
infection via p21 Waf1/Cip1/Sdi1.  J Clin Invest 2007; 117(2):473-81. 
 
